

# **CURRICULUM VITAE**

Updated November 3, 2018

**NAME:** E. Michael Lewiecki, MD, FACP, FACE

## **CONTACT INFORMATION**

New Mexico Clinical Research & Osteoporosis Center  
300 Oak St. NE  
Albuquerque, NM 87106  
USA

[www.nmbonecare.com](http://www.nmbonecare.com)

## **SUMMARY**

Director, New Mexico Clinical Research & Osteoporosis Center,  
Albuquerque, NM  
Director, Bone Health TeleECHO (Extension for Community Healthcare  
Outcomes), UNM Health Sciences Center, Albuquerque, NM  
Clinical Assistant Professor of Medicine, University of New Mexico Health  
Sciences Center, Albuquerque, NM  
Vice President, National Osteoporosis Foundation  
President, Osteoporosis Foundation of New Mexico  
Past President, International Society for Clinical Densitometry  
Review Editor, Osteoporosis International  
Principal investigator, numerous osteoporosis clinical trials  
Author, over 280 publications in peer-reviewed journals, as well as books,  
book chapters, and electronic publications

## **EDUCATION**

Residency: Internal Medicine, University of New Mexico Affiliated Hospitals,  
Albuquerque, New Mexico, 1973 – 1975  
Internship: Rotating, University of New Mexico Affiliated Hospitals,  
Albuquerque, New Mexico, 1972 – 1973  
Medical School: Northwestern University Medical School, MD  
Chicago, Illinois, 1972  
Undergraduate: Amherst College, BA, Cum Laude  
Amherst, Massachusetts, 1968

**CITIZENSHIP:** USA

## **MILITARY**

United States Air Force, 1975 – 1977

## **MEDICAL PRACTICE POSITIONS**

New Mexico Clinical Research & Osteoporosis Center  
Albuquerque, NM  
1998 – Present  
New Mexico Medical Group, Albuquerque, NM  
1986 – 1998  
Private Practice, Albuquerque, New Mexico  
1977 – 1986  
Military Medical Officer, Goodfellow AFB, San Angelo, Texas  
1975 – 1977

### **TEACHING POSITIONS**

University of New Mexico Health Sciences Center  
Clinical Assistant Professor of Medicine  
International Society for Clinical Densitometry  
Faculty, Bone Densitometry Course, Vertebral Fracture Assessment  
Course, Osteoporosis Academy  
American College of Physicians  
Faculty, osteoporosis management and bone densitometry

### **MEDICAL EDUCATION DIRECTORSHIPS**

Santa Fe Bone Symposium (annual event)  
Program Director, 2000 – Present  
New Mexico Bone Club (recurring events 3 to 4 times per year)  
Education Director, 1997 – Present  
UNM Bone Health ECHO (Extension for Community Healthcare  
Outcomes)  
Director, 2015 – Present

### **MEDICAL ADMINISTRATIVE POSITIONS**

President, International Society for Clinical Densitometry  
2003 – 2005  
President, Osteoporosis Foundation of New Mexico  
2000 – Present  
Medical Director, Gentiva Home Health Care, Albuquerque, New Mexico  
2000 – 2004  
Medical Advisor, Albuquerque Osteoporosis Support Group  
1999 – Present  
Osteoporosis Director, New Mexico Clinical Research & Osteoporosis Center  
1998 – Present  
Medical Director, Osteoporosis Center, New Mexico Medical Group  
1997 – 1998  
Medical Director, Horizon Specialty Hospital, Albuquerque, New Mexico  
1995 – 1998  
Medical Director, New Mexico Medical Group, Albuquerque, New Mexico  
1994 – 1998  
Medical Director, St. Francis Gardens, Albuquerque, New Mexico

1993 – 1996  
Medical Director, Health South Rehab. Hospital, Albuquerque, New Mexico  
1991 – 1993  
President, New Mexico Medical Group, Albuquerque, New Mexico  
1986 – 1994  
Chairman, Dept. of Medicine, Presbyterian Hospital, Albuquerque, New Mexico  
1996 – 1997  
Chief of Internal Medicine, Goodfellow AFB Clinic, San Angelo, Texas  
1975 – 1977

## **EDITORIAL POSITIONS**

Senior Editor  
Clinical Investigation, 2010-2015  
Associate Editor  
Journal of Clinical Densitometry, 2009-  
Osteoporosis International, 2015-  
Editorial Board  
Expert Opinion on Biological Therapy, 2010-  
Journal of Bone and Mineral Research, 2016-  
Journal of Clinical Case Reports, 2011-  
Journal of Clinical Trials, 2010-  
Journal of Drug Assessment, 2010-  
Journal of Osteoporosis, 2008-2012  
Osteoporosis International, 2009-  
Osteoporosis and Sarcopenia, 2016-  
Editorial Board Advisor/Consultant  
Current Medical Research & Opinion, 2008-2010  
Medscape Ob/Gyn & Women's Health, 2010-  
Women's Health, 2008-

## **REVIEWER FOR MEDICAL JOURNALS**

Aging Health  
American Journal of Managed Care  
Annals of Internal Medicine  
Archives of Internal Medicine  
Archives of Medical Research  
Archives of Osteoporosis  
Archives of Pediatrics & Adolescent Medicine  
Arthritis & Rheumatism  
Bone  
British Medical Journal Open  
Canadian Medical Association Journal  
Cleveland Clinic Journal of Medicine  
Clinical Drug Investigation  
Clinical Endocrinology  
Clinical and Experimental Medicine

Clinical Interventions in Aging  
Clinical Therapeutics  
Contemporary Clinical Trials  
Current Medical Literature in Rheumatology  
Current Medical Research and Opinion  
Drugs  
Drugs & Aging  
Endocrine  
Endocrine Practice  
Endocrine Research  
EU Endocrinology  
European Journal of Endocrinology  
European Journal of Neurology  
European Journal of Nutraceuticals & Functional Foods  
European Journal of Obstetrics & Gynecology and Reproductive Biology  
Expert Opinion on Drug Delivery  
Expert Opinion on Drug Metabolism & Toxicology  
Expert Opinion on Investigational Drugs  
Expert Opinion on Pharmacotherapy  
Expert Review of Clinical Pharmacology  
Expert Review of Endocrinology & Metabolism  
Future Rheumatology  
Gender Medicine  
Grand Rounds in Oral-Systemic Medicine  
Indian Journal of Orthopaedics  
Journal of Affective Disorders  
Journal of Bone and Mineral Research  
Journal of Clinical Densitometry  
Journal of Clinical Endocrinology & Metabolism  
Journal of Clinical Outcomes Management  
Journal of Epidemiology and Global Health  
Journal of General Internal Medicine  
Journal of Medicine  
Journal of Musculoskeletal and Neuronal Interactions  
Journal of Orthopaedic Trauma  
Journal of the American Geriatrics Society  
Journal of the American Medical Association  
Maturitas  
Mayo Clinic Proceedings  
Molecular and Cellular Therapies  
Nature Clinical Practice Endocrinology & Metabolism  
Nephrology  
New England Journal of Medicine  
Osteoporosis International  
Pharmacy and Therapeutics  
Physicians' Information and Education Research (PIER), ACP

Postgraduate Medicine  
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery  
Seminars in Arthritis & Rheumatism  
Southern Medical Journal  
The Physician and Sportsmedicine  
Women's Health

### **CLINICAL TRIAL DATA MONITORING COMMITTEES**

A randomized, double-blind evaluation of the antiviral efficacy, safety, and tolerability of tenovir disoproxil fumarate versus placebo in adolescents with chronic hepatitis B infection. Gilead. GS-US-174-0115. 2008.

A randomized, double-blind evaluation of the antiviral efficacy, safety, and tolerability of tenovir disoproxil fumarate versus placebo in pediatric patients with chronic hepatitis B infection. Gilead. GS-US-174-0144. 2012.

### **GRANT REVIEWER**

Research into Ageing, London, UK  
Medical Research Council, London, UK  
Health Research Council of New Zealand

### **EXPERT PANELS**

NASA Bone Research and Clinical Advisory Panel  
Ongoing advisory meetings for fracture risk mitigation with long duration spaceflight  
Bone Summit II on the Risk for Early Onset Osteoporosis due to Spaceflight, National Aeronautics and Space Administration, Lyndon B. Johnson Space Center, Houston, Texas, November 4-5, 2013  
Position Development Conference, International Society for Clinical Densitometry, Tampa, Florida, March 21-23, 2013  
Early Onset Osteoporosis Summit, National Aeronautics and Space Administration, Lyndon B. Johnson Space Center, Houston, Texas, June 7-8, 2010  
The State of the Art in the Management of Osteoporosis, The Office on Women's Health of the US Department of Health and Human Services, Washington, DC, July 28-29, 2003  
Position Development Conference, International Society for Clinical Densitometry, Denver, Colorado, July 20-22, 2001

### **BOARD CERTIFICATION**

American Board of Internal Medicine, June 1975 (No. 50061)

### **OTHER CERTIFICATION**

International Society for Clinical Densitometry, Certified Clinical Densitometrist, April 1997 - Present

**MEDICAL LICENSE:** New Mexico, November 1973 (No. 73 - 160)

## **AWARDS**

American Society of Internal Medicine, "Young Internist of the Year", 1986  
International Society for Clinical Densitometry, "ISCD Physician of the Year",  
2001  
International Society for Clinical Densitometry, "Paul D. Miller ISCD Service  
Award", 2006  
American College of Physicians, "Laureate Award", 2006  
The Endocrine Society, "Outstanding Reviewer Recognition Award", 2015

## **PROFESSIONAL ORGANIZATIONS**

American College of Physicians – American Society of Internal Medicine (ACP-  
ASIM)  
Managed Care Committee, 1998 – 1999  
New Mexico Chapter Council Member, 1999 – 2001  
American College of Physicians  
Member, 1975  
Fellow, 1986  
American Association of Clinical Endocrinologists  
Member, 2002  
Fellow, 2007  
American Society for Bone and Mineral Research  
Fellow, 2018  
Professional Practice Committee, 2001 – 2004  
Scientific Program Committee, Abstract Reviewer 2005 - Present  
American Society of Internal Medicine  
Retirement/Investment Committee, 1986  
Group Travel Committee, 1990 – 1992  
Managed Care Committee, 1994 – 1998  
Greater Albuquerque Medical Association, 1975 – Present  
Vice President, 1981  
International Bone and Mineral Society  
International Osteoporosis Foundation  
Council of Scientific Advisors, 2007 – Present  
International Society for Clinical Densitometry  
Board of Directors, 1999 – Present  
Public Policy Committee, Chairman, 1999 – 2001  
Interspecialty Council, Chairman, 2001 – 2003  
Co-chair, 7<sup>th</sup> Annual Scientific Meeting, 2001  
Nominating Committee, Chairman, 2005 – 2006  
Corporate Advisory Committee, Chairman, 2005 – Present  
Marketing Committee, Chairman, 2005 – 2006  
President-Elect, 2001 – 2003  
President, 2003 – 2005

Scientific Advisory Committee, Chairman, 2006 – 2009  
International Relations Committee, Chairman, 2009 – Present  
Public Policy Committee, Chairman, 2015 – Present  
National Osteoporosis Foundation  
Interspecialty Medical Council, 2005 – 2013  
Implementation Committee for *Clinician's Guide to Prevention and Treatment of Osteoporosis*, 2007-2008  
Board of Trustees, 2012 – Present  
Annual Meeting Program Committee, 2017, 2018  
New Mexico Foundation for Medical Care  
Board of Directors, 1980 – 1981  
New Mexico Medical Society, 1975 – Present  
New Mexico Osteoporosis Foundation  
Founder, 1997  
Program Director, Osteoporosis Continuing Education, 1997 – Present  
Chairman, Scientific Advisory Committee, 1997 – Present  
New Mexico Society of Internal Medicine  
Council Member, 1978 – 1998  
Secretary/Treasurer, 1980 – 1981  
President Elect, 1982 – 1983  
President, 1984 – 1985  
The Endocrine Society  
Special Programs Committee, 2014 – Present  
United States Bone and Joint Initiative  
Board of Directors, 2012 – 2013  
World Health Organization  
WHO Scientific Group on Assessment of Osteoporosis at the Primary Care Level, 2004

#### **HOSPITAL CONSULTING STAFF**

Presbyterian Hospitals, Albuquerque, New Mexico  
Lovelace Health Systems, Albuquerque, New Mexico

#### **COMMUNITY ACTIVITIES**

Albuquerque Public Schools, Team Physician, 1985 – Present  
Albuquerque Isotopes (Triple A Baseball), Team Physician, 2002 – Present  
Albuquerque Dukes (Triple A Baseball), Team Physician, 1987 – 2000  
Rio Grande Nature Center, Board of Trustees, 2000 – Present  
Osteoporosis Foundation of New Mexico, President, 2000 – Present

#### **PERSONAL**

Married, 4 children  
Resident of Albuquerque, NM, USA, since 1972

## SCIENTIFIC PRESENTATIONS

Numerous invited presentations have been given at scientific meetings in North America, South America, Europe, and Asia. These have included plenary lectures, keynote presentations, meet-the-professor sessions, oral presentations of abstracts, bone clubs, grand rounds, web-conferences, symposia, workshops, seminars, "round-table" discussions, newsletters, instructional courses, and educational programs recorded for CDs. Topics have included the following:

- Adherence to Osteoporosis Therapy
- Alendronate for the Treatment of Osteoporosis
- Anabolic Therapy for Osteoporosis
- Anticonvulsant Bone Disease
- Basic Bone Physiology
- Bisphosphonate Therapy for Osteoporosis
- BMD, Bone Turnover, and Fractures
- Bone Densitometry for Gastroenterologists
- Bone Densitometry for Neurologists
- Bone Densitometry for Nurse Practitioners
- Bone Densitometry for OB-GYNs
- Bone Densitometry for Orthopedic Surgeons
- Bone Densitometry for Primary Care Physicians
- Bone Densitometry for Rheumatologists
- Bone Densitometry for Urologists
- Bone Density and Bone Quality
- Bone Density Matters
- Bone Density Testing in the Evaluation of Osteoporosis
- Bone Health ECHO / Project ECHO
- Bone Turnover Markers
- Celiac Disease and Skeletal Health
- Clinical Practice Guidelines in the Management of Osteoporosis
- Combination Therapy for Osteoporosis
- Controversies with Osteoporosis
- Cost-utility Analysis for Osteoporosis Treatment
- Denosumab- An Emerging Treatment for Osteoporosis
- Diagnosis of Osteoporosis
- Emerging Therapy for Osteoporosis
- Emerging Treatments for Osteoporosis
- Fracture Intervention Programs
- Fracture Risk Assessment
- Glucocorticoid-induced Osteoporosis
- Hip Fractures
- Hyperparathyroidism
- Ibandronate for the Treatment of Osteoporosis
- Individualizing Osteoporosis Treatment
- Low Bone Density in Premenopausal Women



Managing a Bone Densitometry Facility  
Monitoring Osteoporosis Therapy  
New and Emerging Treatments for Osteoporosis  
NOF Guidelines and FRAX - Benefits and Limitations  
Nonpharmacological Therapy for Osteoporosis  
Non-responders to Osteoporosis Treatment  
Nutrition and Osteoporosis  
Obesity, Osteoporosis, and Bone Density Testing  
Official Positions of the International Society for Clinical Densitometry  
Oral Bone Health and Osteoporosis  
Osteoporosis Evaluation and Treatment  
Osteoporosis in Men  
Osteoporosis Treatment Thresholds  
Pitfalls in Bone Density Testing  
Project ECHO for Osteoporosis  
Raloxifene for the Treatment of Osteoporosis  
RANK Ligand Inhibition and Skeletal Health  
Rationale for Intermittent Bisphosphonate Dosing  
Reporting Fracture Risk  
Rheumatological Diseases and Osteoporosis  
Risedronate for the Treatment of Osteoporosis  
Risk Communication and Shared Decision Making  
Safety of Long-term Bisphosphonate Therapy  
Selective Estrogen Receptor Modulators  
Skeletal Effects of Hyperparathyroidism  
Skeletal Health in Native Americans  
Telementoring for Osteoporosis (Bone Health ECHO)  
Transplantation Osteoporosis  
Treat-to-Target (Treat-to-Goal) for Osteoporosis  
Update on FRAX  
Update on Osteoporosis  
Vertebral Fracture Assessment by DXA  
Vertebral Fractures  
Vertebroplasty and Kyphoplasty  
Vitamin D Deficiency and Insufficiency  
Zoledronic Acid for the Treatment of Osteoporosis

## BIBLIOGRAPHY

### Publications in Peer-reviewed Journals

For direct link to publications listed in PubMed, go to "My Bibliography" at:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/1LGocfQuRrjAo/bibliography/41045340/public/?sort=date&direction=descending>

1. Lewiecki EM, Rahman F. Pruritus: A manifestation of iron deficiency anemia. *JAMA*. 1976;236:2319-2320.
2. Lewiecki EM. CBGC. *JAMA*. 1977;237:2472.
3. Lewiecki EM. Primary plague septicemia. *Rocky Mountain Med J*. 1978;75:201-203.
4. Lewiecki, EM, Mason W. Beeper bite: A jogging complication in physicians. *West J Med*. 1982;136:354.
5. Lewiecki, EM. Vertebroplasty and Kyphoplasty in 2001. *J Clin Densitometry*. 2001;4:185-187.
6. Khan AA, Brown JP, Kendler DL, Leslie WD, Lentle BC, Lewiecki EM, Miller PD, Nicholson RL, Olszynski WP, Watts NB. The 2002 Canadian bone densitometry recommendations: take-home messages. *CMAJ*. 2002;167:1141-1145.
7. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study. *Clin Therapeutics*. 2002;24:1871-1886.
8. Lewiecki EM. Nonresponders to osteoporosis therapy. *J Clin Densitom*. 2003;6:307-314.
9. Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the International Society for Clinical Densitometry. *J Clin Densitom*. 2004;7(1):1-6.
10. Khan AA, Bachrach L, Brown JP, Hanley DA, Josse RG, Kendler DL, Leib ES, Lentle BC, Leslie WD, Lewiecki EM, Miller PD, Nicholson RL, O'Brien C, Olszynski WP, Theriault MY, Watts NB. Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children: a report from the Canadian panel of the international society of clinical densitometry. *J Clin Densitom*. 2004;7(1):51-64.

11. Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the International Society for Clinical Densitometry. *South Med J.* 2004;97(1):107-110.
12. Kiebzak GM, Lewiecki EM, Petak SM. Impact of using the ultradistal radius region of interest on diagnostic classification. *J Clin Densitom.* 2004;7:143-152.
13. Lewiecki EM. Bone density testing in the management of postmenopausal osteoporosis. *Women's Health Primary Care.* 2004;7:84-95.
14. Lewiecki EM. Low bone mineral density in premenopausal women. *South Med J.* 2004;97:544-550.
15. Lewiecki EM. Management of osteoporosis. *Clin Mol Allergy.* 2004;2:9.
16. Lewiecki EM, Kendler DL, Kiebzak GM, Schmeer P, Prince RL, El-Hajj Fuleihan G, Hans D. Special report on the official positions of the International Society for Clinical Densitometry. *Osteoporos Int.* 2004;15:779-784.
17. Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, Downs RW Jr. Official positions of the International Society for Clinical Densitometry. *J Clin Endocrinol Metab.* 2004;89(8):3651-3655.
18. Gluck OS, Maricic MJ, Leib ES, Lewiecki EM. Recommendations regarding individuals in whom bone densitometry should be performed: comment on the article by van Staa et al. *Arthritis Rheum.* 2004;50(8):2715-2716.
19. Binkley N, Kiebzak GM, Lewiecki EM, Krueger D, Gangnon RE, Miller PD, Shepherd JA, Drezner MK. Recalculation of the NHANES database standard deviation improves T-score agreement and reduces osteoporosis prevalence. *J Bone Miner Res.* 2005;20:195-201. Epub. Nov 16, 2004.
20. Lewiecki EM. Premenopausal bone health assessment. *Curr Rheumatol Rep.* 2005;7(1):46-52.
21. Lewiecki EM, Miller PD, Leib ES, Bielzikian JP. Response to "The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry" by John A. Kanis et al. *Osteoporos Int.* 2005;16(5):579-580. Epub Mar 16, 2005.
22. Binkley N, Lewiecki EM. Vitamin D and common sense. *J Clin Densitom.* 2011 Apr-Jun;14(2):95-9.
23. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. *J Bone Miner Res.* 2005;20(6):962-970. Epub 2005 Jan 18.

24. Lewiecki EM, Miller PD, Leib ES, Bilezikian JP. Response to "The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry," by John A. Kanis et al. *J Clin Densitom.* 2005;8(2):143-144.
25. Lewiecki EM. Clinical applications of bone density testing for osteoporosis. *Minerva Med.* 2005;96(5):317-330.
26. Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW Jr, Lentle BC. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. *J Clin Densitom.* 2005;8(4):371-378.
27. Lewiecki EM. Review of guidelines for bone mineral density testing and treatment of osteoporosis. *Curr Osteoporos Rep.* 2005;3(3):75-83.
28. Lewiecki EM. Update on bone density testing. *Curr Osteoporos Rep.* 2005;3(4):136-142. Reprinted in *Curr Prim Care Rep.* 2006;1:255-261.
29. Srivastava AK, Vliet EL, MD, Lewiecki EM, Maricic M, Abdelmalek A, Gluck O, Baylink DJ. Clinical use of serum and urine bone markers in the management of osteoporosis. *Curr Med Res Opin.* 2005;21(4):1015-1026.
30. Cryer B, Binkley N, Simonelli C, Lewiecki EM, Lanza F, Chen E, Petruschke RA, Mullen C, de Papp AE. A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. *Am J Geriatr Pharmacother.* 2005;3:127-136.
31. Hamdy RC, Chesnut CH III, Gass ML, Holick MF, Leib ES, Lewiecki EM, Maricic M, Watts NB. Review of treatment modalities for postmenopausal osteoporosis. *South Med J.* 2005;98:1000-1014.
32. Lewiecki EM. Is alendronate therapy cost-effective for postmenopausal osteopenia? *Nature Clin Pract Endocrinol Metab.* 2005;1(2):74-75.
33. Lewiecki EM. Skeletal health prognostications. *South Med J.* 2006;99(2):105-106.
34. Lewiecki EM, Rudolph LA, Kiebzak GM, Chavez JR, Thorpe BM. Assessment of osteoporosis website quality. *Osteoporos Int.* 2006 May;17(5):741-52. Epub 2006 Jan 31.
35. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain CD, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, for the AMG 162 Bone Loss Study Group.

Denosumab in postmenopausal women with low bone mineral density. *N Engl J Med.* 2006;354:821-831.

36. Lewiecki EM, Richmond B, Miller PD. Uses and misuses of quantitative ultrasonography in managing osteoporosis. *Cleve Clin J Med.* 2006;73(8):742-752.
37. Lewiecki EM. Augmentation procedures for osteoporotic vertebral fractures- An ongoing experiment or emerging standard of care? *South Med J.* 2006 May;99(5):449-50.
38. Vokes T, Bachman D, Baim S, Binkley N, Broy S, Ferrar L, Lewiecki EM, Richmond B, Schousboe J. Vertebral fracture assessment: The 2005 ISCD official positions. *J Clin Densitom.* 2006 Jan-Mar;9(1):37-46. Epub 2006 May 12.
39. Binkley N, Bilezikian J, Kendler D, Leib E, Lewiecki EM, Petak S. Official positions of the International Society for Clinical Densitometry and executive summary of the 2005 Position Development Conference. The 2005 ISCD official positions. *J Clin Densitom.* 2006 Jan-Mar;9(1):4-14. Epub 2006 May 12.
40. Lewiecki EM. Prevention of osteoporotic fractures. *Aging Health.* 2006;2(4):649-659.
41. Shepherd JA, Fan B, Lu Y, Lewiecki EM, Miller PD, Genant HK. Comparison of precision for Prodigy and Delphi for spine and femur scans. *Osteoporos Int.* 2006;17(9):1303-8. Epub 2006 Jul 6.
42. Khan AA, Hanley DA, Bilezikian JP, Binkley N, Brown JP, Hodsman AB, Josse RG, Kendler DL, Lewiecki EM, Miller PD, Olszynski WP, Petak SM, Syed ZA, Theriault D, Watts NB; Canadian Panel of the International Society for Clinical Densitometry. Standards for performing DXA in individuals with secondary causes of osteoporosis. *J Clin Densitom.* 2006 Jan-Mar;9(1):47-57. Epub 2006 Apr 4.
43. Lewiecki EM, Binkley N, Bilezikian JP, Kendler DL, Leib ES, Petak SM. Official positions of the International Society for Clinical Densitometry. *Osteoporos Int.* 2006 Nov;17(11):1700-1. Epub 2006 Aug 18.
44. Ragi-Eis S, Zerbini CA, Provenza JR, Griz LH, de Gregorio LH, Russo LA, Silva NA, Borges JL, de Souza AC, Castro ML, Lewiecki EM. Is it ethical to use placebos in osteoporosis trials? *J Clin Densitom.* 2006 Jul-Sep;9(3):274-80.
45. Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW, Lentle BC. Reply [to Chatterton BE. A rose by any other name, or when is research not research? *J Clin Densitom.* 2006;9:380.] *J Clin Densitom.* 2006 Jul-Sep;9(3):380-381.

46. Lewiecki EM, Laster AJ. Clinical Applications of Vertebral Fracture Assessment by Dual-energy X-ray Absorptiometry. *J Clin Endocrinol Metab.* 2006;91:4215-4222. 2006 Aug 29; [Epub ahead of print].
47. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. *Expert Opin Biol Ther.* 2006 Oct;6(10):1041-50.
48. Lewiecki EM. *Curr Opin Endocrinol Diabetes. Vertebral Fracture Assessment.* 2006;13:509-515.
49. Lewiecki EM. Denosumab: a promising drug for the prevention and treatment of osteoporosis. *Women's Health.* 2006;2(4):517-525.
50. Lewiecki EM, Binkley N, Petak SM. DXA quality matters. *J Clin Densitom.* 2006; 9(4):388-392.
51. Lewiecki EM, Silverman SL. Redefining osteoporosis: when to treat and how long to treat. *Arq Bras Endocrinol Metabol.* 2006;50(4):694-704.
52. Lewiecki EM, Borges JLC. Bone density testing in clinical practice. *Arq Bras Endocrinol Metabol.* 2006;50(4):586-595.
53. Ragi Eis S, Lewiecki EM. Peripheral bone densitometry- clinical applications. *Arq Bras Endocrinol Metabol.* 2006;50(4):596-602.
54. Lewiecki EM. Proceedings of the Santa Fe Bone Symposium 2006. *Women's Health.* 2006;2(6):825-828.
55. Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, J Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L, Jr, Stock JL. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. *Bone.* 2007;40(4):843-851. Epub 2006 Dec 19.
56. Leib ES, Binkley N, Bilezikian JP, Kendler DL, Lewiecki EM, Petak SM. Position Development Conference of the International Society for Clinical Densitometry. Vancouver, BC, July 15-17, 2005. *J Rheumatol.* 2006 Nov;33(11):2319-21.
57. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. *Osteoporos Int.* 2007;18:1023-1031. Epub 2007 Feb 17.
58. Blake GM, Lewiecki EM, Kendler DL, Fogelman I. A review of strontium ranelate and its effect on DXA scans. *J Clin Densitom.* 2007;10(2):113-119. Epub 2007 Feb 28.

59. Khan AA, Colquhoun A, Hanley DA, Jankowski LG, Josse RG, Kendler DL, Lentle B, Leslie WD, Lewiecki EM, O'Neill E, Robertson S, Syed ZA, Tanner SB, Webster D. Standards and guidelines for technologists performing central dual-energy x-ray absorptiometry. *J Clin Densitom.* 2007;10(2):189-195. Epub 2007 Feb 28.
60. Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM. Summary of the International Society for Clinical Densitometry 2005 Position Development Conference. *J Bone Miner Res.* 2007;22:643-645. Epub 2007 Feb 5.
61. Lewiecki EM. Advances in antiresorptive therapy for osteoporosis. *European Musculoskeletal Review.* 2007;1:95-96.
62. Kiebzak GM, Binkley N, Lewiecki EM, Miller PD. Diagnostic agreement at the total hip using different DXA systems and the NHANES III database. *J Clin Densitom.* 2007;10(2):132-137. Epub 2007 April 9.
63. Laster AJ, Lewiecki EM, for the ISCD Board of Directors. *J Clin Densitom.* Vertebral fracture assessment by dual-energy X-ray absorptiometry: insurance coverage issues in the United States. A White Paper of the International Society for Clinical Densitometry. 2007;10(3):227-238. Jun 27, 2007 [Epub ahead of print]
64. Lewiecki EM, Simon JA. Clinical use of bone density testing. *The Female Patient.* 2007;32:35-38.
65. Lewiecki EM, Miller PD, McClung MR, Cohen SB, MD, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA, for the AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. *J Bone Miner Res.* 2007;22:1832-1841. August 20, 2007 [epub ahead of print].
66. Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. *J Clin Endocrinol Metab.* 2007;92(12):4671-4677. Epub August 28, 2007.
67. R Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF. The effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. *J Bone Miner Res.* 2008 Jan;23(1):6-16.
68. Lewiecki EM. Long dosing intervals in the treatment of postmenopausal osteoporosis. *Curr Med Res Opin.* 2007;23(11):2617-2625.
69. Lewiecki EM. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. *Expert Opin Investig Drugs.* 2007 Oct;16(10):1663-72.

70. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. *Expert Opin Drug Saf.* 2007 Nov;6(6):663-72.
71. Miller PD, Chines A, Christiansen C, Hoek H, Kendler D, Lewiecki EM, Woodson G, Levine A, Constantine G, Delmas P. Effects of bazedoxifene on bone mineral density and turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo- and active-controlled study. *J Bone Miner Res.* 2008;23(4):525-535. Erratum in: *J Bone Miner Res.* 2008;23(6):972. Dec 11, 2007 [Epub ahead of print].
72. Lewiecki EM, Bilezikian JP, Cooper C, Hochberg MC, Luckey MM, Maricic M, Miller PD. Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007. *J Clin Densitom.* 2008;11(2):313-324. In Feb 13, 2008 [Epub ahead of print].
73. Lewiecki EM. Medications don't work if patients don't take them. *South Med J.* 2007;100(12):1190-1191.
74. Owens G, Jackson R, Lewiecki EM. An integrated approach: bisphosphonate management for the treatment of osteoporosis. *Am J Manag Care.* 2007;13:S290-S308.
75. Lewiecki EM. Commentary on: Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: A randomized trial: Marini H, Minutoli L, Polito F, et al. *Ann Intern Med* 2007;146:839-847. *South Med J.* 2008;101(1):2.
76. Lewiecki EM, Urig EJ Jr, Williams RC Jr. Tumor-induced osteomalacia: Lessons learned. *Arthritis Rheum.* 2008 Feb 29;58(3):773-777. [Epub ahead of print].
77. Lewiecki EM. Intravenous zoledronic acid for the treatment of osteoporosis. *Curr Osteoporos Rep.* 2008;6(1):17-23.
78. Fan B, Lewiecki EM, Sherman M, Lu Y, Miller PD, Genant HK, Shepherd JA. Improved precision with Hologic Apex software. *Osteoporos Int.* 2008 Mar 29 [Epub ahead of print]
79. Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Lewiecki EM, Silverman S. Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2007 ISCD Position Development Conference. *J Clin Densitom.* 2008;11(1):75-91.
80. Engelke K, Adams JE, Armbrecht G, Augat P, Bogado CE, Bouxsein ML, Felsenberg D, Ito M, Prevrhal S, Hans DB, Lewiecki EM. Clinical use of quantitative computed tomography and peripheral quantitative computed



tomography in the management of osteoporosis in adults: The 2007 ISCD Official Positions. *J Clin Densitom.* 2008 Jan-Mar;11(1):123-62.

81. Krieg MA, Barkmann R, Gonnelli S, Stewart A, Bauer DC, Del Rio Barquero L, Kaufman JJ, Lorenc R, Miller PD, Olszynski WP, Poiana C, Schott AM, Lewiecki EM, Hans D. Quantitative ultrasound in the management of osteoporosis: The 2007 ISCD Official Positions. *J Clin Densitom.* 2008 Jan-Mar;11(1):163-87.
82. Hans DB, Shepherd JA, Schwartz EN, Reid DM, Blake GM, Fordham JN, Fuerst T, Hadji P, Itabashi A, Krieg MA, Lewiecki EM. Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: The 2007 ISCD Official Positions. *J Clin Densitom.* 2008 Jan-Mar;11(1):188-206.
83. Lewiecki EM, Watts NB. New guidelines for prevention and treatment of osteoporosis. *South Med J.* 2009 Jan 9. [Epub ahead of print]. Rapid Response. Published online March 21, 2008.
84. Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG. Adherence to and gastrointestinal tolerability of monthly or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. *Clin Ther.* 2008;30:605-621.
85. Lewiecki EM. Prevention and treatment of postmenopausal osteoporosis. *Obstet Gynecol Clin North Am.* 2008 Jun;35(2):301-315.
86. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, For The AMG 162 Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. *Bone.* 2008 Apr 26. [Epub ahead of print].
87. Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. *Osteoporos Int.* 19(10):1363-1368. Epub 2008 Jun 11.
88. Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): What they mean to the bone densitometrist and bone technologist. *J Clin Densitom.* 2008;11(4):473-477. 2008 Jun 16. [Epub ahead of print]
89. Lewiecki EM, Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S. Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions. *South Med J.* 2008 Jun 14. [Epub ahead of print]
90. Lewiecki EM, Gordon CM, Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB,

Silverman S, Bishop NJ, Leonard MB, Bianchi ML, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS. Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. *Osteoporos Int*. 2008 Jul 17. [Epub ahead of print]

91. Lewiecki EM. Invited commentary. [re: Collinge C, LeBus G, Gardner MJ, Gehrig L. Osteoporosis in orthopaedic trauma patients: a diagnosis and treatment protocol. *J Ortho Trauma*. 2008;22(8):541-547]. *J Ortho Trauma*. 2008;22(8):548-549.
92. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R; LIFT Trial Investigators. Collaborators: Zanchetta J, Kerzberg E, Eden J, Eisman J, Howarda J, MacLennan A, Norman R, Devogelaer J, Reginster Y, Ragi Eis S, Griz L, Zerbini C, Jiménez L, Stepan J, Christiansen C, Valter I, Maasalu K, Vahula K, Orsel P, Delmas P, Benhamou L, Ribot C, Felsenberg D, Spieler W, Dammann H, Lakatos P, Szombati I, Korányi L, Spengler B, Szabo Z, Nafradi L, Takacs K, Alekna V, Krasauskiene A, Jurgutis R, Jasqui S, de la Pena P, Garcia P, Baka A, Jonker J, Øfjord E, Lunde T, Skag A, Sawicki A, Bochenek A, Badurski J, Czerwinski E, Lipinski K, Payer J, Díez A, Gabriel R, Erenus M, Saracoglu F, Sendag F, Reid D, Albertazzia P, Eastell R, Pavela I, Pawaa R, Robinson J, Barrett-Connor E, Boling E, Caldwell J, Bowen P, Wasnich R, Johnson S, Simon J, Lewiecki E, McCluskey D, Sultany G, Kivitz A, Henry W, Downs R, Riera G, Pérez Monteverde A, Grady D, McClung M, Pols H, Davis K, Herrington D, Hendrix S, Neven P, van Diest P, Harbeck N, Senn H, Svane G, Longo M, Davidson B, Kappelle J, Peters R, Prins M. *N Engl J Med*. 2008 Aug 14;359(7):697-708. Comment in: *N Engl J Med*. 2008 Aug 14;359(7):753-5. The effects of tibolone in older postmenopausal women.
93. Lewiecki EM. Vertebroplasty and kyphoplasty update. *Curr Osteoporos Rep*. 2008 Sep;6(3):114-9.
94. Lewiecki EM. A clinician's perspective on the use of zoledronic acid in the treatment of postmenopausal osteoporosis. *J Clin Densitom*. 2008;11(4):478-484. 2008 Aug 29. [Epub ahead of print].
95. Lewiecki EM, Baim S, Siris ES. Osteoporosis care at risk in the United States. *Osteoporos Int*. 2008;19(11):1505-1509. Epub 2008 Aug 29.
96. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. *Bone*. 2008;43(6):1115-1121. 2008 Aug 15. [Epub ahead of print]
97. Lewiecki EM, Keaveny TM, Kopperdahl D, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA. Once-monthly oral ibandronate improves

biomechanical determinants of bone strength in women with postmenopausal osteoporosis. *J Clin Endocrinol Metab.* 2008 Oct 7. [Epub ahead of print]

98. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP; Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators. Collaborators: Bilezikian JP, Delmas PD, Lindsay R, Miller PD, Watts NB, Cahall DL, Grauer A, Meeves S, Cahall DL, Stewart J, Meeves S, Frimpter J, Thomas E, Girard M, Huber D, Borah B, Ebetino H, Gross G, Grauer A, Stewart J, Girard M, Garnero P, Lang TF, Seeman E, Boonen S, Adachi J, Brown J, Hodsman A, Josse R, Ste-Marie LG, Eastell R, Delmas PD, Felsenberg D, Netelenbos C, Papapoulos S, Baker J, Binkley N, Boling E, Bolognese MA, Chubick A, Cohen S, Emkey RD, Greenspan SL, Greenwald M, Hall SL, Hippler S, Johnson C, Kagan R, Kivitz A, Krohn KD, Lewiecki R, Lindsay R, Luckey M, Malamet R, McClung MR, Miller PD, Recker RR, Recknor C, Rooney T, Rosen CJ, Rosenstock J, Saag K, Seltman MA, Silverman SL, Tamayo RE, Watts NB, Weinstein RS, Woodson GC. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. *J Clin Endocrinol Metab.* 2008 Oct;93(10):3785-93. Epub 2008 Aug 5.
99. Beck TJ, Lewiecki EM, Miller PD, Felsenberg D, Liu Y, Ding B, Libanati C. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. *J Clin Densitom.* 2008;11(3):351-359.
100. Lewiecki EM, Lane NE. Common mistakes in the clinical use of bone mineral density testing. *Nat Clin Pract Rheumatol.* 2008;4(12):667-674. 2008 Oct 21. [Epub ahead of print]
101. Lewiecki EM. Zoledronic acid in the management of osteoporosis. *Therapy.* 2008;5(6):829-835.
102. Lewiecki EM. Phytoestrogens and their role in the management of postmenopausal osteoporosis. *South Med J.* 2008 Dec 10. [Epub ahead of print]
103. Lewiecki EM. Is denosumab better than alendronate in the treatment of osteoporosis? *Nat Clin Pract Rheumatol.* 2009;5(2):72-73. 2008 Dec 17 Epub ahead of print.
104. Lewiecki EM. Denosumab for the treatment of postmenopausal osteoporosis. *Women's Health.* 2009;5(1):15.22.
105. Recker RR, Lewiecki EM, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. *Am J Med.* 2009;122(2A):S22-S32.

106. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. *J Clin Endocrinol Metab.* 2009 Feb;94(2):351-365.
107. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. *J Clin Endocrinol Metab.* 2009 Feb;94(2):340-350.
108. Bilezikian JP, Khan AA, Potts JT Jr; on behalf of the Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. The Summary Statement is written on behalf of all Workshop Participants. They should be regarded as co-authors of this paper. Members of The Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism: John P. Bilezikian, Aliya Khan, Andrew Arnold, Maria Luisa Brandi, Edward Brown, Roger Bouillon, Pauline Camacho, Orlo Clark, Pierre D'Amour, Richard Eastell, David Goltzman, David A. Hanley, E. Michael Lewiecki, Stephen Marx, Leif Mosekilde, Janice L. Pasieka, Munro Peacock, Dan Rao, Ian R. Reid, Misheala Rubin, Dolores Shoback, Shonni Silverberg, Cord Sturgeon, Robert Udelsman, J. E. M. Young, and John T. Potts. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. *J Clin Endocrinol Metab.* 2009 Feb;94(2):335-339.
109. Lewiecki EM. Denosumab: an investigational drug for the management of postmenopausal osteoporosis. *Biologics: Targets & Therapy* 2008;2(4):645–653.
110. Lewiecki EM. Intravenous zoledronic acid for the treatment of osteoporosis: the evidence of its therapeutic effect. *Core Evidence.* 2008;3(2):127–136. 2009;4:13-23.
111. Lewiecki EM. Emerging drugs for postmenopausal osteoporosis. *Expert Opin Emerg Drugs.* 2009 Mar;14(1):129-144. 2009 Feb 27 [Epub ahead of print].
112. Lewiecki EM. Pharmacologic therapy to reduce fracture risk: comment on the clinical practice guidelines of the ACP. *Nat Clin Pract Rheumatol.* 2009 Mar;5(3):120-121.
113. Lewiecki EM. Denosumab for the treatment of postmenopausal osteoporosis. *Womens Health (Lond Engl).* 2009 Jan;5(1):15-22.
114. Lewiecki EM, Baim S, Bilezikian JP, Eastell R, LeBoff MS, Miller PD. 2008 Santa Fe Bone Symposium: update on osteoporosis. *J Clin Densitom.* 2009;12(2):135-157.

115. Lewiecki EM. Denosumab update. *Curr Opin Rheumatol*. 2009;21:369-373. Epub May 6, 2009.
116. Lewiecki EM, Binkley N. Evidence-Based Medicine, Clinical Practice Guidelines, and Common Sense in the Management of Osteoporosis. *Endocr Pract*. 2009 Sep-Oct;15(6):573-579. 2009 Jun 2:1-21. [Epub ahead of print]
117. Lewiecki EM, Baim S, Langman CB, Bilezikian JP. The Official Positions of the International Society for Clinical Densitometry: Perceptions and Commentary. *J Clin Densitom*. 2009 Jun 20. [Epub ahead of print]
118. Wilkes MM, Navickis RJ, Chan WW, Lewiecki EM. Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. *Osteoporos Int*. 2010;21(4):679-688. 2009 Jul 2. [Epub ahead of print]
119. Lewiecki EM. Denosumab for joints and bones. *Curr Rheumatol Rep*. 2009 Jul;11(3):196-201.
120. Lewiecki EM. Kyphosis and vertebral fractures: What do we know now? *Aging Health*. 2009;5(4):483-487.
121. Lewiecki EM. Managing osteoporosis: challenges and strategies. *Cleve Clin J Med*. 2009 Aug;76(8):457-66.
122. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Collaborators: Cummings S, Christiansen C, Delmas P, Eastell R, McClung M, Reid I, Siris E, Aqua K, Lee E, Boling E, Bolognese M, Burch F, Cohen S, Fiske D, Petit C, Pierson M, Garrison K, Gallup E, Geisberg H, Hassman D, Helfrich D, Krohn K, Cuevas E, Larson W, Seiler J, Lederman S, Lewiecki M, MacCarter D, McClung M, Miller P, Moffett A Jr, Recknor C, Simon J, Trapp R, Woodson G 3rd, Bone H, Murtaugh T, Ruckle J, Wasnich R, Gallagher C, Dhillon G, Feldman R, Pennington G, Saxe P, Goldberg C, Rogers K, Keller M, Swor M, Rosen A, Stjernholm M, Adachi J, Brown J, Faraawi R, Kendler D, Kremer R, Olszynski W, Yuen CK, McKendry R, Boudreau J, Man Z, Zanchetta J, Mautalen C, de Gregorio L, Eis S, Radominski S, da Silva N, Griz L, Provenza J, Zerbini C, García-Hernández P, Araujo-Arias M, Bueno E, Fuentes-Cantu A, Perez M, Balderas-Acata J, Avila-Armengol H, de la Peña-Rodríguez M, Nicholson G, Ebeling P, Sambrook P, Hooper M, Prins J, Russell A, Reid I, Gilchrist N, Preisinger E, Resch H, Fahrleitner-Pammer A, Huber J, Kudlacek S, Reginster JY, Kaufman JM, Boonen S, Body JJ, Devogelaer JP, Tegibjearg C, Juel R, Alexandersen P, Hoeck HC, Jensen JE, Välimäki M, Salmi J, Delmas P, Fardellone P, Weryha G, Benhamou CL, Maugars Y, Roux C, Stahl HD, Blome-Henning U, Lochman B, Kopsch U, Roitenberg A, Adami S, Brandi M,

Minisola S, Bianchi G, Sinigaglia L, Frediani B, Marcolongo R, Fiore C, Nuti R, Realdi G, Dijkmans B, Laan R, Bruyn G, Deijl A, Meesters E, Lems W, Verhage A, van de Walle V, Halse J, Hoiseth A, Syversen U, Stakkestad J, Minguella J, Mola E, Torres M, Gómez J, Hawkins F, Román J, Alvaro-Gracia J, Del Pino J, Palacios S, Ljunggren O, Toss G, Samsioe G, Mellström D, Löfgren J, Törring O, Lippuner K, Krieg MA, Uebelhart D, Eastell R, Thomas H, Shaw H, Donnachie H, Pavel-Knox I, Robinson J, Kola N, Sarmiento R, Pawa R, Savani N, Kucerova I, Kuba V, Vyskocil V, Kutilek S, Novosad P, Slesinger J, Dokoupilova E, Doubravsky J, Gorgol J, Pavelka K, Valter I, Maasalu K, Kull I, Phenekos C, Lyritis G, Dimitriadis A, Spengler B, Insperger A, Balázs T, Lakatos P, Takács K, Szombati I, Tarján K, Valkusz Z, Torma O, Seregely K, Kaze I, Lejnieks A, Medne A, Tamulaitiene M, Velickiene D, Stonkus S, Brincaat M, Walecki J, Bykowska M, Sidorowicz-Bialynicka A, Szechinski J, Korkosz M, Supronik J, Koziara M, Czerwinski E, Milewicz A, Jeka S, Kania G, Gidzinski P, Sawicki A, Tlustochowicz W, Franek E, Hoszowski K, Pluskiewicz W, Porawska W, Zgliczynski W, Killinger Z, Masaryk P, Kmecova Z, Tomkova S, Spustova V, Steno B, Zbranca E, Codreanu C, Hristov V, Russev T, Ivanova AM, Velev R, Mitkov M, Troev D, Brankovic S, Dimic A, Pilipovic N, Hlatky M, Goldschlager N, Herrington D, Ryan C, Migliorati C, Ruggiero S, Schubert M. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med*. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.

123. Watts NB, Lewiecki EM, Bonnick SL, Laster AJ, Binkley N, Blank RD, Guesens PP, Miller PD, Petak SM, Recker RR, Saag KG, Schousboe J, Siris ES, Bilezikian JP. The clinical value of monitoring bone density in patients treated with bisphosphonates for osteoporosis. *J Bone Miner Res*. 2009. Epub.
124. Aguirre LE, Lewiecki EM. Management of osteoporosis in elderly women. *Ann Long-term Care*. 2009;17(10):35-39.
125. Lewiecki EM. Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. *Ther Clin Risk Management*. 2009;5:817-827. Epub 2009 Nov 2.
126. Lewiecki EM. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. *J Womens Health (Larchmt)*. 2009; Oct;18(10):1615-1626.
127. Lewiecki EM. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. *IDrugs*. 2009 Dec;12(12):799-809.
128. Lewiecki EM. Fracture risk assessment in clinical practice: T-scores, FRAX, and beyond. *Clin Rev Bone Miner Metab*. 2010;8(3):101-112. Published online 30 June 2009.

129. Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G. Efficacy and safety of monthly ibandronate in men with low bone density. *Bone*. 2010;46(4):970-976. Published online January 5.
130. Lewiecki EM. Denosumab - an emerging treatment for postmenopausal osteoporosis. *Expert Opin Biol Ther*. 2010 Jan 22. [Epub ahead of print]
131. Lewiecki EM. Monitoring pharmacological therapy for osteoporosis. *Rev Endocr Metab Disord*. 2010;11(4):261-273. 2010 Feb 9. [Epub ahead of print]
132. Lewiecki EM. Bone: Using FRAX<sup>®</sup> wisely: lessons from Switzerland and beyond. *Nat Rev Endocrinol*. 2010 Mar;6(3):126-128.
133. Lewiecki EM, Bilezikian JP, Laster AJ, Miller PD, Recker RR, Russell RG, Whyte MP. 2009 Santa Fe Bone Symposium. *J Clin Densitom*. 2010 January - March;13(1):1-9.
134. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R; PEARL Study Investigators. Collaborators: Cummings SR, Delmas P, Eastell R, Ensrud K, LaCroix A, Reid D, Sriram U, Vukicevic S, Zanchetta J, Powles T, Allred C, Goss P, Osborne K, Colgan T, Goldstein SR, Neven P, Runowicz CD, Cohen L, Sechtem U, Welty F, Johnson SR, Russell G, Cosman F, Barter P, Laird NM, Gardiol AA, Zanchetta J, Messina OD, Seeman E, Nicholson G, Hooper M, Graham JJ, Eden J, Stuckey BG, Geusens P, Boonen S, De Melo NR, Zerbinini CA, Yuen CK, Brown J, Ste-Marie LG, Adachi J, Hanley DA, Josse RG, Kendler D, Olszynski WP, Castro R, Krpan D, Giljevic Z, Skreb F, Hyldstrup L, Langdahl BL, Rashed A, Maasalu K, Tammema L, Piirisild KL, Heikkinen J, Korman M, Valimaki MJ, Roux CC, Delmas PD, Hartard M, Doren M, Lau E, Balogh A, Horvath K, Tulassay Z, Kanakatte PM, Srinivasan B, Mehrotra RN, Patni R, Menon PS, Thomas M, Seshadri MS, Ammini AC, O'Brien M, Brandi ML, Adami S, Itabashi A, Okamoto S, Fujita N, Sawamoto A, Omata R, Han IK, Alekna V, Kazanavicius G, Jurgutis R, Balderas I, Santos J, Correa-Rotter R, Halse JI, Hoye K, Ofjord ES, Sawicki A, Marcinowska-Suchowierska E, Czerwinski E, Zosin I, Zbranca E, Codreanu C, Gzgzyan AM, Benevolenskaya LI, Dedov II, Oganov R, Smetnik V, Jordaan PJ, De Villiers TJ, Lipschitz S, Ellis G, Calaf J, Hawkins F, Mellstrom D, Kucu kdevci A, Kirazli Y, Keen R, Reid DM, Savani N, Moffett AH Jr, Silverfield JC, Bolognese MA, McKenney JM, Rosenstock J, Greenwald MW, Lewiecki EM, Miller SS, Lederman SN, Chesnut CH 3rd, Gallagher JC, Hangartner TN, Johnson KC, Ensrud K, Cauley JA, LaCroix A, Lewis CE, Broy SB, Sherman L, Barrett-Connor EL, Wallace RB, Orwoll ES. Lasofoxifene in postmenopausal women with osteoporosis. *N Engl J Med*. 2010 Feb 25;362(8):686-696.
135. Lewiecki EM. Treatment of osteoporosis with denosumab. *Maturitas*. 2010;66(2):182-186.

136. Lewiecki EM. Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosis. *Curr Osteoporos Rep.* 2010;8:15–22.
137. Lewiecki EM, Cooper C, Thompson E, Hartl F, Mehta D, Papapoulos SE. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. *Int J Clin Pract.* 2010;64(6):821-826. 2010 Mar 11. [Epub ahead of print]
138. Lewiecki EM. Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosis. *Curr Osteoporos Rep.* 2010 Mar;8(1):15-22.
139. Blank RD, Bilezikian JP, Bonnick SL, Laster AJ, Leib ES, Lewiecki EM, Miller PD, Watts NB, Binkley N. "Evidence-based" or "logic-based" medicine? *Osteoporos Int.* 2010 Oct;21(10):1681-1683. 2010 May 13. [Epub ahead of print]
140. Lewiecki EM. Bone densitometry and vertebral fracture assessment. *Curr Osteoporos Rep.* 2010 Sep;8(3):123-130.
141. Kung AW, Wu CH, Itabashi A, Lee JK, Park HM, Zhao Y, Chan WP, Kendler DL, Leib ES, Lewiecki EM, Bilezikian JP, Baim S; on behalf of the Asia Pacific Panel of ISCD. International Society for Clinical Densitometry Official Positions: Asia-Pacific Region Consensus. *J Clin Densitom.* 2010;13(4):346-351. Jul 20. [Epub ahead of print]
142. Lewiecki EM. Risk Communication and Shared Decision Making in the Care of Patients With Osteoporosis. *J Clin Densitom* 2010 Oct-Dec;13(4):335-45. Epub 2010 Jul 21.
143. Lewiecki EM. Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. *Core Evid.* 2010 Jun 15;4:13-23.
144. Hamdy RC, Baim S, Broy SB, Lewiecki EM, Morgan SL, Tanner SB, Williamson HF. Southern Medical Association algorithm for the management of osteoporosis. *South Med J.* 2010;103(10):1009-1015; quiz 1016.
145. Lewiecki EM. Bisphosphonates for the treatment of osteoporosis: insights for clinicians. *Ther Adv Chronic Dis.* 2010;1(3):115-128.
146. Binkley N, Lewiecki EM. The evolution of fracture risk reduction, *J Bone Miner Res.* 2010;25(10):2098-2100.
147. Lewiecki EM. Bone density testing to monitor osteoporosis therapy in clinical practice. *Am Fam Physician.* 2010 Oct 1;82(7):749.



148. Lewiecki EM. Management of skeletal health in patients with asymptomatic primary hyperparathyroidism. *J Clin Densitom.* 2010 Oct-Dec;13(4):324-34.
149. Lewiecki EM. Clinical use of denosumab for the treatment for postmenopausal osteoporosis. *Curr Med Res Opin.* 2010;26(12):2807-1812. 2010 Nov 4. [Epub ahead of print]
150. Lewiecki EM. Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. *Expert Opin Biol Ther.* 2011;11(1):117-127. Epub 2010 Nov 29.
151. Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR. Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial. *J Clin Endocrinol Metab.* 2011;96(2):394–402. 2010 Dec 15. [Epub ahead of print]
152. Lewiecki EM, Curiel MD, Borges JL, Kung A, Brandi ML, Dimai HP. New and emerging therapies for osteoporosis. *J Osteoporos.* 2010;Dec 26, 2010:318-320. Open access journal available at <http://www.sagehindawi.com/journals/josteo/2010/318320.html>. Article ID 318320. doi:10.4061/2010/318320.
153. Lewiecki EM, Bilezikian JP, Khosla S, Marcus R, McClung MR, Miller PD, Watts NB, Maricic M. Osteoporosis update from the 2010 Santa Fe Bone Symposium. *J Clin Densitom.* 2011 Jan-Mar;14(1):1-21.
154. Lewiecki EM, Miller SA. A piece of my mind. Time to reconsider. *JAMA.* 2011 Mar 16;305(11):1070-1.
155. Lewiecki EM. The Role of Risk Communication in the Care of Osteoporosis. *Curr Osteoporos Rep.* 2011 Sep;9(3):141-148. 2011 Apr 20. [Epub ahead of print]
156. Lewiecki EM. Safety of Long-Term Bisphosphonate Therapy for the Management of Osteoporosis. *Drugs.* 2011 Apr 16;71(6):791-814.
157. Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, Melton LJ, Cummings SR, Kanis JA; IOF CSA Working Group on Fracture Epidemiology. Collaborators (14) Adachi J, Borgström F, Dimai HP, Clark P, Lau E, Lewiecki EM, Lips P, Lorenc R, McCloskey E, Ortolani S, Papaioannou A, Silverman S, Wahl DA, Yoshimura N. Secular trends in the incidence of hip and other osteoporotic fractures. *Osteoporos Int.* 2011 May;22(5):1277-88. Epub 2011 Apr 2.
158. Lewiecki EM. Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis? *Curr Med Res Opin.* 2011 Jul;27(7):1493-7. Epub 2011 Jun 13.

159. Marsh D, Akesson K, Beaton DE, Bogoch ER, Boonen S, Brandi ML, McLellan AR, Mitchell PJ, Sale JE, Wahl DA; IOF CSA Fracture Working Group. Collaborators (8) Cooper C, Goldhahn J, Lewiecki EM, Lyritis G, Obrant K, Silverman S, Siris E, Stenmark J. Coordinator-based systems for secondary prevention in fragility fracture patients. *Osteoporos Int.* 2011 Jul;22(7):2051-65. Epub 2011 May 24.
160. Lewiecki EM. Osteoporosis. *Ann Intern Med.* 2011 Jul 5;155(1):ITC11.
161. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV; Task Force of the FRAX Initiative. Interpretation and use of FRAX in clinical practice. *Osteoporos Int.* 2011;22(9):2395-2411. 2011 Jul 21. [Epub ahead of print]
162. Boonen S, Wahl DA, Nauroy L, Brandi ML, Bouxsein ML, Goldhahn J, Lewiecki EM, Lyritis GP, Marsh D, Obrant K, Silverman S, Siris E, Akesson K; for the CSA Fracture Working Group of the International Osteoporosis Foundation. Balloon kyphoplasty and vertebroplasty in the management of vertebral compression fractures. *Osteoporos Int.* 2011 Dec;22(12):2915-34. 2011 Jul 26. [Epub ahead of print]
163. Binkley N, Lewiecki EM. Vitamin D and common sense. *J Clin Densitom.* 2011 Apr-Jun;14(2):95-9.
164. Genant HK, Lewiecki EM, Fuerst T, Fries M. Effect of monthly ibandronate on hip structural geometry in men with low bone density. *Osteoporos Int.* 2012 Jan;23(1):257-265. 2011 Aug 3. [Epub ahead of print]
165. Lewiecki EM, Compston JE, Miller PD, Adachi JD, Adams JE, Leslie WD, Kanis JA, Moayyeri A, Adler RA, Hans DB, Kendler DL, Diez-Perez A, Krieg MA, Masri BK, Lorenc RR, Bauer DC, Blake GM, Josse RG, Clark P, Khan AA; FRAX(®) Position Development Conference Members. Official Positions for FRAX(®) Bone Mineral Density and FRAX(®) Simplification From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). *J Clin Densitom.* 2011 Jul-Sep;14(3):226-236.
166. Lewiecki EM, Compston JE, Miller PD, Adachi JD, Adams JE, Leslie WD, Kanis JA; FRAX(®) Position Development Conference Members. FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. *J Clin Densitom.* 2011 Jul-Sep;14(3):223-225.

167. Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Cooper C, Dawson-Hughes B, El-Hajj Fuleihan G, Leslie WD, Lewiecki EM, Luckey MM, McCloskey EV, Papapoulos SE, Poiana C, Rizzoli R; FRAX(®) Position Development Conference Members. Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®) Executive Summary of the 2010 Position Development Conference on Interpretation and Use of FRAX(®) in Clinical Practice. *J Clin Densitom.* 2011 Jul-Sep;14(3):171-180.
168. Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR; HORIZON Pivotal Fracture Group. Collaborators (269) Horowitz Z, Orloff J, Black D, Cummings S, Delmas P, Eastell R, Reid I, Boonen S, Cauley J, Cosman F, Lakatos P, Leung PC, Man Z, Lau E, Jasqui S, Mautalen C, Rosario-Jansen T, Caminis J, Eriksen EF, Mesenbrink P, Raisz L, Bauer P, Compston J, DeMets D, Hirschberg R, Johnell O, Ralston S, Wallace R, Farkough M, Flood M, Bauer D, Palermo L, Lang T, Kerzberg E, Man Z, Mautalen C, Ridruejo M, Tate G, Velasco J, Hooper M, Kotowicz M, Nash P, Prince R, Roberts A, Sambrook P, Dobnig H, Finkenstedt G, Hoefle G, Klaushofer K, Pecherstorfer M, Peichl P, Body J, Boonen S, Devogelaer JP, Geusens P, Kaufman J, Brenol J, Kochen J, Lederman R, Radominski S, Szejnfeld V, Zerbini C, Adachi J, Brown J, Choquette D, Hanley D, Josse R, Kendler D, Kremer R, Morin F, Olszynski W, Papaioannou A, KinYuen C, Chen B, Lin S, Casas N, Chalem M, Jaller J, Molina J, Aro H, Heikkinen J, Kröger H, Mäkinen L, Saltevo J, Salmi J, Välimäki M, Benhamou CL, Delmas P, Fardellone P, Werhya G, Allolio B, Felsenberg D, Happ J, Hartard M, Hensen J, Kaps P, Kekow J, Moericke R, Ortloff B, Schneider P, Wassenberg S, Leung PC, Balogh A, Gomor B, Hidvégi T, Koranyi L, Lakatos P, Poór G, Tulassay Z, Pollak RD, Eshed V, Foldes AJ, Ish-Shalom S, Vered I, Weiss M, Adami S, Barone A, Bianchi G, Giannini S, Isaia GC, Luisetto G, Minisola S, Molea N, Nuti R, Ortolani S, Passeri M, Rubinacci A, Seriola B, Sinigaglia L, Choi WH, Kang MI, Kim GS, Kim HS, Kim YK, Lim SK, Son HY, Yoon HK, Abud C, Garcia P, Jasqui S, Ochoa L, Orozco J, Santos J, Reid I, Elle S, Halse J, Høiseth A, Olav H, Røed HI, Skag A, Stakkestad J, Syversen U, Badurski J, Czerwinski E, Lorenc R, Marciniowska-Suchowierska E, Sawicki A, Supronik J, Ailamazyan E, Benevolenskaya L, Dreval A, Dvoretzky L, Dyomina R, Mazurov V, Melnichenko G, Mkrtoumyan A, Orlov-Morozov A, Ostroumova O, Pikhak E, Shemerovskaya T, Shostak N, Skripnikova I, Smetnik V, Tsyrlina E, Usova G, Zalevskaya A, Zazerskaya I, Zotkin E, Ljunggren O, Lofgren J, Palmér M, Saaf M, Stenström M, Hasler P, Lamy O, Lippuner K, Merlin C, Rizzoli R, Theiler R, Tyndall A, Uebelhart D, Chen JF, Chen PQ, Chin LS, Hwang JS, Yang TS, Jirapinyo M, Jirapinyo M, Sattaya R, Sriussadaporn S, Supasin S, Taechakraichana N, Wilawan K, Donnachie H, Eastell R, Fraser W, McLellan A, Reid D, Abruzzo J, Ackerman R, Adler R, Aloia J, Birbara C, Bode B, Bone H, Brandon D, Cauley J, Cosman F, Dionne D, Downs R Jr, Dreyfus J, Elinoff V, Emkey R, Fanciullo J, Fiske D, Genaro P, Gollapudi M, Gordon R, Hennessey J, Howard P, Johnson K, Johnston C, Kagan R, Kafka S, Kaine J, Klein T, Koltun W, Leboff M, Levine B, Lewiecki EM, Lewis CE, Licata A, Lillestol M, Lubin B, Malamet R, Mangione A, Matkovic V,

- Mehta D, Miller P, Miller S, Murphy FT, Natrass S, Podlecki D, Recknor C, Rosen C, Rowe D, Rude R, Schnitzer T, Sherrer Y, Silverman S, Stephenson K, Troupin B, Tucci J, Villareal R, Watts N, Weinstein R, Weinstein R, Weitz M, White R. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. *J Bone Miner Res*. 2011 May;26(5):984-992. doi: 10.1002/jbmr.292.
169. Lewiecki EM. New targets for intervention in the treatment of postmenopausal osteoporosis. *Nat Rev Rheumatol*. 2011 Sep 20;7(11):631-638. 2011 Sep 20. doi: 10.1038/nrrheum.
170. Lewiecki EM. Sclerostin: a novel target for intervention in the treatment of osteoporosis. *Discov Med*. 2011 Oct;12(65):263-273.
171. Moayyeri A, Adams JE, Adler RA, Krieg MA, Hans D, Compston J, Lewiecki EM. Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis. *Osteoporos Int*. 2012;23(1):143-153. 2011 Oct 27. [Epub ahead of print]
172. Lewiecki EM. Unmet needs in the care of postmenopausal osteoporosis. *Am J Pharm Benefits*. 2011;3(4):e77-e84. Available at <http://www.ajpblive.com/articles/Unmet-Needs-in-the-Care-of-Postmenopausal-Osteoporosis>.
173. Lewiecki EM. Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. *Drug, Healthcare and Patient Safety*. 2011;3:79-91. Available at [http://www.dovepress.com/articles.php?article\\_id=8765](http://www.dovepress.com/articles.php?article_id=8765).
174. Lewiecki EM, Bilezikian JP. Denosumab for the Treatment of Osteoporosis and Cancer-Related Conditions. *Clin Pharmacol Ther*. 2012 Jan;91(1):123-133. 2011 Dec 7. doi: 10.1038/clpt.2011.268. [Epub ahead of print]
175. Lewiecki EM, Bilezikian JP, Jankowski LG, McCloskey EV, Miller PD, Morgan SL, Orwoll ES, Potts JT Jr. Proceedings of the 2011 Santa Fe Bone Symposium. *J Clin Densitom*. 2012 Jan-Mar;15(1):1-20.
176. Lewiecki EM. To treat or not to treat: reducing fracture risk in postmenopausal women. *The Female Patient*. 2012;37:11-16.
177. Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS; Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators. Collaborators (16) Yaneva D, Cseuz R, Bagul N, Govindraj S, Abdulhakim E, Sarmiento R, Ellahbadi R, Shaw H, Thomas H, Greenwald M, Kivitz A, Lewiecki M, Aloia J, Gallagher J, Schwartz E, Shergy W. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. *J Bone Miner Res*. 2012 Aug;27(8):1821-9. doi: 10.1002/jbmr.1602.

178. Lewiecki EM, Laster AJ, Miller PD, Bilezikian JP. More bone density testing is needed, not less. *J Bone Miner Res.* 2012 Apr;27(4):739-42. doi: 10.1002/jbmr.1580.
179. McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. *J Bone Miner Res.* 2012 Mar 19. doi: 10.1002/jbmr.1606. [Epub ahead of print]
180. Lewiecki EM, Miller PD, Bilezikian JP. Bone-density testing interval and transition to osteoporosis. *N Engl J Med.* 2012 Apr 19;366(16):1546-7; author reply 1547-8.
181. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT. Benefits and Risks of Bisphosphonate Therapy for Osteoporosis. *J Clin Endocrinol Metab.* 97(7):2272-2282. 2012 Apr 20. [Epub ahead of print]
182. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, Miller PD, Woodson GC 3rd, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA. Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial. *J Clin Endocrinol Metab.* 2012 Aug;97(8):2799-808. doi: 10.1210/jc.2012-1262. Epub 2012 Jun 14. PMID: 22701017.
183. Orwoll E, Tegljbærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren O, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Siddhanti S, Grauer A, Hall JW, Boonen S. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. *J Clin Endocrinol Metab.* 2012 Sep;97(9):3161-3169. doi: 10.1210/jc.2012-1569. Epub 2012 Jun 21. PMID: 22723310.
184. Lewiecki EM, Binkley N. Bone Density Testing Intervals and Common Sense. *Curr Osteoporos Rep.* 2012 Sep;10(3):217-220. doi: 10.1007/s11914-012-0111-6. 2012 Jun 22. [Epub ahead of print]. PMID: 22723124.
185. Lewiecki EM. Preventing Fractures in Diabetic Dialysis Patients. *Int J Endocrinol Metab.* 2012;10(4):640-641. DOI: 10.5812/ijem.5384
186. Lewiecki EM, Miller SA. Suicide affects all of us. *Lancet.* 2012 Jun 23;379(9834):2316-2318. PMID: 22726502.

187. McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. *Osteoporos Int.* 2013 Jan;24(1):227-35. doi: 10.1007/s00198-012-2052-4. Epub 2012 Jul 10.
188. Bilezikian JP, Zerbinì , Lewiecki EM, Borges JL, Miller PD, Hans D, Camargos BM, McClung M. In Memoriam: Sergio Ragi-Eis, MD, CCD, CDT (April 8, 1962 – February 22, 2012). *J Clin Densitometry.* 2012;15(3):257-259.
189. Simon JA, Recknor C, Moffett AH Jr, Adachi JD, Franek E, Lewiecki EM, McClung MR, Mautalen CA, Ragi-Eis S, Nicholson GC, Muschitz C, Nuti R, Törring O, Wang A, Libanati C. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. *Menopause.* 2013 Feb;20(2):130-7. doi: 10.1097/gme.0b013e318267f909. PMID: 23010883
190. Lewiecki EM, Miller SA. Suicide, Guns, and Public Policy. *Am J Public Health.* 2013 Jan;103(1):27-31. doi: 10.2105/AJPH.2012.300964. Epub 2012 Nov 15. 2012 Nov 15. [Epub ahead of print]. PMID: 23153127
191. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM. Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday. *Am J Med.* 2013 Jan;126(1):13-20. doi: 10.1016/j.amjmed.2012.06.023. Epub 2012 Nov 20.
192. Lewiecki EM. Monoclonal antibodies for the treatment of osteoporosis. *Expert Opin Biol Ther.* 2013 Feb;13(2):183-96. doi: 10.1517/14712598.2012.740006. Epub 2012 Dec 19.
193. Lewiecki EM. Imaging Technologies for Assessment of Skeletal Health in Men. *Curr Osteoporos Rep.* 2013 Mar;11(1):1-10. doi: 10.1007/s11914-012-0128-x.
194. Cummings SR, Cosman F, Eastell R, Reid IR, Mehta M, Lewiecki EM. Goal-directed treatment of osteoporosis. *J Bone Miner Res.* 2013 Mar;28(3):433-8. doi: 10.1002/jbmr.1854. PMID: 23300146
195. Lewiecki EM, Cummings SR, Cosman F. Treat-to-target for Osteoporosis: Is Now the Time? *J Clin Endocrinol Metab.* 2013 Mar;98(3):946-53. doi: 10.1210/jc.2012-3680. Epub 2013 Jan 21.
196. Lewiecki EM, Miller PD. Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. *J Clin Densitom.* 2013 Jan-Mar;16(1):28-32. doi: 10.1016/j.jocd.2012.11.013. PMID: 23374738

197. Lewiecki EM, Adler RA, Bilezikian JP, Bouxsein ML, Marcus R, McClung MR, Miller PD, Tanner SB, Randall S. Osteoporosis Update From the 2012 Santa Fe Bone Symposium. *J Clin Densitom.* 2013 Oct-Dec;16(4):584-600. doi: 10.1016/j.jocd.2013.01.001. Epub 2013 Feb 15.
198. Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, Northcutt AR, Kravitz BG, Paul G, Cobitz AR, Nino AJ, Fitzpatrick LA. Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women with Type 2 Diabetes Mellitus. *J Clin Endocrinol Metab.* 2013 Apr;98(4):1519-28. doi: 10.1210/jc.2012-4018. Epub 2013 Feb 28.
199. Orwoll ES, Adler RA, Amin S, Binkley N, Lewiecki EM, Petak SM, Shapses SA, Sinaki M, Watts NB, Sibonga JD. Skeletal health in long-duration astronauts: Nature, assessment and management recommendations from the NASA bone summit. *J Bone Miner Res.* 2013 Jun;28(6):1243-55. doi: 10.1002/jbmr.1948. PMID: 23553962
200. Lewiecki EM. Is it time for physicians to focus on the public health threat of gun violence? *Ann Intern Med.* 2013 Jun 4;158(11):851-2. doi: 10.7326/0003-4819-158-11-201306040-00021.
201. Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C; IOF Fracture Working Group. Collaborators (18) Akesson K, Boonen S, Brandi ML, Cooper C, Dell R, Goemaere S, Goldhahn J, Harvey N, Hough S, Javaid MK, Lewiecki M, Lyritis G, Marsh D, Napoli N, Obrant K, Silverman S, Siris E, Sosa M. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. *Osteoporos Int.* 2013 Aug;24(8):2135-52. doi: 10.1007/s00198-013-2348-z. Epub 2013 Apr 16.
202. Lewiecki EM. Preventing fractures in diabetic dialysis patients. *Int J Endocrinol Metab.* 2012 Fall;10(4):640-1. doi: 10.5812/ijem.5384. Epub 2012 Sep 30.
203. Lewiecki EM. Bone Density Measurement and Assessment of Fracture Risk. *Clin Obstet Gynecol.* 2013 Dec;56(4):667-76. doi: 10.1097/GRF.0b013e3182a8ad7e. Review. PMID: 24022502
204. Lewiecki EM, Miller PD, Harris ST, Bauer DC, Davison KS, Dian L, Hanley DA, McClung MR, Yuen CK, Kendler DL. Understanding and Communicating the Benefits and Risks of Denosumab, Raloxifene, and Teriparatide for the Treatment of Osteoporosis. *J Clin Densitom.* 2014 Oct-Dec;17(4):490-5. doi: 10.1016/j.jocd.2013.09.018. Epub 2013 Oct 25. Review. PMID: 24206867
205. Furst DE, Mandell B, Calabrese LH, Cather JC, Clauw DJ, Deodhar A, Kremer JM, Lewiecki EM, McMahon M, Ritchlin CT. Proceedings of the 5th Annual Perspectives in Rheumatic Diseases. *Semin Arthritis Rheum.* 2013 Dec;43(3):416-9. doi: 10.1016/j.semarthrit.2013.06.002.

206. Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV; Epidemiology and Quality of Life Working Group of IOF. Collaborators: Kanis JA, Cooper C, Adachi J, Borgström F, Clark P, Cummings S, Diaz-Curiel M, Dimai HP, Harvey N, Hilgsmann M, Lau E, Lewiecki M, Lips P, Lorenc R, McCloskey E, Ortolani S, Papioannou A, Silverman S, Sosa M, Szulc P, Yoshimura N. Worldwide uptake of FRAX. *Arch Osteoporos*. 2014 Dec;9(1):166. doi: 10.1007/s11657-013-0166-8. Epub 2014 Jan 14.
207. Sharifi M, Lewiecki EM. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. *Expert Rev Clin Pharmacol*. 2014 May;7(3):281-91. doi: 10.1586/17512433.2014.893819. Epub 2014 Mar 3. Review. PMID: 24580081
208. Lewiecki EM, Bilezikian JP, Bonewald L, Compston JE, Heaney RP, Kiel DP, Miller PD, Schousboe JT. Osteoporosis Update: Proceedings of the 2013 Santa Fe Bone Symposium. *J Clin Densitom*. 2014 Jul-Sep;17(3):330-43. doi: 10.1016/j.jocd.2013.11.006. Epub 2014 Mar 7.
209. Rothman MS, Miller PD, Lewiecki EM, Bilezikian JP. Bone Density Testing: Science, the Media, and Patient Care. *Curr Osteoporos Rep*. 2014 Jun;12(2):227-229. PMID: 24659466
210. Costa AG, Bilezikian JP, Lewiecki EM. Update on romosozumab: a humanized monoclonal antibody to sclerostin. *Expert Opin Biol Ther*. 2014 May;14(5):697-707. doi: 10.1517/14712598.2014.895808. Epub 2014 Mar 25. PMID: 24665957
211. Lewiecki EM. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. *Ther Adv Musculoskelet Dis*. 2014 Apr;6(2):48-57. PMID: 24688605
212. Kleerekoper M, Greenspan SL, Lewiecki EM, Miller PD, Kendler DL, Maricic M, Keaveny TM, Kopperdahl DL, Ruff VA, Wan X, Janos B, Krohn K. Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength. *J Bone Joint Surg Am*. 2014 Jun 4;96(11):e90. [Epub ahead of print]
213. Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, Dempster D, Lewiecki EM, Jian-Min L, Minisola S, Rejnmark L, Silva BC, Walker MD, Bilezikian JP. Current Issues in the Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop. *J Clin Endocrinol Metab*. 2014 Oct;99(10):3580-94. doi: 10.1210/jc.2014-1415. Epub 2014 Aug 27. PMID: 25162667
214. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R. Clinician's Guide to Prevention and Treatment of Osteoporosis. *Osteoporos Int*.



2014 Oct;25(10):2359-81. doi: 10.1007/s00198-014-2794-2. Epub 2014 Aug 15. Erratum in: Osteoporos Int. 2015 Jul;26(7):2045-7. PMID: 25182228

215. Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. *Osteoporos Int.* 2015 Jan;26(1):361-72. doi: 10.1007/s00198-014-2871-6. Epub 2014 Sep 19. PMID: 25236877
216. Langdahl BL, Teglbaerg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Mirza F, Siddhanti S, Orwoll E. A 24-month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. *J Clin Endocrinol Metab.* 2015 Apr;100(4):1335-42. doi: 10.1210/jc.2014-4079. Epub 2015 Jan 21.
217. Zaheer S, LeBoff M, Lewiecki EM. Denosumab for the treatment of osteoporosis. *Expert Opin Drug Metab Toxicol.* 2015 Mar;11(3):461-70. doi: 10.1517/17425255.2015.1000860. Epub 2015 Jan 22. Review. PMID: 25614274
218. Lewiecki EM. Biological therapy: chronicling 15 years of progress. *Expert Opin Biol Ther.* 2015 Feb 2:1-3. [Epub ahead of print] No abstract available. PMID: 25643326
219. Sharifi M, Ereifej L, Lewiecki EM. Sclerostin and skeletal health. *Rev Endocr Metab Disord.* 2015 Jun;16(2):149-56. doi: 10.1007/s11154-015-9311-6. Review. PMID: 25669441
220. Lewiecki EM, Bilezikian JP, Binkley N, Hans D, Krueger D, Miller PD, Oates M, Shane E. Update on osteoporosis from the 2014 Santa Fe Bone symposium. *Endocr Res.* 2015;40(2):106-19. doi: 10.3109/07435800.2015.1005746. Epub 2015 Mar 24. PMID: 25803304
221. Lewiecki EM. Osteoporosis: Clinical Evaluation. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, editors. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. PMID: 25905277
222. Costa AG, Bilezikian JP, Lewiecki EM. The potential use of antisclerostin therapy in chronic kidney disease - mineral and bone disorder. *Curr Opin Nephrol Hypertens.* 2015 Jul;24(4):324-329.
223. Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster JY, Törring O, Kendler DL, Daizadeh NS, Wang A, O'Malley CD, Wagman RB, Libanati C,

- Lewiecki EM. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. *Osteoporos Int*. 2015 Jun 12. [Epub ahead of print]
224. Shah AD, Shoback D, Lewiecki EM. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. *Int J Womens Health*. 2015 Jun 2;7:565-80. doi: 10.2147/IJWH.S73244. eCollection 2015.
225. Lewiecki EM. Secondary fracture prevention via a Fracture Liaison Service. *Womens Health (Lond Engl)*. 2015 Jun;11(3):269-271. doi: 10.2217/whe.15.5. No abstract available. PMID: 26102465
226. Drake MT, Clarke BL, Lewiecki EM. The Pathophysiology and Treatment of Osteoporosis. *Clin Ther*. 2015 Jul 7. pii: S0149-2918(15)00860-7. doi: 10.1016/j.clinthera.2015.06.006. [Epub ahead of print]
227. Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. *Osteoporos Int*. 2015 Jul 23. [Epub ahead of print]
228. Broy SB, Cauley JA, Lewiecki ME, Schousboe JT, Shepherd JA, Leslie WD. Fracture Risk Prediction by Non-BMD DXA Measures: the 2015 ISCD Official Positions Part 1: Hip Geometry. *J Clin Densitom*. 2015 Jul-Sep;18(3):287-308. doi: 10.1016/j.jocd.2015.06.005. PMID: 26277848
229. Lewiecki EM. Firearm-Related Injury and Death in the United States. *Ann Intern Med*. 2015 Aug 18;163(4):323-4. doi: 10.7326/L15-5124-2. No abstract available. PMID: 26280424
230. Byreddy DV, Bouchonville II MF, Lewiecki EM. Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors. *Climacteric*. 2015 Oct 21:1-8. [Epub ahead of print] PMID: 26488130
231. Kendler DL, Bauer DC, Davison KS, Dian L, Hanley DA, Harris ST, McClung MR, Miller PD, Schousboe JT, Yuen CK, Lewiecki EM. Vertebral fractures: clinical importance and management. *Am J Med*. 2016 Feb;129(2):221.e1-10. doi: 10.1016/j.amjmed.2015.09.020. Epub 2015 Oct 30. Review. PMID: 26524708
232. Lewiecki EM, Bouchonville MF 2nd, Chafey DH, Bankhurst A, Arora S. Bone Health ECHO: telementoring to improve osteoporosis care. *Womens Health (Lond Engl)*. 2016 Jan;12(1):79-81. doi: 10.2217/whe.15.97. Epub 2015 Dec 23. PMID: 26696393

233. Lewiecki EM. Clinical Vignettes: Using Non-BMD Measurements in Clinical Practice. *Clinic Rev Bone Miner Metab*. 2015. Epub. DOI 10.1007/s12018-015-9200-2
234. Lewiecki EM, Baron R, Bilezikian JP, Gagel RE, Leonard MB, Leslie WD, McClung MR, Miller PD. Proceedings of the 2015 Santa Fe Bone Symposium: Clinical Applications of Scientific Advances in Osteoporosis and Metabolic Bone Disease. *J Clin Densitom*. 2016 Jan;19(1):102-16. doi: 10.1016/j.jocd.2015.11.003. Epub 2015 Dec 29. Review. PMID: 26750746
235. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao SD, Miller PD, Woodson GC 3rd, Lindsay R, Binkley N, Alam J, Ruff VA, Gallagher ER, Taylor KA. A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women with Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial. *J Bone Miner Res*. 2016 Jul;31(7):1429-39. doi: 10.1002/jbmr.2804. Epub 2016 Mar 8.
236. Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Janos B, Ruff VA. Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study. *J Clin Endocrinol Metab*. 2016 Apr;101(4):1353-63. doi: 10.1210/jc.2015-4181. Epub 2016 Feb 9. PMID: 26859106
237. Lewiecki EM, Binkley N. What we don't know about osteoporosis. *J Endocrinol Invest*. 2016 May;39(5):491-3. doi: 10.1007/s40618-016-0442-8. No abstract available. PMID: 26902997
238. Lewiecki EM, Binkley N, Morgan SL, Shuhart CR, Camargos BM, Carey JJ, Gordon CM, Jankowski LG, Lee JK, Leslie WD, on behalf of the International Society for Clinical Densitometry. Best Practices for Dual-Energy X-ray Absorptiometry Measurement and Reporting: International Society for Clinical Densitometry Guidance. *J Clin Densitom*. 2016 Apr-Jun;19(2):127-40. doi: 10.1016/j.jocd.2016.03.003. Epub 2016 Mar 22. PMID: 27020004
239. Miller CG, Bogado CC, Nino A, Northcutt AR, Yu HJ, Lewiecki EM, Paul G, Cobitz A, Wooddell MJ, Bilezikian JP, Fitzpatrick LA. Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint. *J Clin Densitom*. 2016 Oct;19(4):485-491. doi: 10.1016/j.jocd.2016.02.003. PMID: 27052635.
240. Bandeira L, Lewiecki EM, Bilezikian JP. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. *Expert Opin Drug Metab*

Toxicol. 2016 Jun;12(6):681-9. doi: 10.1080/17425255.2016.1175436. Epub 2016 Apr 18. Review. PMID: 27070719

241. Modi A, Sajjan S, Lewiecki EM, Harris ST, Papadopoulos Weaver J. Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population. *Clin Ther*. 2016 May;38(5):1074-80. doi:10.1016/j.clinthera.2016.03.027. Epub 2016 Apr 21.
242. Blain H, Masud T, Dargent-Molina P, Martin FC, Rosendahl E, van der Velde N, Bousquet J, Benetos A, Cooper C, Kanis JA, Reginster JY, Rizzoli R, Cortet B, Barbagallo M, Dreinhöfer KE, Vellas B, Maggi S, Strandberg T; EUGMS Falls and Fracture Interest Group; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), Osteoporosis Research and Information Group (GRIO), and International osteoporosis Foundation (IOF). Neira Alvarez M, Annweiler C, Bernard PL, Beswetherick N, Bischoff-Ferrari HA, Bloch F, Boddaert J, Bonnefoy M, Bourdel-Marchasson I, Capisizu A, Che H, Gorjão Clara J, Combe B, Delignieres D, Eklund P, Emmelot-Vonk M, Freiburger E, Gouvain JB, Goswami N, Guldmond N, Casas Herrero Á, Joël ME, Björg A, Kemoun G, Kiss I, Kolk H, Kowalski ML, Krajčík Š, Kutsal YG, Lauretani F, Macijauskienė J, Mellingsæter M, Mourey F, Nourashemi F, Nyakas C, Puisieux F, Rambourg P, González Ramírez A, Rapp K, Rolland Y, Ryg J, Sahota O, Snoeijs S, Stephan Y, Thomas E, Todd C, Trembl J, Adachi R, Agnusdei D, Body JJ, Bruyère O, Burckardt P, Cannata-Andia JB, Carey J, Chan DC, Chevalley T, Cohen-Solal M, Dawson-Hughes B, Dennison EM, Devogelaer JP, Fardellone P, Féron JM, Diez Perez A, Felsenberg D, Glueer C, Harvey N, Hiligsmann M, Javaid MK, Jörgensen NR, Kendler D, Kraenzlin M, Leslie WD, Lewiecki EM, Nakamura T, Papaioannou A, Roux C, Silverman S, Henriquez MS, Thomas T, Vasikaran S, Watts NB, Weryha G, Bousson V, Breuil V, Chapuis L, Laroche M, Legrand E, Lespessailles E, Morel J. A Comprehensive Fracture Prevention Strategy in Older Adults: The European Union Geriatric Medicine Society (EUGMS) Statement. *J Nutr Health Aging*. 2016;20(6):647-52. doi: 10.1007/s12603-016-0741-y.
243. Lewiecki EM, Boyle JF, Arora S, Bouchonville MF 2nd, Chafey DH. Telementoring: a novel approach to reducing the osteoporosis treatment gap. *Osteoporos Int*. 2017 Jan;28(1):407-411. doi: 10.1007/s00198-016-3708-2. Epub 2016 Jul 20.
244. Borges JLC, Haddad LP, Lewiecki EM. Bone Loss or a Case of Mistaken Gender? *J Clin Exp Orthop*. 2016;2:3. doi: 10.4172/2471-8416.100020
245. Javaid MK, Kyer C, Mitchell PJ, Chana J, Moss C, Edwards MH, McLellan AR, Stenmark J, Pierroz DD, Schneider MC, Kanis JA, Akesson K, Cooper C; IOF Fracture Working Group; EXCO. Collaborators: Brandi M, Chandran M, Chevalley T, Goemaere S, Goldhahn J, Harvey N, Hough S, Lewiecki E, Lyritis G, Napoli N, Silverman S, Sosa M, Dawson-Hughes B, Reginster J, Rizzoli R. Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture® Best Practice Framework tool.

Osteoporos Int. 2015 Nov;26(11):2573-8. doi: 10.1007/s00198-015-3192-0. Epub 2015 Jun 13.

246. Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. *Osteoporos Int.* 2017 Jan;28(1):1-19. doi: 10.1007/s00198-016-3716-2. Epub 2016 Sep 9.
247. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. *Endocr Pract.* 2016 Sep 2;22(Suppl 4):1-42. PMID: 27662240.
248. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. *Endocr Pract.* 2016 Sep 2;22(Suppl 4):1-42. PMID: 27662240
249. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. *N Engl J Med.* 2016 Oct 20;375(16):1532-1543. PMID: 27641143
250. DeFina LF, Leonard D, Willis BL, Barlow CE, Finley CE, Jenkins MR, Pence BC, Zhang Y, Chyu MC, Lewiecki EM, Shen CL. High Cardiorespiratory Fitness Is Associated with Reduced Risk of Low Bone Density in Postmenopausal Women. *J Womens Health (Larchmt).* 2016 Oct;25(10):1073-1080. PMID: 27749191
251. Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer D, Black D, Brown T, Cheung AM, Cody K, Cooper C, Diez-Perez A, Eastell R, Hadji P, Hosoi T, De Beur SJ, Kagan R, Kiel DP, Reid I, Solomon DH, Randall S. Goal-Directed Treatment for Osteoporosis: A Progress Report from the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. *J Bone Miner Res.* 2017 Jan;32(1):3-10. doi: 10.1002/jbmr.3039. Epub 2016 Dec 27. PMID: 27864889.

252. Silverman SL, Adachi JD, Dennison E; International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. Collaborators (24) Abrahamsen B, Adachi J, Borgström F, Bruyère O, Clark P, Cooper C, Dennison E, Diaz Curiel M, Dimai HP, Harvey N, Hiligsmann M, Kanis JA, Lau E, Lips P, Lewiecki EM, Lorenc E, McCloskey E, Papaioannou A, Prieto Alhambra D, Ortolani S, Silverman S, Sosa M, Szulc P, Yoshimura N. Bisphosphonate drug holidays: we reap what we sow. *Osteoporos Int.* 2016 Mar;27(3):849-52. doi: 10.1007/s00198-015-3453-y. Epub 2015 Dec 14. PMID: 26667246.
253. Modi A, Sajjan S, Insinga R, Weaver J, Lewiecki EM, Harris ST. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years. *Osteoporos Int.* 2017 Apr;28(4):1355-1363. doi: 10.1007/s00198-016-3886-y. Epub 2017 Jan 5.
254. Bandeira L, Lewiecki EM, Bilezikian JP. Romosozumab for the treatment of osteoporosis. *Expert Opin Biol Ther.* 2017 Feb;17(2):255-263. doi: 10.1080/14712598.2017.1280455. Review. PMID: 28064540
255. McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. *Osteoporos Int.* 2017 May;28(5):1723-1732. doi: 10.1007/s00198-017-3919-1. Epub 2017 Jan 31. PMID: 28144701
256. Lewiecki EM, Bilezikian JP, Bukata SV, Camacho P, Clarke BL, McClung MR, Miller PD, Shepherd J. Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases. *J Clin Densitom.* 2017 Apr - Jun;20(2):134-152. doi: 10.1016/j.jocd.2017.01.001. Epub 2017 Feb 6.
257. Watts NB, Brown JP, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, Wagman RB, Wang A, Daizadeh NS, Smith S, Bone HG. Safety Observations With Three Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. *J Bone Miner Res.* 2017 Jul;32(7):1481-1485. doi: 10.1002/jbmr.3119. Epub 2017 Apr 3. PMID: 28277603
258. Weaver J, Sajjan S, Lewiecki EM, Harris ST, Marvos P. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture. *J Manag Care Spec Pharm.* 2017 Apr;23(4):461-471. doi: 10.18553/jmcp.2017.23.4.461.
259. Hanley DA, McClung MR, Davison KS, Dian L, Harris ST, Miller PD, Lewiecki EM, Kendler DL; Writing Group for the Western Osteoporosis Alliance. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the balance of benefits and risks of long-term osteoporosis therapies. *Am J Med.* 2017 Jul;130(7):862.e1-862.e7. doi: 10.1016/j.amjmed.2017.03.002. Epub 2017 Mar 27. Review. PMID: 28359721

260. Wright NC, Foster PJ, Mudano AS, Melnick JA, Lewiecki EM, Shergy WJ, Curtis JR, Cutter GR, Danila MI, Kilgore ML, Lewis EC, Morgan SL, Redden DT, Warriner AH, Saag KG. Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study. *Osteoporos Int.* 2017 Aug;28(8):2495-2503. doi: 10.1007/s00198-017-4073-5. Epub 2017 May 24. Erratum in: *Osteoporos Int.* 2017 Aug;28(8):2505. PMID: 28540506
261. Binkley N, Blank RD, Leslie WD, Lewiecki EM, Eisman JA, Bilezikian JP. Osteoporosis in Crisis: It's Time to Focus on Fracture. *J Bone Miner Res.* 2017 Jul;32(7):1391-1394. doi: 10.1002/jbmr.3182. Epub 2017 Jun 15.
262. Weaver J, Sajjan S, Lewiecki EM, Harris ST. Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients. *J Manag Care Spec Pharm.* 2017 Jul;23(7):735-744. doi: 10.18553/jmcp.2017.23.7.735. PMID: 28650253
263. Lewiecki EM. Bone Health TeleECHO for Orthopedists and Rheumatologists. *Ortho & Rheum Open Access* 2017;7(4): 555716. 002 DOI: 10.19080/OROAJ.2017.07.555716. Available online at <https://juniperpublishers.com/oroaj/pdf/OROAJ.MS.ID.555716.pdf>
264. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. *Endocr Pract.* 2016 Sep;22(9):1111-8. doi: 10.4158/EP161435.ESGL. Erratum in: *Endocr Pract.* 2017 Mar;23 (3):383. PMID: 27643923
265. Rothman MS, Lewiecki EM, Miller PD. Bone Density Testing is the Best Way to Monitor Osteoporosis Treatment. *Am J Med.* Oct;130(10):1133-1134. Jul 4. pii: S0002-9343(17)30640-X. doi: 10.1016/j.amjmed.2017.05.044. [Epub ahead of print] No abstract available. PMID: 28687261
266. Shapiro JR, Lewiecki EM. Hypophosphatasia in Adults: Clinical Assessment and Treatment Considerations. *J Bone Miner Res.* 2017 Jul 21. doi: 10.1002/jbmr.3226. [Epub ahead of print] PMID: 28731215
267. Lewiecki EM. Osteoporosis: Treat-to-Target. *Curr Osteoporos Rep.* 2017 Apr;15(2):103-109. doi: 10.1007/s11914-017-0350-7.

268. Borges JLC, de M Miranda IS, Lewiecki EM. The Clinical Utility of Vertebral Fracture Assessment in Predicting Fractures. *J Clin Densitom.* 2017 Jul - Sep;20(3):304-308. doi: 10.1016/j.jocd.2017.06.016. Epub 2017 Jul 18. Review. PMID: 28729044
269. Borges JL, Maia JL, Silva RF, Lewiecki EM. Diagnosing vertebral fractures: missed opportunities. *Rev Bras Reumatol.* 2015 Sep-Oct;55(5):464-7. doi: 10.1016/j.rbr.2014.12.008. Epub 2015 Feb 7. English, Portuguese. PMID: 25772659
270. Lewiecki EM, Diaz Curiel M, Borges JL, Kung A, Brandi ML, Dimai HP. Corrigendum to "New and Emerging Therapies for Osteoporosis". *J Osteoporos.* 2017;2017:4175180. doi: 10.1155/2017/4175180. Epub 2017 Jun 28. PMID: 28744390
271. Lovato C, Lewiecki EM. Emerging Anabolic Agents in the Treatment of Osteoporosis. *Expert Opin Emerg Drugs.* 2017 Sep;22(3):247-257. doi: 10.1080/14728214.2017.1362389. Epub 2017 Aug 4. Review. PMID: 28756709
272. Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Melby TE, Ruff VA. Remodeling- and Modeling-Based Bone Formation with Teriparatide versus Denosumab: A Longitudinal Analysis from Baseline to 3 Months in the AVA Study. *J Bone Miner Res.* 2017 Oct 12. doi: 10.1002/jbmr.3309. [Epub ahead of print] PMID: 29024120
273. Lewiecki EM, Binkley N. DXA: 30 years and counting: Introduction to the 30th anniversary issue. *Bone.* 2017 Nov;104:1-3. doi: 10.1016/j.bone.2016.12.013. Epub 2016 Dec 18.
274. Lewiecki EM, Bilezikian JP, Carey JJ, Dell RM, Gordon CM, Harris ST, McClung MR, Miller PD, Rosenblatt M. Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis. *J Clin Densitom.* 2017 Nov 20. pii: S1094-6950(17)30247-0. doi: 10.1016/j.jocd.2017.10.041. [Epub ahead of print] Review. PMID: 29229501
275. Carey JJ, Lewiecki EM, Blank RD, Shuhart CR, Buehring B. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. *Ann Intern Med.* 2017 Dec 19;167(12):901. doi: 10.7326/L17-0487. No abstract available. PMID: 29255868
276. Lewiecki EM. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. *Ann Intern Med.* 2017 Dec 19;167(12):902. doi: 10.7326/L17-0484. No abstract available. PMID: 29255865



277. Lewiecki EM, Rochelle R, Bouchonville MF 2nd, Chafey DH, Olenginski TP, Arora S. Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis. *J Endocr Soc.* 2017 Nov 6;1(12):1428-1434. doi: 10.1210/js.2017-00361. eCollection 2017 Dec 1. PMID: 29264466
278. Lewiecki EM, Binkley N, Bilezikian JP. Stop the war on DXA! *Ann N Y Acad Sci.* 2018 Apr 29. doi: 10.1111/nyas.13707. [Epub ahead of print]. PMID: 29707801
279. Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C, Milmont CE, Meisner PD, Libanati C, Grauer A. Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. *J Bone Miner Res.* 2018 May 11. doi:10.1002/jbmr.3439. [Epub ahead of print] PMID: 29750828
280. Cipriani C, Pepe J, Minisola S, Lewiecki EM. Adverse effects of media reports on the treatment of osteoporosis. *J Endocrinol Invest.* 2018 May 14. doi: 10.1007/s40618-018-0898-9. [Epub ahead of print] Review. PMID: 29761280
281. Chan DD, Chang LY, Akesson KE, Mitchell P7, Chen CH, Lewiecki EM, Lee JK, Lau TC, Songpatanasilp T, Lee KB, Kim KJ, Chen JF, Huang KE, Gau YL, Chang YF, Ebeling P, Xia W, Yu W0, Suzuki A, Hew FL, Mercado-Asis LB, Chung YS, Tsai KS, Lin GT, Yang RS, Wu CH. Consensus on best practice standards for Fracture Liaison Service in the Asia-Pacific region. *Archives of Osteoporosis.* 2018 May 12;13(1):59. doi: 10.1007/s11657-018-0463-3.
282. Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S. A Phase 3 Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. *J Clin Endocrinol Metab.* 2018 Jun 20. doi: 10.1210/jc.2017-02163. [Epub ahead of print] PMID: 29931216
283. Reginster JY, Hattersley G, Williams GC, Hu MY, Fitzpatrick LA, Lewiecki EM. Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide. *Calcif Tissue Int.* 2018 Jun 27. doi: 10.1007/s00223-018-0450-0. [Epub ahead of print] PMID: 29951742
284. Silverman SL, Siris E, Belazi D, Recknor C, Papaioannou A, Brown JP, Gold DT, Lewiecki EM, Quinn G, Balasubramanian A, Yue S, Stolshek B, Kendler DL. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. *Arch Osteoporos.* 2018 Aug 7;13(1):85. doi: 10.1007/s11657-018-0491-z. PMID: 30088189
285. Miller PD, Bilezikian JP, Lewiecki EM, Watts NB, Carey JJ. To The Editor. *J Bone Miner Res.* 2018 Aug 13. doi: 10.1002/jbmr.3566. [Epub ahead of print] PMID: 30102788

286. Kendler DL, Chines A, Brandi ML, Papapoulos S, Lewiecki EM, Reginster JY, Muñoz Torres M, Wang A, Bone HG. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. *Osteoporos Int.* 2018 Sep 22. doi: 10.1007/s00198-018-4687-2. [Epub ahead of print] PMID: 30244369
287. Lewiecki EM, Bilezikian JP, Giangregorio L, Greenspan SL, Khosla S, Kostenuik P, Krohn K, McClung MR, Miller PD, Pacifici R. Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis. *J Clin Densitom.* 2018 Sep 22. pii: S1094-6950(18)30200-2. doi: 10.1016/j.jocd.2018.09.010. [Epub ahead of print] Review. PMID: 30366683
288. Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT, Halbout P, Jiwa F, Lewiecki EM, Pinto D, Adachi JD, Al-Daghri N, Bruyère O, Chandran M, Cooper C, Harvey NC, Einhorn TA, Kanis JA, Kendler DL, Messina OD, Rizzoli R, Si L, Silverman S. Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. *Osteoporos Int.* 2018 Oct 31. doi: 10.1007/s00198-018-4744-x. [Epub ahead of print] PMID: 30382319
289. Lewiecki EM. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. *Ther Adv Musculoskelet Dis.* 2018 Oct 22;10(11):209-223. doi: 10.1177/1759720X18805759. eCollection 2018 Nov. Review. PMID: 30386439

## Online Peer-reviewed Clinical Reviews

1. Lewiecki EM. Overview of DXA. In: UpToDate. Rose BD (Ed). UpToDate. <http://www.uptodate.com/index.asp>. Wellesley, MA. 2005. 2006. 2007. 2008. 2009. 2010. 2011. 2012. 2013. 2014. 2015. 2016. 2017. 2018.
2. Lewiecki EM. Prevention of osteoporosis. In: UpToDate. Rose BD (Ed). UpToDate. <http://www.uptodate.com/index.asp>. Wellesley, MA. 2005. 2006. 2007. 2008. 2009. 2010. 2011. 2012. 2013. 2014. 2015. 2016. 2017. 2018.
3. Lewiecki EM. Osteoporotic fracture risk assessment. In: UpToDate. Rose BD (Ed). UpToDate. <http://www.uptodate.com/index.asp>. Wellesley, MA. 2007. 2008. 2009. 2010. 2011. 2012. 2013. 2014. 2015. 2016. 2017. 2018.
4. Lewiecki EM. Osteoporosis. In: ACP's PIER: Physicians' Information and Educational Resource. <http://pier.acponline.org/index.html>. 2006. 2007. 2008. 2009. 2010. 2011. 2012. 2013.
5. Lewiecki EM. Osteoporosis: Clinical evaluation. In ENDOTEXT at: <http://www.endotext.org>. Published by MDText.com, South Dartmouth, MA 02728. 2010. 2011. 2012. 2013. 2014. 2015. 2016. 2017.

## Books

1. Lewiecki EM. *Mike's Manual: A Clinician's Guide to the Management of Osteoporosis*. Editions 1-6. Copyright © 1998, 1999, 2000, 2001, 2002, 2003. Published by New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM.
2. Hamdy RC, Lewiecki EM. *Osteoporosis*. Oxford University Press. Oxford, UK, and New York City, NY. 2013.

## Book Chapters

1. Lewiecki EM, Miller PD. Bone density and fracture risk in primary hyperparathyroidism. Chapter 13 in *Handbook of Parathyroid Diseases: A Case-based Practical Guide*. Khan AA, Clark OH (eds). DOI 10.1007/978-1-4614-2164-1\_13. Springer Science+Business Media, LLC. 2012.
2. Lewiecki EM. Monitoring therapy for osteoporosis. Chapter 15 in *Osteoporosis: Diagnosis and Management*. Stovall D (ed). ISBN: 978-1-119-96891-7. Wiley-Blackwell. Oxford, UK. A John Wiley & Sons, Ltd. 2013.
3. Lewiecki EM. Evaluation of the patient with or at risk for osteoporosis. Chapter 68, pages 1481-1504, in *Osteoporosis*. Fourth Edition. Marcus R, Feldman D, Dempster DW, Luckey M, Cauley JA (eds). Elsevier Inc. 2013.
4. Lewiecki EM. Bone density measurement and assessment of fracture risk. In *Clinical Obstetrics and Gynecology*. Schnatz PF, Landon MB (eds). Wolters Kluwer, Lippincott Williams & Wilkins. 2013;56(4):667-676.
5. Silva BC, Cusano NE, Hans D, Lewiecki EM, Bilezikian JP. Skeletal Imaging in Primary Hyperparathyroidism. In *The Parathyroids, Basic and Clinical Concepts*. Third Edition. John P. Bilezikian JP, MD (ed); Marcus R, Levine MA, Marcocci C, Silverberg SJ, Potts JT, Jr. (assoc eds). Elsevier Academic Press. 2014.
6. Lewiecki EM. Integrated Clinical View on Long-term Management of Patients with Osteoporosis. Chapter 22, pages 309-320, in *Anabolic and Antiresorptive Therapy*. Edited by Stuart L. Silverman and Bo Abrahamsen. ISBN 978-3-319-23639-1. Springer Science+Business Media. New York, NY. 2015.
7. Lewiecki EM, Miller PD, Watts NB. Standard Techniques of Bone Mass Measurement in Adults. Chapter 32. Pages 252-259. In *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, Ninth Edition. Edited by John P. Bilezikian. © 2019 American Society for Bone and Mineral Research. Published 2019 by John Wiley & Sons, Inc. Companion website: [www.wiley.com/go/asbmrprimer](http://www.wiley.com/go/asbmrprimer).

8. Costa AG, Lewiecki EM, Bilezikian JP. Denosumab. Chapter 72. Pages 553-558. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Ninth Edition. Edited by John P. Bilezikian. © 2019 American Society for Bone and Mineral Research. Published 2019 by John Wiley & Sons, Inc. Companion website: [www.wiley.com/go/asbmrprimer](http://www.wiley.com/go/asbmrprimer).
9. Bandeira L, Lewiecki EM. Strontium Ranelate and Calcitonin. Chapter 75. Pages 573-578. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Ninth Edition. Edited by John P. Bilezikian. © 2019 American Society for Bone and Mineral Research. Published 2019 by John Wiley & Sons, Inc. Companion website: [www.wiley.com/go/asbmrprimer](http://www.wiley.com/go/asbmrprimer).

## Monographs and Other Publications in Print

1. Lewiecki EM. Bone density measurement for osteoporosis detection. Hospital Healthcare Europe 2003/2004. The Official HOPE Reference Book. Copyright © 2003. Campden Publishing, Ltd., London, UK. R31-R32.
2. Lewiecki EM. New bone densitometry position statements. The First Messenger. 2004;13(2):15,19.
3. Lewiecki EM. Case study: Fracture risks and individual patient treatment decisions. Osteoporosis Today. 2004;4(3):1-2.
4. Lewiecki EM. Chronic pain, osteoporosis, and bone density testing. Practical Pain Management. 2004;4:12-17.
5. Lewiecki EM. Update on osteoporosis, Sixth International Symposium on Osteoporosis: current status and future directions. Women's Health 2005;1(1):23-25.
6. Binkley N, Lewiecki EM. (Eds). Osteoporosis Management, Part 1: The Role of Bone Densitometry. International Society for Clinical Densitometry. 2005. [monograph]
7. Binkley N, Lewiecki EM. (Eds). Osteoporosis Management, Part 2: Prevention and Treatment. International Society for Clinical Densitometry. 2005. [monograph]
8. Lewiecki EM. Drugs' side effects rarer than fractures. Albuquerque Journal. August 12, 2006.
9. Lewiecki EM. Case studies in osteoporosis: common scenarios and lessons learned. J Musculoskel Med. 2007;24(2):50-59.
10. Lewiecki EM. Alert: CMS reimbursement cuts put osteoporosis care in grave peril. The First Messenger. 2006;15(6):7.
11. Lewiecki EM. Grand rounds with Dr. Michael Lewiecki. Grand Rounds in Oral-Systemic Medicine. 2007;2(2):6-9.
12. Lewiecki EM. Osteoporosis treatment: Defining goals, optimizing strategies. Family Practice News and Internal Medicine News. 2010.
13. Lewiecki EM, Bilezikian JP, Miller PD, Recker RR, Russell RGG. Highlights from the 2009 Santa Fe Bone Symposium. CME Newsletter.
14. Lewiecki EM [contributing medical editor]. Overview of osteoporosis. In Osteoporosis, fracture prevention and therapeutic management edition.

15. Lewiecki EM. Making important clinical decisions in osteoporosis management. *J Musculoskel Med*. 2008;25:11-19.
16. Bilezikian JP, Lewiecki EM, McClung MR, Watts NB. Treatments in osteoporosis and other bone loss conditions: potential role of biologic anti-RANK ligand therapy. *Medical Crossfire*. 2008.
17. Lewiecki EM. Osteoporosis: 9 questions physicians often ask. *Consultant*. July 2008;594-603.
18. Lewiecki EM. Crisis in osteoporosis care. *The Female Patient*. 2009;34(1):17-18.
19. Aguirre LE, Lewiecki EM. Review of zoledronic acid in the treatment of postmenopausal osteoporosis. *Hospital Pharmacy Europe*. 2009;43:45-48.
20. Lewiecki EM. The case for DXA. *The Female Patient*. 2009;34(3):13-14.

## Electronic Educational Publications and Video Programs

1. Lewiecki EM. Assessment of Fracture Risk. *Medscape Ob/Gyn & Women's Health*. 2005;10(1): © Medscape <http://www.medscape.com/viewarticle/506083>.
2. Silverman SL, Zaidi M, Lewiecki EM, Landesberg R. Postmenopausal osteoporosis: putting the risk for osteonecrosis of the jaw into perspective. © Medscape <http://www.medscape.com/viewarticle/552518>. Accessed March 2, 2007.
3. Binkley N, Lewiecki EM, Lyles KW, Saag KG. Modifying Outcomes in Osteoporosis: Bridging the Gap for the Older Adult. American Geriatrics Society, <http://www.americangeriatrics.org/education/2007osteoporosis.shtml>, accessed 10/8/07.
4. Bilezikian JP, Lewiecki EM, Miller PD. Applying Principles to Practice in the Treatment of Osteoporosis. <http://bonedensitycme.com/>, accessed 12/1/07.
5. Lewiecki EM, Petak SM. Managing osteoporosis in primary care. *Therapeutic Insights* [quarterly online newsletter of the American Medical Association]. Spring 2008. <http://www.ama-assn.org/ama/pub/category/17041.html>.
6. Alexander IM, Lewiecki EM. Identification and Treatment of Postmenopausal Osteoporosis. Medscape. <http://www.medscape.com/viewprogram/17528>. Accessed October 28, 2008.
7. Miller PD, Baim S, Lewiecki EM. New frontiers in osteoporosis management. *Expert Insights*. <http://www.expertinsightscme.com/elewiecki.cfm>. Accessed November 18, 2008.
8. Lewiecki EM. Emerging Therapies for the Treatment of Osteoporosis. Medscape. <http://www.medscape.com/viewarticle/583201>. Accessed December 16, 2008.
9. Lewiecki EM. Clinical Insights Based on Proceedings from the ASBMR 31st Annual Meeting. Focus on treatment. <http://www.projectsinknowledge.com/cp/Activity/indexb.cfm?pretestAction=npt&jn=1891&sj=1896.02>. Accessed October 14, 2009.
10. <http://www.livingmedicaltextbook.org/Activity/index.cfm?jn=1892&sj=1892.01&i=O> S. Accessed May 20, 2010.
11. Lewiecki EM [contributing editor]. Monitoring. In *Osteoporosis, fracture prevention and therapeutic management* edition. <http://www.livingmedicaltextbook.org/Activity/index.cfm?jn=1892&sj=1892.06&i=O> S. Accessed May 20, 2010.



12. Lewiecki EM. Balancing the benefits and risks of osteoporosis treatment. WebMD Osteoporosis Exchange. <http://forums.webmd.com/3/osteoporosis-exchange/forum/350?@904.UMUSa45ifbF@>. Accessed May 24, 2010.
13. Lewiecki EM. What a bone density test can do and who should have one. WebMD Osteoporosis Exchange. <http://forums.webmd.com/3/osteoporosis-exchange/forum/306?@69.zNrOaUL0fiZ@>. Accessed May 24, 2010.
14. Lewiecki EM. Perspective on atypical femur fractures associated with bisphosphonate treatment for osteoporosis. ORTHOSuperSite. <http://www.orthosupersite.com/view.aspx?rid=83561>. 2011. Accessed May 17, 2011.
15. Lewiecki EM. Initiating Aggressive Management of Osteoporosis Following Fragility Fracture: An Evidence-Based Guide for Orthopedists. <http://opencme.org/course/initiating-aggressive-management-of-osteoporosis-following-fragility-fracture-evidence-based->. Accessed February 2, 2012.
16. Lewiecki EM, Miller PD. Bone density and fracture risk in primary hyperthyroidism. Chapter in Handbook of Parathyroid Diseases: A case-based practical guide. Khan AA, Clark OH (Eds.). Springer Science+Business Media. Berlin, Germany. 2012. Available online at <http://www.springer.com/medicine/internal/book/978-1-4614-2163-4>. Accessed March 18, 2012.
17. Lewiecki EM, Egol KA, Singer AJ. Collaborative Post Fracture Amangement. Reach MD. Available at <http://www.reachmd.com/cmedetails.aspx?sid=6624>. Accessed November 5, 2012.
18. Lewiecki EM. Osteoporosis treatment gap comes at a high price. Clinical Pharmacist, Vol 9, No 2, online | DOI: 10.1211/CP.2017.20202282. Available at [http://www.pharmaceutical-journal.com/20202282.article?utm\\_campaign=2483\\_PJ\\_weekly\\_roundup&utm\\_medium=email&utm\\_source=Pharmaceutical%20Journal](http://www.pharmaceutical-journal.com/20202282.article?utm_campaign=2483_PJ_weekly_roundup&utm_medium=email&utm_source=Pharmaceutical%20Journal). Accessed February 14, 2017.

## Abstracts

1. Lewiecki EM. Primary plague septicemia: A Case Report and Review of the Literature. American College of Physicians New Mexico Scientific Meeting. December 1-3, 1977. Albuquerque, NM.
2. Lewiecki EM, Bennahum DA. The historical origins of physician reimbursement. American College of Physicians New Mexico Scientific Meeting. December 1-3, 1988. Albuquerque, NM.
3. Lewiecki EM. Osteoporosis prevalence with community-based referrals for bone densitometry. American College of Physicians New Mexico Scientific Meeting. November 19-21, 1998. Albuquerque, NM.
4. Lewiecki EM. Osteoporosis prevalence with community-based referrals for bone densitometry. International Society for Clinical Densitometry Annual Scientific Meeting. January 14-17, 1999. New Orleans, LA.
5. Lewiecki EM, Rosen C, Bockman RS, Vanaman LK, Yates J, Palmisano J, Smith ME. Alendronate 70 mg once weekly and alendronate 10 mg once daily preference study in postmenopausal women with osteoporosis. J Bone Miner Res. 2001;16(Suppl 1):S404.
6. Simon JA, Portman D, Lewiecki EM, Palmisano J, Smith ME, Wang L, Yates J, Vanaman LK. Alendronate 70 mg once weekly and alendronate 10 mg once daily preference study in postmenopausal women with osteoporosis. North American Menopause Society Annual Meeting. October 4-6, 2001. New Orleans, LA.
7. Lewiecki EM. Anticonvulsant bone disease. American College of Physicians – American Society of Internal Medicine New Mexico Scientific Meeting. December 6-8, 2001. Albuquerque, NM.
8. Lewiecki EM, Rudolph LA. Skeletal site selection for bone density testing in elderly women. American College of Physicians – American Society of Internal Medicine New Mexico Scientific Meeting. December 6-8, 2001. Albuquerque, NM.
9. Palmisano J, Lewiecki EM, Rosen C, Bockman RS, Vanaman LK, Smith ME, Wang L, Yates J. Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis, Fifth International Symposium on Clinical Advances in Osteoporosis. March 6-9, 2002. Honolulu, HI.
10. Lewiecki EM, Rudolph LA. Loss of bone density with bisphosphonate therapy for osteoporosis. American College of Physicians – American Society of Internal Medicine New Mexico Scientific Meeting. November 14-16, 2002. Albuquerque, NM.

11. Lewiecki EM, Rudolph LA. Bisphosphonate treatment of osteoporosis in patients with impaired renal function. American College of Physicians – American Society of Internal Medicine New Mexico Scientific Meeting. November 14-16, 2002. Albuquerque, NM.
12. Greenwald L, Bardwell A, Kushner P, Malinak J, Lewiecki M, Rude R, Silverman S, Greenwald M. Format of ultrasound report influences patient compliance with treatment and understanding of risk. *J Bone Miner Res.* 2002;17(Suppl 1):S418.
13. Lewiecki, EM, Rudolph LA. Oral bisphosphonates for treatment of osteoporosis in elderly patients with impaired renal function. *J Bone Miner Res.* 2002;17(Suppl 1):S367.
14. Lewiecki EM, Rudolph LA. How common is loss of bone mineral density in elderly clinical practice patients receiving oral bisphosphonate therapy for osteoporosis? *J Bone Miner Res.* 2002;17(Suppl 1):S367.
15. Palmisano J, Lewiecki EM, Rosen C, Bockman RS, Vanaman LK, Smith ME, Wang L, Thompson D, Yates, J. Preference study of alendronate 70 Mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis. *Osteoporosis Int.* 2002;13(Suppl 3):S43.
16. Lewiecki EM, Rudolph LR, Chavez JR. Changes in healthcare provider attitudes and behavior concerning estrogen therapy for the management of osteoporosis. *J Bone Miner Res.* 2003;18(Suppl 2):S272.
17. Lewiecki EM, Rudolph LR, Chavez JR. Changes in patient perceptions of estrogen therapy for the management of osteoporosis. *J Bone Miner Res.* 2003;18(Suppl 2):S272.
18. Kiebzak GM, Lewiecki EM, Petak SM. Diagnosis of osteoporosis using the ultradistal radius region of interest on the diagnosis of osteoporosis. *J Bone Miner Res.* 2003;18(Suppl 2):S314.
19. Rudolph LA, Lewiecki EM, Kaplan FS. Treatment of fibrodysplasia ossificans progressiva: Case Report and Review of the Literature. *J Bone Miner Res.* 2003;18(Suppl 2):S387.
20. Rudolph LA, Lewiecki EM, Kaplan FS. Treatment of fibrodysplasia ossificans progressiva: Case Report and Review of the Literature. *J Clin Densitom.* 2003;6:194.
21. Kiebzak GM, Lewiecki EM, Petak SM. Impact of using the ultradistal radius region of interest on the diagnosis of osteoporosis. *J Clin Densitom.* 2003;6:184.

22. Lewiecki EM, Miller PD. Precision comparison of two DXA densitometers – Prodigy and Delphi. *J Bone Miner Res.* 2003;18(Suppl 2):S205.
23. Licata AA, Lewiecki EM, Satterwhite JH, Chen P, Misurski DA, Wagman RB. Correlations between early changes in bone turnover markers and bone mineral density response to teriparatide in postmenopausal women with osteoporosis. The Endocrine Society Annual Meeting. New Orleans, LA. 2004.
24. Cohen S, McClung M, Lewiecki M, Bolognese M, Woodson G, Moffett M, Peacock M, Miller P, Lederman S, Holloway DL, Liu T, Bekker PJ. A rapid and profound suppression of bone turnover is seen with AMG 162 SC given every six months in postmenopausal women with low BMD. American College of Rheumatology. San Antonio, TX. 2004.
25. Recker RR, Lewiecki EM, Drezner MK. Monthly oral ibandronate effectively reduces bone resorption in postmenopausal women: 1-year results from the MOBILE study. World Conference of Family Doctors (WONCA/AAFP). October 13-17, 2004. Orlando, FL.
26. McClung MR, Lewiecki EM, Bolognese MA, Woodson G, Moffett A, Peacock M, Miller PD, Lederman S, Chestnut CH, Murphy R, Holloway DL, Bekker PJ. AMG 162 increases bone mineral density (BMD) within 1 month in postmenopausal women with low BMD. *J Bone Miner Res.* 2004;19(Suppl 1):S20.
27. Lewiecki EM, Miller PD, Lorenc R, Hughes C, Bonvoisin B, McClung MR. Oral monthly ibandronate is well tolerated in women with postmenopausal osteoporosis: 1-year results from MOBILE. *J Bone Miner Res.* 2004;19(Suppl 1):S446.
28. McClung M, Kiel D, Lindsay R, Lewiecki EM, Bolognese M, Leary E, Bone H. A 12-month dose-response study of atorvastatin effects on bone in postmenopausal women. *J Bone Miner Res.* 2004;19(Suppl 1):S322.
29. Binkley N, Drezner MK, Krueger D, Lewiecki EM, Miller PD, Shepherd JA, Kiebzak GM. Recalculation of the NHANES database standard deviation improves T-score agreement and reduces osteoporosis prevalence. *J Bone Miner Res.* 2004;19(Suppl 1):S223.
30. Lewiecki EM, Rudolph LA, Kiebzak GM. Evaluation of osteoporosis website quality. *J Clin Densitom.* 2005;8:243.
31. Lewiecki EM, Miller PD. Bone mineral density increases with extended interval ibandronate injection are greater than daily oral ibandronate: 1 year results from DIVA. *J Clin Densitom.* 2005;8:248.

32. Miller PD, Lewiecki EM. Bone mineral density analysis of MOBILE study shows monthly oral ibandronate at least equivalent to daily oral ibandronate. *J Clin Densitom.* 2005;8:247.
33. Adami S, Delmas PD, Prince R, Lewiecki EM, Hughes C, Ward P, Masanauskaite D, Reid DM. Intermittent intravenous ibandronate injections and daily oral ibandronate provide similar decreases in bone resorption: 1-year results from DIVA. *European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.* Rome, Italy. 2005.
34. McClung MR, SB Cohen SB, Lewiecki EM, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Chesnut CH, Lain DD, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Liu T, Bekker PJ, Fitzpatrick LA. AMG 162 increases bone mineral density and decreases bone turnover in postmenopausal women with low bone mass. *European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.* Rome, Italy. 2005.
35. Bolognese MA, Miller PD, Civitelli R, Lewiecki EM. Monthly oral ibandronate is effective and safe in women with postmenopausal osteoporosis (PMO): 1-year results from the MOBILE study. *Endocr Pract.* 2005;11(Suppl 1):44.
36. Lewiecki EM, Johnston CC Jr, Gallagher R, Amonkar MM, Ettinger MP. Oral bisphosphonate adherence is better with once-weekly than once-daily regimens, but remains suboptimal. *Endocr Pract.* 2005;11(Suppl 1):41.
37. Lewiecki EM, Amonkar MM, Bonnicks SL, Ettinger MP, Zaidi M. High usage of concomitant medications among women with postmenopausal osteoporosis. *Endocr Pract.* 2005;11(Suppl 1):40.
38. Lewiecki EM et al. Daily and once-monthly oral ibandronate have similar safety profiles in elderly and younger women: 1-year results from the MOBILE study. *American Geriatrics Society Annual Meeting.* Orlando, FL. 2005.
39. Miller PD, Drezner MK, Lewiecki EM, Bolognese MA. Once-monthly ibandronate is at least as effective as daily dosing: MOBILE 2-year results. *North American Menopause Society Annual Meeting.* San Diego, CA. 2005.
40. Lewiecki EM, Zaidi M, Drezner MK, Recknor C. Intermittent intravenous ibandronate is at least as effective as daily oral ibandronate: 1-year DIVA results. *North American Menopause Society Annual Meeting.* San Diego, CA. 2005.
41. Cohen SB, Lewiecki EM, Zack DJ, Fitzpatrick LA. AMG 162 and parameters of immune function in postmenopausal women. *J Bone Miner Res.* 2005;20(Suppl 1):S295.

42. Recker R, Kendler D, Recknor C, Rooney T, Lewiecki EM, Utian W, Cauley J, Lorraine J, Qu Y, Kulkarni P, Plouffe L, Stock J. Effects of raloxifene or alendronate on fracture risk reduction: results from the EVA (Evista®/alendronate comparison) trial. *J Bone Miner Res.* 2005;20(Suppl 1):S97.
43. McClung M, Siris E, Cummings S, Bone H, Recker R, Delmas P, Zanchetta J, Lewiecki M, Zerbin C, Miller S10, Wolter K, Proulx J, Radecki D, Brunell R. Lasofoxifene increased BMD of the spine and hip and decreased bone turnover markers. *J Bone Miner Res.* 2005;20(Suppl 1):S97.
44. Lewiecki EM, Emkey R, Adami S, Rowell L, Mairon N, Bonvoisin B, Felsenberg D. Once-monthly oral ibandronate is safe and well tolerated in women with postmenopausal osteoporosis: MOBILE 2-year analysis. *J Bone Miner Res.* 2005;20(Suppl 1):S285.
45. Drezner MK, Ste-Marie LG, Nuti R, Benhamou C, Leigh C, Ward P, Masanauskaite D, Lewiecki EM. Safety and tolerability of intravenous ibandronate injections: DIVA 1-year analysis. *J Bone Miner Res.* 2005;20(Suppl 1):S396.
46. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Liu Y, A Wang, Fitzpatrick LA. RANK ligand inhibition with AMG 162 leads to continued increases in bone mineral density (BMD) in postmenopausal women after two years of treatment. *Arthritis Rheum.* 2005;52:4108.
47. Emkey R, Zaidi M, Lewiecki EM, Burdeska A, Mairon N, Hughes C, Eisman J. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study. *American College of Rheumatology Annual Meeting.* 2005.
48. Lewiecki EM, McClung M, Civitelli R. Safety of once-monthly ibandronate in postmenopausal osteoporosis: MOBILE 2-year data. *International Society for Clinical Densitometry Annual Meeting. San Diego, CA.* 2006. *J Clin Densitom.* 2006;9(2):249.
49. Civitelli R, Emkey R, Zaidi M, Lewiecki EM. Safety of intravenous ibandronate injections in Postmenopausal Osteoporosis: DIVA 2-Year Findings. *International Society for Clinical Densitometry Annual Meeting. San Diego, CA.* 2006. *J Clin Densitom.* 2006;9(2):247.
50. Recker R, Lewiecki EM, Miller P, Emkey R. BMD improvements in postmenopausal osteoporosis: MOBILE shows continued superiority of once-monthly ibandronate at 2-years. *International Society for Clinical Densitometry Annual Meeting. San Diego, CA.* 2006. *J Clin Densitom.* 2006;9(2):248.
51. Lewiecki EM, Miller P, Civitelli R, Silverman S. Suppression of bone turnover markers at 3 months maintained at 2 years with once-monthly ibandronate:

- MOBILE 2-year data. International Society for Clinical Densitometry Annual Meeting. San Diego, CA. 2006. *J Clin Densitom.* 2006;9(2):249.
52. Bonnicksen SL, Friend K, Lewiecki EM, Piziak V. Adherence to ibandronate in patients intolerant of alendronate or risedronate: the PRIOR study. International Society for Clinical Densitometry Annual Meeting. San Diego, CA. 2006. *J Clin Densitom.* 2006;9(2):247.
  53. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Liu Y, Wang A, Fitzpatrick LA. Denosumab (AMG 162) Inhibition of RANK Ligand Increases Bone Mineral Density in Postmenopausal Women with Low Bone Mineral Density After Two Years of Treatment. International Society for Clinical Densitometry Annual Meeting. San Diego, CA. 2006. *J Clin Densitom.* 2006;9(2):243.
  54. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Liu Y, Wang A, Fitzpatrick LA. Denosumab (AMG 162) Inhibition of RANK Ligand Increases Bone Mineral Density in Postmenopausal Women After Two Years of Treatment. Sixth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO).Vienna. March 2006. *Osteoporos Int.* 2006;17(Suppl 1):S4.
  55. Miller PD, Lewiecki EM, Liu Y, Zack DJ, Fitzpatrick LA, Cohen SB. Subanalyses and Supplemental Safety of Denosumab (AMG 162) in a Phase 2 Study in Postmenopausal Women with Low Bone Mineral Density (BMD). Sixth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO).Vienna. March 2006. *Osteoporos Int.* 2006;17(Suppl 1):S60.
  56. McClung M, Siris E, Cummings S, Bone H, Recker R, Delmas P, Zanchetta J, Lewiecki M, Zerbin C, Miller S, Wolter K, Proulx J, Radecki D, Brunell R. Lasofoxifene increases the spine and hip BMD and decreases bone turnover markers in postmenopausal women with low or normal BMD. Sixth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO).Vienna. March 2006. *Osteoporos Int.* 2006;17(Suppl 1):S7.
  57. Lewiecki EM, Friend KE, Bolognese M, Zaidi M. Intravenous ibandronate injections in postmenopausal osteoporosis: BMD and serum CTX efficacy at 1 and 2 years from DIVA study. *Endocr Pract.* 2006;12(Suppl 2):42.
  58. Zaidi M, Lewiecki EM, Bolognese MA, Friend KE. Safety and tolerability of intravenous ibandronate: 1- and 2-year data from DIVA study. *Endocr Pract.* 2006;12(Suppl 2):45.
  59. Bolognese MA, Zaidi M, Friend K, Lewiecki EM. Once-monthly ibandronate in postmenopausal osteoporosis: 2-year efficacy and safety data from MOBILE. *Endocr Pract.* 2006;12(Suppl 2):46.

60. Lewiecki EM, Piziak V, Zaidi M, Petak S, Friend K, Gieschke R, Dempster D. Modeling of serum CTX levels with daily and monthly oral ibandronate. *Endocr Pract.* 2006;12(Suppl 2):45.
61. Lewiecki EM, Koltun A, Kornowski A. Patients intolerant to oral alendronate or risedronate prefer intravenous ibandronate over oral dosing. International Osteoporosis Foundation World Congress on Osteoporosis. Toronto, Canada. 2006.
62. Miller PD, Lewiecki EM, Peacock M, Wang A, Fitzpatrick LA. Denosumab (AMG 162) Treatment for two years increases BMD and reduces markers of bone turnover irrespective of baseline weight and BMI. European Calcified Tissue Society Symposium on Calcified Tissues. Prague, Czech Republic. 2006.
63. Watts NB, Lewiecki EM, Miller PD, Bolognese MA, Liu Y, Austin M, Fitzpatrick LA. Percentage of BMD responders with denosumab at 24 months and comparisons to alendronate and placebo. *ENDO.* Boston. 2006.
64. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Liu Y, Wang A, Fitzpatrick LA. The RANK ligand inhibitor denosumab (AMG 162) increases bone mineral density (BMD) in postmenopausal women with low bone mass after 2 years of treatment. European Congress of Rheumatology (EULAR). Amsterdam. 2006.
65. Bianchi G, Sambrook PN, Lewiecki EM, Delmas PD. Low incidence of flu-like illness with intravenous ibandronate injections: DIVA 2-year results. European Congress of Rheumatology (EULAR). Amsterdam. 2006.
66. Fitzpatrick LA, Miller PD, Lewiecki EM, Wang A, Liu Y, Zack DJ, Cohen SB. Denosumab increases BMD over 2 years in postmenopausal women with low BMD with no alterations in measured parameters of immune function. International Conference on Osteoimmunology. Crete, Greece. 2006.
67. Dasic D, Lewiecki EM, Miller PD, Sunyecz S, Emkey R. MOBILE 2-year: efficacy and tolerability of once-monthly ibandronate in postmenopausal osteoporosis. *ACOG.* 2006.
68. Lewiecki EM, Adami S, Bianchi G, Sambrook P, Hughes C, Mairon N, Jonkanski I, Bolognese M. The DIVA study: hip bone density improvements with intermittent intravenous ibandronate injections. *J Bone Miner Res.* 2006;21(Suppl 1):S70.
69. Kendler D, Recker R, Lewiecki EM, Cauley J, Binkley N, Olszynski WP, Lorraine J, Qu Y, Wong M, Plouffe Jr L, Stock JL. Relationships between bone mineral density and breast cancer risk (Gail score) in postmenopausal women with low bone mass or osteoporosis. *J Bone Miner Res.* 2006;21(Suppl 1):S348.



70. Miller P, Simonelli C, Lewiecki EM, Barr CE, Genant H. Significant increases in bone mineral density observed from 1 to 2 years in women with PMO after treatment with monthly oral ibandronate. *J Bone Miner Res.* 2006;21(Suppl 1):S289.
71. Laster A, Bone H, Bonnicks SL, Kornowski A, Lewiecki EM. Interim analysis of PRIOR study of ibandronate in patients intolerant of alendronate or risedronate: intravenous dosing is preferred. *J Bone Miner Res.* 2006;21(Suppl 1):S288.
72. Beck TJ, Miller PD, Lewiecki EM, Felsenberg D, Sun L, Libanati C, Liu Y, Fitzpatrick LA. Denosumab improves the structural geometry of the proximal femur in postmenopausal women with low bone mass. *J Bone Miner Res.* 2006;21(Suppl 1):S71.
73. Lewiecki EM, Binkley N, Petak SM. Impact of DXA quality on patient care: clinician and technologist perceptions. *J Bone Miner Res.* 2006;21(Suppl 1):S354.
74. Faulkner KG, Shepherd JA, Gaither KW, Fan B, Lewiecki EM, Miller PD, Genant HK. Disagreement in hip strength analysis results between GE Lunar and Hologic DXA systems. *J Bone Miner Res.* 2006;21(Suppl 1):S86.
75. Sunyecz J, Lewiecki EM, Emkey R, Barr C, Genant H. Continued improvements in bone mineral density observed from 1 to 2 years after treatment with monthly oral ibandronate. The North American Menopause Society Annual Meeting. Nashville. 2006.
76. Laster A, Martens M, Bonnicks SL, Kornowski A, Lewiecki EM. Interim analysis of the PRIOR study of ibandronate (Boniva) in patients intolerant of alendronate (Fosamax) or risedronate (Actonel): GI symptoms improve with oral and IV ibandronate. American College of Rheumatology Annual Meeting. 2006. *Arth Rheum.* 2006;54(9)(Suppl):S582.
77. Lane N, Genant H, Barr C, Lewiecki EM, Maricic M. Continued increases in bone mineral density in women with postmenopausal osteoporosis following 1 and 2 years of IV ibandronate therapy. American College of Rheumatology Annual Meeting. 2006. *Arth Rheum.* 2006;54(9)(Suppl):S306.
78. Lewiecki EM, Reginster J-Y, Elizondo-Alanis LJ, Neate C, Adami S. Progressive bone density gains with once-monthly oral ibandronate: the MOBILE Study Long-Term Extension. American College of Rheumatology Annual Meeting. 2006. *Arth Rheum.* 2006;54(9)(Suppl):S584.
79. Martens M, Koltun W, Friend K, Lewiecki EM, Silverman S. Interim PRIOR study results: women intolerant of weekly oral bisphosphonates prefer IV ibandronate. ACOG. 2007.

80. Derman R, Lewiecki EM, Harley C, Barr CE, Poston S. Persistence with bisphosphonate therapy is better with monthly ibandronate versus weekly bisphosphonates. AACE Annual Meeting. 2007.
81. Miller PD, Lewiecki EM, Zaidi M, Friend KI. Ibandronate injections demonstrate favorable renal tolerability. AACE Annual Meeting. 2007.
82. Felsenberg D, Miller PD, Lewiecki EM, Libanati C, Liu Y, Beck TJ. Hip structural analysis of the proximal femur in postmenopausal women with low bone mass treated with denosumab. ECCEO. 2007.
83. Lewiecki EM, Bonnicksen SL, Friend K, Laster A. PRIOR study of ibandronate in patients intolerant of alendronate or risedronate: intravenous (I.V.) dosing is preferred. ECCEO. 2007.
84. Laster A, Bonnicksen SL, Friend KE, Lewiecki EM. Intravenous ibandronate is preferred by patients intolerant of alendronate or risedronate: results from the PRIOR study. ECTS. 2007.
85. Miller PD, Lewiecki EM, Felsenberg D, Libanati C, Liu Y, Beck TJ. Effects of denosumab on structural geometry of the proximal femur in postmenopausal women with low bone mass as determined by hip structural analysis. J Clin Densitom. 2007;10(2):200.
86. Miller PD, Lewiecki EM, Kohles J. A pooled analysis demonstrates IV ibandronate injection is associated with a favorable renal safety profile. J Clin Densitom. 2007;10(2):218.
87. Shepherd J, Fan B, Sherman M, Lu Y, Lewiecki EM, Miller PD, Genant H. Precision assessment of the Hologic Apex software. J Clin Densitom. 2007;10(2):209.
88. Kendler D, Lewiecki EM, Zhang J, Robertson S. Strontium health supplements: assessment of tablets by DXA. J Clin Densitom. 2007;10(2):203.
89. Stock JL, Kendler DL, Recker R, Lewiecki EM, Cauley J, Binkley N, Olszynski WP, Lorraine J, Qu Y, Wong M, Plouffe Jr L. Relationships between bone mineral density and breast cancer risk (by Gail model) in postmenopausal women with low bone mass or osteoporosis. J Clin Densitom. 2007;10(2):214.
90. Epstein S, Emkey RD, Lewiecki EM, Recker R, Cosman F, Sedarati F. The first head-to-head comparison of efficacy and safety of once-monthly ibandronate with once-weekly alendronate: rationale and design of the MOTION clinical trial. Osteoporos Int. 2007;18(Suppl 2):S223.

91. Miller PD, Christiansen C, Hoek HC, Kendler DL, Lewiecki EM, Woodson G, Ciesielska M, Chines AA, Constantine G, Delmas PD. Efficacy of bazedoxifene for prevention of postmenopausal osteoporosis: results of a 2-Year, phase III, placebo- and active-controlled study. ASBMR. 2007.
92. Silverman SL, Cramer JA, Sunyecz JA, Sarawate C, Harley C, Blumentals WA, Poston S, Lewiecki EM. Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12 month results from two retrospective databases. ASBMR. 2007.
93. Delmas PD, Lewiecki EM, Ragi-Eis S, Sedarati F, Leigh C, Cosman F. The MOTION study: tolerability of monthly ibandronate and weekly alendronate in women with postmenopausal osteoporosis. ASBMR. 2007.
94. Miller P, Bolognese M, Lewiecki EM, McClung M, Ding B, Liu Y, San Martin J. Effect of denosumab on bone mineral density and bone turnover markers: 48-month results. ASBMR. 2007.
95. Piziak VK, Babbitt AM, Kohles JD, Lewiecki EM. Comparable adherence and improvement in gastrointestinal (GI) tolerability with monthly oral and quarterly intravenous ibandronate in patients who discontinued previous bisphosphonates because of GI intolerance. ASBMR. 2007.
96. Kendler DL, Lewiecki EM, Hage-Moussa R, Robertson ST, Zhang J. Non-pharmaceutical strontium and calcium supplements have inconsistent mineral analyses and DXA imaging analyses. ASBMR. 2007.
97. Recker RR, Delmas PD, Reid I, Boonen S, Halse J, Garcia P, Supronik J, Lewiecki EM, Ochoa L, Miller M, Harti F, Gasser JA, Mesenbrink P, Hu H, Ericksen EF. The effects of zoledronic acid 5 mg once yearly on bone remodeling and structure in osteoporotic women are consistent across age. ASBMR. 2007.
98. Laster A, Bonnicksen SL, Friend KE, Lewiecki EM. Intravenous ibandronate is preferred by patients intolerant of alendronate or risedronate: results from the PRIOR study. ECTS. 2007.
99. Cramer JA, Silverman SL, Sarawate C, Harley C, Blumentals WA, Poston S, Lewiecki EM. Improved persistence at 12 months with monthly bisphosphonate therapy compared to weekly bisphosphonates: results from two retrospective databases. ACR/ARHP. 2007.
100. Lewiecki EM, Recker RR, Sedarati F, Neate C, Miller PD. Bone mineral density gains with monthly oral ibandronate (150mg) and weekly oral alendronate (70mg) after 12 months: results from the MOTION Study. ACR/ARHP. 2007.

101. Lewiecki EM, Sedarati F, Neate C, Lorenc R. The MOBILE study long-term extension: continuing improvements in efficacy with monthly oral ibandronate (150 mg). IBMS. 2007.
102. Lewiecki EM, Pfeilschifter J, Grant R, Neate C, Czerwinski E. Continuing improvements in the efficacy of intravenous ibandronate injection: DIVA study long-term extension. IBMS. 2007.
103. Shepherd JA, Fan B, Sherman M, Lu Y, Lewiecki EM, Miller PD, Genant HK. Precision assessment of the Hologic Apex software. IBMS. 2007.
104. Martens MG, Koltun W, Kohles JD, Lewiecki EM, Silverman SL. PRIOR study results: women intolerant of weekly oral bisphosphonates prefer intravenous ibandronate. ACOG. 2007.
105. Lewiecki EM, Keaveny TM, Genant HK, Engelke K, Enslin MB, Dasic G, Davies RY, Kivitz A. Effects of once-monthly oral ibandronate on lumbar spine bone quality and strength assessed by volumetric quantitative computed tomography and finite element analysis. ISCD. 2008.
106. Kivitz A, Keaveny TM, Genant HK, Fuerst T, Enslin MB, Dasic G, Davies R, Lewiecki EM. Once-monthly oral ibandronate effect on hip bone quality and strength assessed by volumetric quantitative computed tomography and finite element analysis in postmenopausal women with osteoporosis. ISCD. 2008.
107. Carceller P, Dendler DL, Hans D, Lewiecki EM, Baim S, Binkley. Automated software in DXA quality control: retrospective versus real time analysis of daily phantom scans. ISCD. 2008.
108. Miller PD, Christiansen C, Hoek HC, Kendler DL, Lewiecki EM, Woodson G, Ciesielska M, Chines AA, Constantine G, Delmas P. Efficacy of bazedoxifene for the prevention of postmenopausal osteoporosis: results of a 2-year, phase III, placebo- and active-controlled study. ECCEO. 2008.
109. Miller PD, Bolognese M, Lewiecki EM, McClung M, Ding B, Austin M, Liu Y, Libanati C. Evaluation of denosumab in a 48-month randomized, blinded, phase 2 trial. ECCEO. 2008.
110. Lewiecki EM, Miller PD, Christiansen C, Hoek HC, Kendler DL, Woodson G, Ciesielska M, Chines AA, Constantine G, Delmas P. Efficacy of bazedoxifene for the prevention of postmenopausal osteoporosis: results of a 2-year, phase 3, placebo-and active-controlled study. ECTS. 2008.
111. Lewiecki EM, Genant HK, Engelke K, Fuerst T, Fries M, Enslin M, Fitzpatrick LA, Kivitz A. Hip Structural Analysis Based on DXA Data in Women with

Postmenopausal Osteoporosis Receiving Once-Monthly Oral Ibandronate for 12 Months. ASBMR. 2008.

112. Kivitz A, Keaveny TM, Genant HK, Engelke K, Fuerst T, Kopperdahl D, Fries M, Dasic G, Fitzpatrick LA, Lewiecki EM. QCT and FEA Assessment of Proximal Femur Bone Quality and Strength in Women with Postmenopausal Osteoporosis Receiving Once-Monthly Oral Ibandronate for 12 Months. ASBMR. 2008.
113. Wilkes MM, Roberta NJ, Chan WW, Lewiecki EM. Bisphosphonates and Osteoporotic Fractures in Highly Compliant/Persistent Postmenopausal Women. ASBMR. 2008.
114. Woods A, Krueger D, Miller PD, Baim S, Lewiecki EM, Binkley N. Do Different Densitometers, or Use of T-score vs. Z-score, Affect Fracture Risk Estimation? ASBMR. 2008.
115. Kendler D, Miller PD, Christiansen C, Hoek HC, Adachi JD, Lewiecki EM, Woodson G, Ciesielska M, Chines AA, Constantine G, Delmas PD. Efficacy of bazedoxifene for the prevention of postmenopausal osteoporosis: results of a 2-year, phase III, placebo- and active-controlled study. Canadian Rheumatology Association. 2008.
116. Fuerst T, Genant HK, Engelke K, Dasic G, Fries M, Lewiecki EM, Bolognese MA. Sample Size Considerations for Clinical Trials of Antiresorptive Therapies Using Quantitative Computed Tomography. ISCD. 2009.
117. Genant HK, Keaveny TM, Kopperdahl DL, Fuerst T, Engelke K, Dasic G, Fries M, Bolognese MA, Lewiecki EM. Multivariate Correlations between Quantitative Computed Tomography Parameters and Femoral Strength Change over 12 Months in Osteoporotic Postmenopausal Women Receiving Ibandronate or Placebo. ISCD. 2009.
118. Lewiecki EM, Barr C, Dasic G. Ibandronate does not increase risk of atrial fibrillation: results of a pooled analysis. NOF. 2009.
119. Wilkes M, Navickis R, Chan W, Lewiecki EM. Bisphosphonates and osteoporotic fractures in highly compliant/persistent postmenopausal women. NOF. 2009.
120. Genant HK, Keaveny TM, Kopperdahl DL, Fuerst T, Engelke, Dasic G, Fries M, Bolognese MA, Lewiecki EM. Multivariate correlations in femoral strength and QCT bone mineral content in osteoporotic women receiving once-monthly oral ibandronate or placebo. ASBMR. 2009.
121. Miller P, Bolognese M, Lewiecki EM, McClung M, Weinstein R, Ding B, Wagman RB, San Martin J. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 6 year results. ASBMR. 2009.

122. Miller P, Bolognese M, Lewiecki EM, McClung M, Weinstein R, Ding B, Wagman RB, San Martin J. The effects of 6 years of denosumab treatment on bone mineral density and biochemical markers of bone turnover. ACR. 2009.
123. Lewiecki EM. Challenges in the diagnosis and therapy of osteoporosis. Arq Bras Endocrinol Metab. 2009;53(Suppl 7):S800.
124. Lewiecki EM. Clinical impact of low quality bone densitometry exams. Arq Bras Endocrinol Metab. 2009;53(Suppl 7):S801.
125. Miller P, Bolognese M, Lewiecki EM, Weinstein R, Ding B, Wagman RB, San Martin J, McClung M. Six-year safety and efficacy data from denosumab Phase 2 extension study. ISCD-NOF. 2010.
126. Genant HK, Fuerst T, Forero-Schwanhaeuser S, Fries M, Lewiecki EM. Effect of monthly ibandronate on hip structural geometry in men with low bone density. ISCD-NOF. 2010.
127. Miller P, Bolognese M, Lewiecki EM, Weinstein R, Ding B, Wagman RB, San Martin J, McClung M. The effect of denosumab treatment on CTX levels over the dosing interval: data from 6 years of continuous experience. ENDO. 2010.
128. Bilezikian JP, Kravitz BG, Lewiecki EM, Miller CG, Northcutt AR, Paul G, Cobitz A, Nino AJ, Fitzpatrick LA. Effects of Rosiglitazone on Bone: Assessing QCT Parameters in a Mechanistic Study in Postmenopausal Women with Type 2 Diabetes Mellitus. ASBMR. 2010.
129. Wagman RB, Miller P, Bolognese M, Lewiecki EM, McClung M, Weinstein R, Ding B, San Martin J. Effects of 6 years' denosumab treatment on bone density and turnover in postmenopausal women with low bone mass results from a phase 2 clinical trial extension. EULAR. 2010.
130. McCloskey EV, Johansson H, Oden A, Austin A, Siris E, Wang A, Chapurlat R, Lorenc R, Lewiecki EM, Libanati C, Kanis JA. Denosumab reduces the risk of all osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. IOF ECCEO. 2011.
131. McClung M, Lewiecki EM, Bolognese MA, Peacock M, Weinstein R, Ding B, Geller ML, Grauer A, Wagman RB, Miller P. Effects of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: 8-Year Results of a Phase 2 Clinical Trial. ASBMR. 2011.
132. Simon J, Recknor C, Moffet A, Adachi J, Franek E, Lewiecki EM, Mautalen CA, Ragi Eis S, Nicholson GC, Muschitz C, Nuti R, Tørring O, Wang A, Libanati C. Effects of Denosumab on Radius BMD, Strength, and Wrist Fractures: Results

From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Study. ASBMR. 2011.

133. Orwoll E, Teglbjærg CS, Langdahl B, Chapurlat R, Czerwinski E, Kendler DL, Reginster J-Y, Kivitz A, Lewiecki EM, Miller P, Bolognese MA, Bone HG, Ljunggren Ö, Abrahamsen B, Yang Y-C, Grauer A, Libanati C, Hall JW, Boonen S. A Phase 3 Study of the Efficacy and Safety of Denosumab in Men With Low Bone Mineral Density: Design of the ADAMO Trial. ASBMR. 2011.
134. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor C, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, Miller P, Woodson III GC, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA. Skeletal Histomorphometry in Patients On Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: 6-Month Results of a Randomized Clinical Trial. ASBMR. 2011.
135. McClung MR, Lewiecki EM, Bolognese MA, Peacock M, Weinstein RL, Ding B, Geller ML, Grauer A, Wagman RB, Miller PD. Effects of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: 8-Year Results of a Phase 2 Clinical Trial. ACR. 2011.
136. McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Chapurlat R, Lorenc R, Lewiecki M, Libanati C, A Kanis JA. Denosumab reduces the risk of all osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX®. ECCEO. 2011.
137. Moayyeri A, Adams JE, Adler RA, Blake GM, Krieg M-A, Hans D, Compston J, Lewiecki EM. Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis. ECCEO. 2011.
138. Chapurlat R, McCloskey E, Lewiecki M, Kanis J, Johansson H, Oden A, Austin M, Siris E, Wang A, Libanati, Lorenc R. Le denosumab (DMAb) réduit le risque de fractures ostéoporotiques cliniques chez les femmes ménopausées, en particulier celles présentant un risque fracturaire modéré a élevé évalué par FRAX®. SFR (France). 2011.
139. McClung MR, Lewiecki EM, Bolognese MA, Peacock M, Weinstein RL, Ding B, Geller ML, Ho PR, Wagman RB, Miller PD. The Effects of 8 Years of Continuous Denosumab Treatment on Bone Mineral Density and Biochemical Markers of Bone Turnover in a Phase 2 Study. ISCD. 2012.
140. Miller PD, Lewiecki EM, Brandi ML, Adachi JD, Recknor C, Wang A, Hall JW, Boonen S. Efficacy of Denosumab in Increasing Hip Bone Mineral Density in Older Versus Younger Women with Postmenopausal Osteoporosis. ISCD. 2012.
141. Lewiecki EM, Prince RL, Kendler DL, Franek E, Zanchetta J, Zapalowski C, Ferreira I, Wagman RB. Effects of Denosumab on 1/3 Radius Bone Mineral

Density in Postmenopausal Women Across Randomized Controlled Clinical Trials. ISCD. 2012.

142. Boonen S, Miller PD, Lewiecki EM, Brandi ML, Adachi JD, Recknor C, Wang A, Hall JW. Denosumab increases total hip bone mineral density in older women with postmenopausal osteoporosis. ECCEO. 2012.
143. McClung MR, Lewiecki EM, Bolognese MA, Peacock M, Weinstein RL, Ding B, Geller ML, Grauer A, Ho P-R, Wagman RB, Miller PD. Denosumab continues to affect bone mineral density and biochemical markers of bone turnover for up to 8 years: results of a phase 2 extension trial. ECCEO. 2102.
144. Muschitz C, Simon J, Recknor C, Moffet A, Adachi J, Franek E, Lewiecki EM, Mautalen CA, Ragi Eis S, Nicholson GC, Nuti R, Tørring O, Wang A, Libanati C. Wirkung von Denosumab auf BMD und Knochenfestigkeit am Radius sowie die Inzidenz von Radiusfrakturen: Ergebnisse der FREEDOM-Studie. DVO. 2012.
145. Gruntmanis U, Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster J-Y, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Yang Y-C, Wagman RB, Siddhanti S, Grauer A, Hall JW, Boonen S. Denosumab for the Treatment of Men With Low Bone Mineral Density. ENDO. 2012.
146. Franek E, Lewiecki EM, Prince RL, Kendler DL, Zanchetta J, Ferreira I, Wagman RB, Zapalowski C. Denosumab Increased Distal Radius Bone Mineral Density in Postmenopausal Women Across Randomized Controlled Clinical Trials. ECTS. 2012.
147. Hall JW, Miller PD, Lewiecki EM, Brandi ML, Adachi JD, Recknor C, Wang A, Boonen S. The Effects of Denosumab in Increasing Hip Bone Mineral Density in Older Versus Younger Women with Postmenopausal Osteoporosis. AANP. 2012.
148. Hall JW, Gruntmanis U, Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster J-Y, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Yang Y-C1, Wagman RB, Siddhanti S, Grauer A, and Boonen S. Effect of treatment with denosumab on bone mineral density (BMD) in men with low BMD. ANZBMJ. 2012.
149. McClung MR, Devogelaer J-P, Kendler D, Czerwinski E, Ljunggren Ö, Bolognese MA, Bone HG, Lewiecki EM, Miller PD, Gruntmanis U, Smith MR, Yang Y, Wang A, Goessl C, Wagman RB, Hall JW, Boonen S. Effects of Denosumab on Bone Mineral Density and the Bone Resorption Marker sCTX in Men With Low BMD Compared With Men With Prostate Cancer Receiving Androgen Deprivation Therapy and Women With Postmenopausal Osteoporosis. ASBMR. 2012.



150. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao S, Miller PD, Woodson GC III, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA. Differential Effects of Teriparatide and Zoledronic Acid on the Outer and Inner Surfaces of Cortical Bone in Postmenopausal Women with Osteoporosis: Results from the SHOTZ Trial. *ASBMR*. 2012.
151. Wright NC, Oliveira A, Warriner AH, Curtis JR, Binkley N, Cummings SR, Hochberg MC, LaCroix A, Lewiecki EM, Schousboe JT, Solomon DH, Wallace RB, Saag KG. What are the Most Clinically Relevant and Feasible Pragmatic Osteoporosis Clinical Trial Designs? *ACR*. 2012.
152. Shen CL, Leonard D, Willis B, Wright B, Jenkins M, Pence BC, Zhang Y, Chyu MC, Lewiecki EM, Defina L. Positive association between cardiorespiratory fitness and femoral neck bone mineral density: Cooper Center Longitudinal Study. *American College of Sports Medicine*. 2012. *Medicine & Science in Sports & Exercise* 2012;45(5S):1140.
153. McClung MR, Devogelaer J-P, Kendler DL, Czerwiński E, Ljunggren Ö, Bolognese MA, Bone HG, Lewiecki EM, Miller PD, Gruntmanis U, Smith MR, Yang Y, Wang A, Goessl C, Wagman RB, Hall JW, Boonen S. Effects of Denosumab in Men with Low Bone Mineral Density (BMD) Compared With Those in Men With Prostate Cancer Receiving Androgen Deprivation Therapy and Women with Postmenopausal Osteoporosis (PMO). *Australian and New Zealand Bone and Mineral Society, Melbourne, Australia; September 8–11, 2013*.
154. Lippuner K, Roux C, Bone HG, Zapalowski C, Minisola S, Franek E, Lakatos P, Kendler D, Lewiecki EM, Mautalen C, Jensen S, Wang A, Daizadeh N, Wagman RB, Boonen S. Low fracture rates maintained with 7 years of denosumab treatment for postmenopausal osteoporosis: results from the first 4 years of the FREEDOM Extension. *Australian and New Zealand Bone and Mineral Society, Melbourne, Australia; September 8–11, 2013*.
155. David Dempster, David L Kendler, Jesse Hall, Steven Boonen, Michael Bolognese, Roland Chapurlat, Stefan Goemaere, Lars Hyldstrup, E Michael Lewiecki, Paul Miller, Yu-Ching Yang, Rachel B Wagman, Bente Langdahl. Effect of Denosumab Treatment on Bone Histology and Histomorphometry in Men With Low Bone Mineral Density. *ASBMR*. 2013.
156. Ferrari S, Adachi JD, Zapalowski C, Miller PD, Reginster J-Y, Törring O, Daizadeh N, Wang A, O'Malley C, Wagman RB, Lewiecki EM. Further Reduction in Nonvertebral Fracture Rate Is Observed Following 3 Years of Denosumab Treatment: Results With Up to 7 Years in the FREEDOM Extension. *ASBMR*. 2013.

157. Papapoulos S, Lippuner K, Roux C, Hall J, Kendler D, Lewiecki EM, Brandi M, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster J-Y, Jensen S, Daizadeh N, Wang A, Geller M, Wagman RB, Bone HG. Eight Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the First Five Years of the FREEDOM Extension. ASBMR. 2013.
158. Chwan-Li Shen, Laura Defina, David Leonard, Benjamin Willis, Beth Wright, Marjorie Jenkins, Barbara C. Pence, Yan Zhang, Ming-Chein Chyu, E. Michael Lewiecki. Association between cardiorespiratory fitness and risk of osteopenia or osteoporosis in women: Cooper Center Longitudinal Study. ASBMR. 2013.
159. David W Dempster, Hua Zhou, Robert R Recker, Jacques P Brown, Michael A Bolognese, Christopher P Recknor, David L Kendler, E Michael Lewiecki, David A Hanley, D Sudhaker Rao, Paul D Miller, Grattan C Woodson III, Robert Lindsay, Neil Binkley, Boris Janos, Jahangir Alam, Fangqiu Zhang, Valerie A Ruff, Kathleen A Taylor. A Longitudinal Study of Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid, the SHOTZ Study. ASBMR. 2013.
160. Lippuner K, Roux C, Bone HG, Zapalowski C, Minisola S, Franek E, Lakatos P, Kendler D, Lewiecki EM, Mautalen C, Jensen S, Wang A, Daizadeh N, Wagman RB, Boonen S. Denosumab Treatment of Postmenopausal Women With Osteoporosis for 7 Years: Clinical Fracture Results From the First 4 Years of the FREEDOM Extension. ESCEO-IOF; Rome, Italy; April 18, 2013.
161. Silverman SL, Siris ES, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Pinzone JJ, Siddhanti S, Stolshek B, Recknor C. Baseline Characteristics and Design of a Prospective Observational Study in the United States and Canada to Evaluate Persistence With Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis. ENDO; San Francisco, CA, USA; June 15-18, 2013.
162. S Ferrari, JD Adachi, K Lippuner, C Zapalowski, PD Miller, J-Y Reginster, O Törring, DL Kendler, N Daizadeh, A Wang, CD O'Malley, RB Wagman, C Libanati, EM Lewiecki. Long-term denosumab therapy further reduces the rate of non-vertebral fractures in women with persisting low hip BMD after 3 years. ECTS. 2014.
163. S Papapoulos, K Lippuner, C Roux, CJF Lin, D Kendler, EM Lewiecki, M Brandi, E Czerwiński, E Franek, P Lakatos, C Mautalen, S Minisola, J-Y Reginster, S Jensen, N Daizadeh, A Wang, M Gavin, RB Wagman, HG Bone. Eight Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the First Five Years of the FREEDOM Extension. ECCEO. 2014.
164. EM Lewiecki, S Papapoulos, K Lippuner, C Roux, CJF Lin, D Kendler, M Brandi, E Czerwiński, E Franek, P Lakatos, C Mautalen, S Minisola, J-Y Reginster, S Jensen, N Daizadeh, A Wang, M Gavin, RB Wagman, HG Bone. Effect of

Denosumab Treatment in Postmenopausal Women With Osteoporosis: Eight-year Results From the FREEDOM Extension, Phase 3 Clinical Trial. ICE/ENDO. 2014.

165. BL Langdahl, CS Teglbjaerg, PR Ho, R Chapurlat, E Czerwinski, DL Kendler, JY Reginster, A Kivitz, EM Lewiecki, PD Miller, MA Bolognese, MR McClung, HG Bone, Ö Ljunggren, B Abrahamsen, U Gruntmanis, YC Yang, RB Wagman, S Siddhanti, E Orwoll. Denosumab for the Treatment of Men With Low Bone Mineral Density: 24-month Results From the ADAMO Trial. ICE/ENDO. 2014.
166. Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Quinn G, Balasubramanian A, Mirza FM, Ho P, Siddhanti S, Stolshek B, Recknor C. Persistence With Prolia® (Denosumab) for 1 Year in Relation to Patient-reported Data: Interim Results From a Prospective Observational Study of Postmenopausal Women With Osteoporosis. ASBMR. 2014.
167. Ferrari S, Libanati C, Lin CFJ, Adami S, Brown JP, Cosman F, Czerwiński E, de Gregório LH, Malouf J, Reginster J-Y, Daizadeh NS, Wang A, Wagman RB, Lewiecki EM, Cummings S. Percentage of Women Achieving Non-osteoporotic BMD T-scores at the Spine and Hip Over 8 Years of Denosumab Treatment. ASBMR. 2014.
168. Lippuner K, Roux C, Papapoulos S, Hall J, Kendler D, Lewiecki EM, Brandi M7, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster J-Y, Jensen S, Daizadeh N, Wang A, Geller M, Wagman RB, Bone HG. Acht Jahre Behandlung mit Denosumab bei postmenopausalen Frauen mit Osteoporose: Ergebnisse der fünf ersten Jahren der FREEDOM Verlängerungsstudie. EULAR. 2014.
169. Roux C, Papapoulos S, Lippuner K, Lin CJF, Kendler D, Lewiecki EM, Brandi M, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster J-Y, Jensen S, Daizadeh N, Wang A, Gavin M, Wagman RB, Bone HG. Effect of Eight Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Five-year Results From the FREEDOM Extension. EULAR. 2014.
170. Ferrari S, Adachi JD, Zapalowski C, Miller PD, Reginster J-Y, Törring O, Daizadeh N, Wang A, O'Malley C, Wagman RB, Lewiecki EM Réduction complémentaire du taux de fractures non vertébrales après 3 ans de traitement par denosumab: résultats jusqu'à 7 ans dans l'extension de FREEDOM. FSR. 2014.
171. Roux C, Papapoulos S, Lippuner K, Hall J, Kendler D, Lewiecki EM, Brandi M, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola, Reginster J-Y, Jensen S, Daizadeh N, Wang A, Geller M, Wagman RB, Bone HG. Traitement par denosumab pendant 8 ans chez des femmes ménopausées ostéoporotiques: résultats des 5 premières années de l'extension de FREEDOM. FSR. 2014.

172. S Papapoulos, K Lippuner, C Roux, CJF Lin, D Kendler, EM Lewiecki, M Brandi, E Czerwiński, E Franek, P Lakatos, C Mautalen, S Minisola, J-Y Reginster, S Jensen, N Daizadeh, A Wang, M Gavin, RB Wagman, Effects of 8 years of denosumab treatment in women with postmenopausal osteoporosis: Results from the first 5 years of the FREEDOM extension ANZSGM Annual Scientific Meeting, Melbourne, 28-30 May, 2014.
173. S Ferrari, C Libanati, CJF Lin, S Adami, JP Brown, F Cosman, E Czerwiński, LH de Gregório, J Malouf, J-Y Reginster, NS Daizadeh, A Wang, RB Wagman, EM Lewiecki, S Cummings. Percentage of Women Achieving Non-osteoporotic BMD T-scores at the Spine and Hip Over 8 Years of Denosumab Treatment. ACR. 2014.
174. Fan B, EM Lewiecki, P Miller, HK Genant, JA Shepherd. TBS Precision and Accuracy Comparison between the Hologic and GE-Lunar DXA Systems. IBDW. Hong Kong. 2014.
175. NB Watts, JP Brown, S Papapoulos, EM Lewiecki, DL Kendler, P Dakin, RB Wagman, A Wang, NS Daizadeh, S Smith, HG Bone. Safety Observations With Three Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Pivotal 3-year Trial and Subjects Who Crossed Over to Denosumab During the Extension. ACR. 2015.
176. S Ferrari, C Libanati, CJF Lin, S Adami, JP Brown, F Cosman, E Czerwiński, LH de Gregório, J Malouf, J-Y Reginster, NS Daizadeh, A Wang, RB Wagman, EM Lewiecki. Relationship Between Total Hip BMD T-score and Incidence of Nonvertebral Fracture With up to 8 Years of Denosumab Treatment. ACR. 2015.
177. Kenneth G. Saag, Peter Alexandersen, Claude-Laurent Benhamou, Nigel Gilchrist, Johan Halse, E. Michael Lewiecki, Kurt Lippuner, Michael McClung, Masataka Shiraki, Carolyn A. DaSilva, Nadia Verbruggen, Boyd B. Scott, Antonio Lombardi. Efficacy of Odanacatib in Postmenopausal Women With Osteoporosis: Subgroup Analyses of Data From the Phase 3 Long-Term Odanacatib Fracture Trial. ACR. 2015.
178. David W. Dempster, Hua Zhou, Robert R. Recker, Jacques P. Brown, Christopher P. Recknor, E. Michael Lewiecki, Paul D. Miller, Sudhaker D. Rao, David L. Kendler, John H. Krege, Jahangir Alam, Kathleen A. Taylor, Boris Janos, Valerie A. Ruff. Anabolism Versus Antiresorption (AVA Study): A Comparison of the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women with Osteoporosis Using Quadruple Labeled Histomorphometry. ASBMR. 2015.
179. S Ferrari, C Libanati, CJF Lin, S Adami, JP Brown, F Cosman, E Czerwiński, LH de Gregório, J Malouf, J-Y Reginster, NS Daizadeh, A Wang, RB Wagman, EM Lewiecki. Relationship Between Total Hip BMD T-score and Incidence of

Nonvertebral Fracture With up to 8 Years of Denosumab Treatment. ASBMR. 2015.

180. NB Watts, JP Brown, S Papapoulos, EM Lewiecki, DL Kendler, P Dakin, RB Wagman, A Wang, NS Daizadeh, S Smith, HG Bone. Safety Observations With Three Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During FREEDOM and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. ASBMR. 2015.
181. Kenneth G. Saag, Peter Alexandersen, Claude-Laurent Benhamou, Nigel Gilchrist, Johan Halse, E. Michael Lewiecki, Kurt Lippuner, Michael McClung, Masataka Shiraki, Carolyn A. DaSilva, Nadia Verbruggen, Boyd B. Scott, Antonio Lombardi. Efficacy of Odanacatib in Postmenopausal Women With Osteoporosis: Subgroup Analyses of Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT). ASBMR. 2015.
182. DL Kendler, SL Silverman, E Siris, JP Brown, DT Gold, EM Lewiecki, C Simonelli, G Quinn, S Yue, B Stolshek, C Recknor. Effect of Denosumab on BMD Outcomes in Persistent Patients in a Prospective Observational Study. ASBMR. 2015.
183. SL Silverman, E Siris, DL Kendler, D Belazi, JP Brown, DT Gold, EM Lewiecki, A Papaioannou, C Simonelli, G Quinn, S Yue, LI Cheng, B Stolshek, C Recknor. Factors Affecting Persistence With Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis: Results From a Prospective Observational Study. ASBMR. 2015.
184. S Papapoulos, C Roux, HG Bone, P Dakin, E Czerwiński, D Frey, D Kendler, EM Lewiecki, J Malouf, D Mellström, J Y Reginster, H Resch, N Daizadeh, A Wang, M Gavin, RB Wagman, ML Brandi. Denosumab Treatment in Postmenopausal Women With Osteoporosis for up to 9 Years: Results Through Year 6 of the FREEDOM Extension. ECCEO-IOF. 2015.
185. Paul Miller, Gary Hattersley, Michael Lewiecki, Edith Lau, Peter Alexandersen, Tomas Hala, Sorica Mustatea, Bettina Storgaard Nedergaard, Annesofie Krogsaa, Jan Slesinger, Cristiano A F Zerbini, Ivo Valter, Zydrune Visockiene, Beata Jendrych, Alan G Harris, Gregory C Williams, Ming-yi Hu, Dennis Black, Luis A Russo. Treatment with Abaloparatide Significantly Reduces Wrist Fractures Compared to Teriparatide - Results of the Phase 3 ACTIVE Trial. ECTS. 2015.
186. EM Lewiecki, S Horlait, T Blicharski, S Goemaere, K Lippuner, P Meisner, PD Miller, A Miyauchi, J Maddox, N Daizadeh, A Grauer. Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men With Osteoporosis. ACR. 2016.
187. DL Kendler, A Chines, ML Brandi, S Papapoulos, EM Lewiecki, J-Y Reginster, M Muñoz Torres, A Wang, HG Bone. The Risk of Subsequent Osteoporotic Fractures

Is Decreased in Patients Experiencing Fracture While on Denosumab: Results From the FREEDOM and FREEDOM Extension Studies. ACR. 2016.

188. Ethel Siris, Nicola Pannacciulli, Paul D Miller, E Michael Lewiecki, Roland Chapurlat, Esteban Jódar-Gimeno, Nadia S Daizadeh, Rachel B Wagman, John A Kanis. Denosumab Treatment for 10 Years in Postmenopausal Women With Osteoporosis Was Associated With Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-predicted Probability. ACR. 2016.
189. Daria B. Crittenden, Jonathan D. Adachi, Neil Binkley, Edward Czerwinski, Serge Ferrari, Lorenz C. Hofbauer, Edith Lau, E. Michael Lewiecki, Akimitsu Miyauchi, Cristiano A. F. Zerbini, Cassandra E. Milmont, Li Chen, Judy Maddox, Paul D. Meisner, Cesar Libanati, Andreas Grauer. Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis. ACR. 2016.
190. Jessica Weaver, Shiva Sajjan, E. Michael Lewiecki, and Steven T. Harris. Prevalence and cost of subsequent fractures among US patients with an incident fracture. AMCO. 2016.
191. Ankita Modi, Xiaoqin Yang, E. Michael Lewiecki, Steven T. Harris, Panagiotis Mavros, and Shiva Sajjan. Burden of Osteoporosis Treatment Discontinuation among Senior Women: Analysis of Fractures and Resource Utilization. AMPC. 2016.
192. Jessica Weaver, Shiva Sajjan, E. Michael Lewiecki, and Steven T. Harris. Diagnosis and Treatment of Osteoporosis Before and After Fragility Fractures: A Side-by-Side Analysis of US Commercially Insured and Medicare Advantage Osteoporosis Patients. AMPC. 2016.
193. Jessica Weaver, Shiva Sajjan, E. Michael Lewiecki, and Steven T. Harris. Prevalence and cost of subsequent fractures among US patients with an incident fracture. AMPC. 2016.
194. S Ferrari, C Libanati, CJF Lin, JP Brown, F Cosman, E Czerwiński, LH de Gregório, J Malouf, J-Y Reginster, NS Daizadeh, A Wang, RB Wagman, EM Lewiecki. Relationship Between Total Hip BMD T-score and Incidence of Nonvertebral Fracture With Up to 10 Years of Denosumab Treatment. ANZBMS. 2016.
195. DL Kendler, A Chines, ML Brandi, S Papapoulos, EM Lewiecki, J-Y Reginster, C Roux, M Munoz Torres, A Wang, HG Bone. The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab: Results From the FREEDOM and FREEDOM Extension Studies. ASBMR. 2016.

196. EM Lewiecki, RA Adler, JR Curtis, R Gagel, KG Saag, AJ Singer, E Siris, NC Wright, H Yun, PM Steven. Hip Fractures and Declining DXA Testing: at a Breaking Point? ASBMR. 2016.
197. E. Michael Lewiecki, Matthew F. Bouchonville II, David H. Chafey, Sanjeev Arora. Bone Health ECHO: An Innovative Strategy of Telementoring to Improve Osteoporosis Care in Underserved Communities. ASBMR. 2016.
198. Nicole C. Wright, P. Jeffrey Foster, Amy S. Mudano, Jeffrey R. Curtis, Gary R. Cutter, Maria I. Danila, Meredith L. Kilgore, C. Elizabeth Lewis, Ruth E. McConnell, Joshua A. Melnick, E. Michael Lewiecki, William J. Shergy, Sarah L. Morgan, David T. Redden<sup>1</sup>, Kenneth G. Saag. Improving Feasibility for The Effectiveness of Discontinuing bisphosphonates (EDGE) Trial: A Pilot Study. ASBMR. 2016.
199. Felicia Cosman, Daria B. Crittenden, Jonathan D. Adachi, Neil Binkley, Edward Czerwinski, Serge Ferrari, Lorenz C. Hofbauer, Edith Lau, E. Michael Lewiecki, Akimitsu Miyauchi, Cristiano A. F. Zerbini, Cassandra E. Milmont, Li Chen, Judy Maddox, Paul D. Meisner, Cesar Libanati, Andreas Grauer. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. ASBMR. 2016.
200. Ethel Siris, Nicola Pannacciulli, Paul D Miller, E Michael Lewiecki, Roland Chapurlat, Esteban Jódar-Gimeno, Nadia S Daizadeh, Rachel B Wagman, John A Kanis. Denosumab Treatment for 10 Years in Postmenopausal Women With Osteoporosis Was Associated With Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-predicted Probability. ASBMR. 2016.
201. David W. Dempster, Hua Zhou, Robert R. Recker, Jacques P. Brown, Christopher P. Recknor, E. Michael Lewiecki, Paul D. Miller, Sudhaker D. Rao, David L. Kendler, Robert Lindsay, John H. Krege, Jahangir Alam, Kathleen A. Taylor, Valerie A. Ruff. Longitudinal Changes in Modeling- and Remodeling-Based Bone Formation with an Anabolic vs. an Antiresorptive Agent in the AVA Osteoporosis Study. ASBMR. 2016.
202. EM Lewiecki, D Black, G Hattersley, GC Williams, T Hu, LA Fitzpatrick, J-Y Reginster. Abaloparatide-SC Is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared With Teriparatide. ASBMR. 2016.
203. S Ferrari, S Adami,<sup>2</sup> JP Brown, F Cosman, E Czerwiński, LH de Gregório, J Malouf, J-Y Reginster, NS Daizadeh, A Wang, RB Wagman, EM Lewiecki. Relationship Between Total Hip BMD T-score and Incidence of Nonvertebral Fracture With up to 10 Years of Denosumab (DMAb) Treatment. ECCEO. 2016.
204. Kenneth G. Saag, Peter Alexandersen, Claude-Laurent Benhamou, Nigel Gilchrist, Johan Halse, E. Michael Lewiecki, Kurt Lippuner, Michael McClung, Masataka Shiraki, Carolyn A. DaSilva<sup>1</sup>, Nadia Verbruggen, Boyd B. Scott, and Antonio

- Lombardi. Efficacy of Odanacatib in Postmenopausal Women with Osteoporosis: Subgroup Analyses of Data from the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT). ECTS. 2016.
205. Ankita Modi, Shiva Sajjan, Jessica Weaver, E. Michael Lewiecki, Steven T. Harris. Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population. ESCEO. 2016.
206. Ankita Modi, Shiva Sajjan, Ralph Insinga, Jessica Weaver, Steven T. Harris, E. Michael Lewiecki. Real-world Persistence with Injectable Osteoporosis Therapy. ESCEO. 2016.
207. E. Michael Lewiecki, Matthew F. Bouchonville II, David H. Chafey, Jeannie F. Boyle, Sanjeev Arora. Telementoring with Bone Health ECHO to Improve Osteoporosis Care in Underserved Areas. ISCD. 2016.
208. E. Michael Lewiecki, Matthew Bouchonville, David Chafey, Veronica Apodaca, Rachelle Rochelle. Bone Health ECHO. An Innovative Strategy for Reducing the Osteoporosis Treatment Gap. MetaECHO. 2016.
209. F Cosman, DB Crittenden, JD Adachi, N Binkley, E Czerwinski, S Ferrari, LC Hofbauer, E Lau, EM Lewiecki, A Miyauchi, CAF Zerbini, CE Milmont, L Chen, J Maddox, PD Meisner, C Libanati, A Grauer. Fracture Risk Reduction With Romosozumab: Results of a Phase 3 Study in Postmenopausal Women With Osteoporosis. ESCEO. 2017.
210. J-Y Reginster, DM Black, G Hattersley, G Williams, T Hu, LA Fitzpatrick, EM Lewiecki. Abaloparatide-SC for Postmenopausal Osteoporosis: Analysis of the Number Needed to Treat Compared with Teriparatide. ESCEO. 2017.
211. E Siris, N Pannacciulli, PD Miller, EM Lewiecki, R Chapurlat, E Jódar Gimeno, NS Daizadeh, RB Wagman, JA Kanis. Denosumab Treatment for 10 Years in Postmenopausal Women With Osteoporosis Was Associated With Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-predicted Probability. WCO. 2017.
212. E. Michael Lewiecki, Natalie R. Weiss, Matthew F. Bouchonville II, David H. Chafey, Sanjeev Arora. Bone Health TeleECHO™ Improves Self-Confidence in Managing Patients with Osteoporosis. MetaECHO. 2017.
213. E. Michael Lewiecki, Natalie Weiss, Matthew F. Bouchonville II, David H. Chafey, Sanjeev Arora. Progress Report for 15 Months of Bone Health TeleECHO Clinic: A Strategy to Improve Osteoporosis Care in Underserved Areas. ISCD-NOF. 2017.



214. DL Kendler, A Chines, ML Brandi, S Papapoulos, EM Lewiecki, J-Y Reginster, C Roux, M Munoz Torres, A Wang, HG Bone. The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab: Results From the FREEDOM and FREEDOM Extension Studies. ENDO. 2017.
215. Felicia Cosman, Daria B Crittenden, Serge Ferrari, Aliya Khan, Nancy E Lane, Kurt Lippuner, Toshio Matsumoto, Cassandra E Milmont, Cesar Libanati, and Andreas Grauer. FRAME Study: The Foundation Effect of Rebuilding Bone With One Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. ASBMR. 2017.
216. E Michael Lewiecki, Rajani V Dinavahi, Marise Lazaretti-Castro, Peter R Ebeling, Jonathan D Adachi, Akimitsu Miyauchi, Evelien Gielen, Cassandra E Milmont, Cesar Libanati, Andreas Grauer. Continued Fracture Risk Reduction After 12 Months of Romosozumab Followed by Denosumab Through 36 Months in the Phase 3 FRAME (FRActure study in postmenopausal woMen with ostEoporosis) Extension. ASBMR. 2017.
217. E. Michael Lewiecki, Natalie Weiss, Matthew F. Bouchonville II, David H. Chafey, Sanjeev Arora. Bone Health TeleECHO to Address the Crisis in Osteoporosis Treatment: 18 Month Progress Report. ASBMR. 2017.
218. S Ferrari, PW Butler, DL Kendler, PD Miller, C Roux, AT Wang, RB Wagman, EM Lewiecki. Ten-year Continued Nonvertebral Fracture Reduction in Postmenopausal Osteoporosis With Denosumab Treatment. ASBMR. 2017.
219. E.M. Lewiecki, S.A. Williams, R. Gut. Challenges in Osteoporosis Awareness and Management: Results from a Survey of U.S. Postmenopausal Women. AMCP. 2017.
220. J.Y. Reginster, D.M. Black,<sup>2</sup> G. Hattersley, G. Williams, L.A. Fitzpatrick,<sup>5</sup> E.M. Lewiecki. The Number Needed to Treat to prevent a Fragility Fracture: Comparison of Abaloparatide-SC and Teriparatide. AMCP. 2017.
221. E. Michael Lewiecki, Rajani Dinavahi, Marise Lazaretti-Castro, Peter R. Ebeling, Jonathan D. Adachi, Akimitsu Miyauchi, Evelien Gielen, Cassandra E. Milmont, Cesar Libanati, Andreas Grauer. A Continued Fracture Risk Reduction After 12 Months of Romosozumab Followed by Denosumab Through 36 Months in the Extension of a Phase 3 Fracture Study in Postmenopausal Women With Osteoporosis. ACR. 2017.
222. S Ferrari, PW Butler, DL Kendler, PD Miller, C Roux, AT Wang, RB Wagman, EM Lewiecki. Ten-year Continued Nonvertebral Fracture Reduction in Postmenopausal Osteoporosis With Denosumab Treatment. ACR. 2017.



## CLINICAL TRIALS

### **Osteoporosis and Sarcopenia Trials (Principal Investigator, Unless Otherwise Noted)**

1. A Multi-Center, Open-Label, Randomized, Crossover, Preference Study of Oral Alendronate Sodium 70 mg Once Weekly and 10 mg Once Daily in Postmenopausal Women with Osteoporosis. Merck 164-00. Closed 2001.
2. A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability and Clinical Effects of Twice-Daily Doses of an Oral Calcimimetic Agent (AMG-073) in Subjects With Primary Hyperparathyroidism (PHPT). Amgen 990160 AMG-073. Closed 2001.
3. The Effect of Ortho Tri-Cyclen® on Bone Mineral Density in Pediatric Subjects with Anorexia Nervosa: A Double-Blind, Placebo-Controlled Study. Ortho-McNeil CAPPs-169. Phase 2. Closed 2003.
4. A Prospective and Randomized Controlled Study to Evaluate the Performance of Inflatable Bone Tamps in the Percutaneous Treatment of Painful Osteopenic Vertebral Body Compression Fractures. Kyphon 2000-1. Closed 2001.
5. Safety and efficacy of droloxifene for preventing bone loss in normal early postmenopausal women. Pfizer. 1998-2000. Closed.
6. Osteoporosis prevalence with community-based referral for bone densitometry. Investigator-initiated study. 1998.
7. Loss of bone density with bisphosphonate therapy for osteoporosis. Investigator-initiated study. 2002.
8. Bisphosphonate treatment of osteoporosis in patients with impaired renal function. Investigator-initiated study. 2002.
9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of Oral Alendronate Sodium Once Weekly for the Prevention and Treatment of Glucocorticoid-Induced Bone Loss. Merck 193. Closed 2003.
10. A Study of the Safety & Efficacy of Lasofoxifene for the Prevention of Bone Loss and for Lipid Lowering in Postmenopausal Women at Risk for Osteoporosis. (OPAL). Pfizer A2181003. Closed 2003. [Subinvestigator]
11. Double-Blind, Placebo-Controlled, Dose Ranging Trial to Evaluate the Efficacy of Atorvastatin on Bone Mineral Density and Markers for Bone Turnover in

- Postmenopausal Women with Dyslipidemia and at Risk for Osteoporosis. (BONES). Pfizer A2581049. Closed 2003. [Subinvestigator]
12. Impact of using the ultradistal radius region of interest on the diagnosis of osteoporosis. Investigator-initiated study. 2003. [Subinvestigator]
  13. Changes in patient perceptions of estrogen therapy for the management of osteoporosis. Investigator-initiated study. 2003.
  14. A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Raloxifene on Bone Mineral Density in Postmenopausal Women with Osteoporosis (EFFECT Study – Efficacy of Fosamax® vs. Evista® Comparison Trial. (EFFECT). Merck 189. Closed 2004.
  15. An 18-Month, Double-Blind, Placebo-Controlled, Phase III, Trial with a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women with Postmenopausal Osteoporosis. (TOP). NPS Allelix ALX1-11-93001. Closed 2004.
  16. Evaluation of osteoporosis website quality. Investigator-initiated study. 2004.
  17. Evaluation of precision and correlation of bone density measurements using the GE Lunar Prodigy and Hologic Delphi. GE Healthcare. Closed 2003.
  18. A randomized, double-blind, multicenter, placebo-controlled study to compare the safety and tolerability of an oral buffered solution of Alendronate Sodium 70mg once weekly versus placebo for the treatment of osteoporosis in postmenopausal women. (OASIS). Merck 219-00. Closed 2004.
  19. A Multi-Center, Double Blind, Randomized, Placebo and Raloxifene Controlled Study to Assess Safety and Efficacy Of TSE-424 in the Prevention Of Postmenopausal Osteoporosis. Wyeth 3068A-1. Closed 2004.
  20. Comparison of Raloxifene to Alendronate in Postmenopausal Women with Osteoporosis. (EVA). Lilly H3S-US-GGKO. Phase 4. Closed 2004.
  21. A multinational Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Clinical Trial of the Effects of Tibolone on the incidence of New Vertebral Fractures in Osteoporotic Postmenopausal Women. (LIFT). Organon 32962. Closed 2004.
  22. Diagnostic capabilities using T-scores are comparable between Delphi and Prodigy. Investigator-initiated study. 2004. [Subinvestigator]
  23. An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, fhPTH(1-84), ALX1-11, in Women

with Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001. (OLES). NPS Allelix CL1-11-002. Phase 3.

24. Fracture Incidence Reduction and Safety of TSE-424 Compared to Placebo and Raloxifene in Osteoporotic Postmenopausal Women. Wyeth-Ayerst 3068A1-300-US.
25. A study of the safety and efficacy of lasofoxifene for prevention of bone loss & for lipid lowering in postmenopausal women at risk for osteoporosis. (OPAL). Pfizer A218-1003-5042. Phase 3. Closed 2003.
26. Postmenopausal evaluation and risk-reduction with lasofoxifene. (PEARL). Pfizer A2181002. Phase 3. 2001-2006.
27. A double-blind placebo-controlled trial of the safety, toleration and efficacy of lasofoxifene 0.25 mg/d and raloxifene 60 mg/d for the prevention of bone loss in postmenopausal women. (CORAL). Pfizer A2181030. Phase 3. 2003-xxxx. [Subinvestigator]
28. A multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. (HORIZON-PFT: Pivotal Fracture Trial). Novartis CZOL446H2301. Phase 3. 2001-2006.
29. Skeletal site selection for bone density testing in elderly women. Investigator-initiated study. Self-funded. 2001.
30. A randomized, double-blind, placebo controlled, multi-dose phase 2 study to determine the efficacy, safety and tolerability of AMG 162 in the treatment of postmenopausal women with low bone mineral density. Amgen AMG 162 – 20010223. Phase 2.
31. Randomized, double-blind, parallel groups, multi-center study to compare the efficacy and safety of monthly oral administration of 100 mg and 150 mg ibandronate with 2.5 mg daily oral ibandronate in postmenopausal osteoporosis. (MOBILE). Hoffman La Roche BM16549. Phase 3. 2002-2005.
32. Randomized, double-blind, parallel groups, multicenter study to compare the efficacy and safety of two IV ibandronate dose regimens (2 mg q 2 mo, 3 mg 2 q 3 mo) with 2.5 mg daily oral ibandronate in postmenopausal osteoporosis. (DIVA). Hoffman La Roche BM16550. Phase 3. 2002-2005.
33. Randomized, double-blind, double-dummy, parallel group, multi-center study to compare the efficacy and safety of once monthly oral administration of 150 mg ibandronate with once-weekly oral administration of 70 mg alendronate in

postmenopausal osteoporosis – non-inferiority trial. (MOTION). Hoffman La-Roche MM17385A.

34. Clinical Investigation for Using Pulsed Electromagnetic Fields to Slow or Reverse Progression of Bone Mineral Density Loss in Osteoporotic Patients. Orthofix U10P.
35. A study to evaluate the effects of calcium supplementation on the efficacy and safety of recombinant human parathyroid (ALX1-11) in postmenopausal women with osteoporosis (CAP study). NPS Allelix CL1-11-008. Phase 3. 2003-2005.
36. An open label study of the effect of teriparatide (PTH[1-34]) on bone turnover markers in postmenopausal women with osteoporosis treated previously with risedronate or alendronate. (OPTAMISE). Aventis HMR4003B/4034. Phase 4. 2003-
37. Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast cancer Incidence in Postmenopausal Women with Osteoporosis or with Low Bone Density. (GENERATION). Lilly H4Z-MC-GJAD.
38. A study to evaluate AMG 162 in the treatment of postmenopausal osteoporosis. (FIRST). Amgen AMG 162 – 20030216. Phase 3. 2004-
39. A 2-year, randomized, multi-center, double-blind, placebo controlled study to determine the efficacy and safety of intravenous zoledronic acid 5mg administered either annually at randomization and 12 months, or administered at randomization only in the prevention of bone loss in postmenopausal women with osteopenia. Novartis CZOL446N2312.
40. Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis. Amgen AMG 162 – 20040132. Phase 3.
41. A randomized, placebo-controlled, parallel-groups study to evaluate the effects of 1-year administration of 2MD with or without calcium and vitamin D supplements on bone mineral density, bone biomarkers and calcium metabolism in postmenopausal women with osteopenia. (ROSE). Pfizer A5771001. Phase 2a. 2004-2006.
42. A Long-Term Prospective Observational Study of the Effectiveness, Safety and Tolerability of FORTEO Therapy in the Community Setting. (DANCE). Eli Lilly B3D-US-GHCQ. Phase 4.
43. An open label, multi-center study to determine level of adherence to monthly oral or every 3 month intravenous ibandronate treatment in postmenopausal women with osteoporosis or osteopenia, who are GI intolerant of daily and/or weekly alendronate or risedronate. (PRIOR). Roche ML-18058 A. Phase 3b.

44. Randomized, multicenter, double-blind, double-dummy, parallel group study to determine the efficacy and safety of intravenous zoledronic acid 5 mg annually compared to oral alendronate 70 mg weekly for the treatment of osteoporosis in men. Novartis CZOL446M2308. Phase 3.
45. A 3-year, double-blind extension to CZOL446H2301 to evaluate the long term safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. Novartis CZOL446H2301E1. 2005 –
46. A one year, parallel, placebo-controlled, double-blind, randomized study to assess the effect of monthly 150 mg oral ibandronate dosing versus placebo on bone quality and strength at the proximal femur in women with osteoporosis (IQ Study). GSK BON103593. 2005 –
47. Double-blind, placebo-controlled, randomized, multicenter study to assess the efficacy and safety of oral ibandronate 150 mg once monthly in postmenopausal women with osteopenia. (PREVENTION). Hoffmann-La Roche BA18492. 2005 -
48. A pilot study to assess the adjunctive use of Physio-Stim® to slow or reverse progression of bone mineral density loss in osteoporotic subjects. Orthofix Inc. U2OP. 2005.
49. A double-blind, randomized, placebo- and active-controlled efficacy and safety study of bazedoxifene/conjugated estrogens combinations for prevention of endometrial hyperplasia and prevention of osteoporosis in postmenopausal women. Wyeth Research. 3115A1-304-WW.
50. A one-year, parallel, placebo-controlled, randomized (2:1) double-blind study of one year duration to assess the effect of oral ibandronate 150 mg, once-monthly versus placebo on LS BMD in men with osteoporosis. GSK. BAN105960. 2006.
51. A randomized, double blind, placebo-controlled study to evaluate the effects of alendronate on bone mineral density in perimenopausal women with low bone mineral density. Merck Frosst Canada & Co. Protocol 17841. 2006.
52. A phase 2, double-blind, randomized, placebo-controlled, daily-dose, proof-of-concept study of a vitamin D compound (DP001 soft gel capsules) in postmenopausal women with osteopenia. Deltanoid Pharmaceuticals. 2MD-3H-2B. 2006.
53. A one-year partial double-blinded, randomized, multi-center, multi-national study to assess the effects of combination therapy of annual zoledronic acid (5 mg) and daily subcutaneous teriparatide (20 mcg) on postmenopausal women with severe osteoporosis. Novartis. CZOL446H2409. 2006.

54. An open-label, single-arm extension study to evaluate the long-term safety of denosumab administration in postmenopausal women with low bone mineral density. Amgen. AMG20050233. 2006.
55. A randomized study evaluating the effect on renal function of ibandronate administered as an i.v. bolus injection compared to an i.v. infusion, and alendronate oral administered once weekly, in postmenopausal women with osteoporosis at high risk for renal disease (DIVINE). Roche. BA20341, 2007.
56. An open label, single arm, extension study to evaluate the long term safety and sustained efficacy of Denosumab (AMG 162) in the treatment of postmenopausal osteoporosis. Amgen. AMG200602289. 2007.
57. A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium. Merck. MK018-0822, 2007.
58. The effects of teriparatide on bone microarchitecture as determined by high resolution magnetic resonance imaging topological analysis. Lilly. B3D-US GDHJ. 2007.
59. A 52-week randomized, double-blind, multicenter, mechanistic study with a 24 week open-label follow-up to evaluate the effect of Avandia™ on bone in postmenopausal women with type 2 diabetes mellitus. GSK. AVD111179. 2008.
60. A phase 4, randomized, double-blind, placebo-controlled study of evaluate the effect of pioglitazone compared to placebo on bone metabolism in impaired fasting glucose, postmenopausal women for 1 year of treatment. Takeda. AD4833\_402. 2008.
61. A randomized, double-blind, multiple dose, placebo-controlled, parallel group, 48-week, study of oral recombinant salmon calcitonin compared to calcitonin nasal spray in postmenopausal osteoporotic women. Unigene Laboratories. UGL-OR0801. 2008.
62. A double-blind, randomized, placebo- and active-controlled efficacy and safety study of the effects of bazedoxifene/conjugated estrogens combinations on endometrial hyperplasia and prevention of osteoporosis in postmenopausal women. Wyeth. Phase 3. 3115A1-3307-WW.
63. A randomized, placebo-controlled, multi-dose phase 2 study to determine the efficacy, safety and tolerability of AMG 785 in the treatment of postmenopausal women with low bone mineral density. Amgen. AMG785 20060326. 2009.



64. Skeletal Histomorphometry In Patients On Teriparatide Or Zoledronic Acid Therapy (SHOTZ). Lilly. B3D-US-GHDL. 2009.
65. A Sub-Study To Explore Biomarkers Of Physical Function In The Phase III Randomized, Placebo-Controlled Clinical Trial To Assess The Safety And Efficacy Of Odanacatib (MK-0822) To Reduce The Risk Of Fracture In Osteoporotic Postmenopausal Women Treated With Vitamin D And Calcium. Merck. 0822 Protocol 035-00. 2009.
66. A multi-center, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of denosumab versus placebo in males with low bone mineral density (ADAMO). Amgen. 20080098. 2009.
67. A phase III randomized, placebo-controlled clinical trial to assess the safety and efficacy of odanacatib (MK-0822) in the treatment of men with osteoporosis treated with vitamin D and calcium. Merck. 053-00. 2010.
68. Phase I, randomized, double-blind, placebo-controlled study to evaluate the effect of dexlansoprazole 60 mg delayed release capsules and esomeprazole 40 mg delayed release capsules on bone homeostasis in healthy postmenopausal female subjects. Takeda. TAK-390MR\_104. 2010.
69. Prospective observational study to evaluate persistence with Prolia® (denosumab) in postmenopausal women with osteoporosis in routine clinical practice. Amgen. 20101218. 2011.
70. Psychometric validation of the modified Osteoporosis Assessment Questionnaire (OPAQ) and a short battery of performance measures. Oxford Outcomes. 2011.
71. An open-label, randomized study to estimate the percent change from baseline in lumbar spine bone mineral density after 3 months of AMG 785 administration in postmenopausal women with low bone mineral density previously treated with alendronate. Amgen. 20110253. 2012.
72. A multicenter, international, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of AMG 785 treatment in postmenopausal women with osteoporosis (FRAME). Amgen. 20070337. 2012.
73. A blinded extension to 5 years of a phase 3 randomized, placebo-controlled clinical trial to assess the safety and efficacy of odanacatib (MK-0822) to reduce the risk of fracture in osteoporotic postmenopausal women treated with vitamin D and calcium. Merck. 018-10. 2012.
74. Teriparatide and risedronate in the treatment of patients with severe postmenopausal osteoporosis: comparative effects on vertebral fractures (VERO). Lilly. B3D-EW-GHDW. 2012.

75. Anabolism versus antiresorption: a quadruple-labeling histomorphometry study to compare the mechanism of action of teriparatide and denosumab in postmenopausal women with osteoporosis (AVA). Lilly. B3D-US-GHDV. 2012.
76. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the effects of odanacatib (MK-0822) on bone mineral density (BMD) and overall safety in the treatment of osteoporosis in postmenopausal women previously treated with an oral bisphosphonate. Merck. MK-0822-076-01. 2013.
77. A randomized, double-blind, parallel group, multicenter study of the safety and efficacy of 3 month subcutaneous REG1033 treatment in patients with sarcopenia. Regeneron. 2013.
78. A Multicenter, Double-blind, Randomized Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis. Amgen. Protocol 20120187. 2013.
79. A phase 1, randomized, open-label parallel group study comparing two types of self-injected romosozumab. Amgen. Protocol 20120279. 2014.
80. Effectiveness of Discontinuing bisphosphonates Study: R21 Pilot Study (EDGE). University of Alabama at Birmingham. 2015.
81. Changes in Biochemical Markers of Bone Turnover (serum CTX and P1NP) after initiation of a "Drug Holiday" from Bisphosphonates. National Bone Health Alliance. 2015.
82. A randomized study comparing the effects of PF708 and Forteo in patients with osteoporosis. Pfenex Inc. PF708-301. 2016.
83. A phase 3b, multicenter, placebo-controlled, double-blind, dose-finding study in adult patients with type I, III or IV osteogenesis imperfecta treated with BPS804. Mereo BioPharma. MBPS205. 2017.
84. A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men with Osteoporosis. BA058-05-019. Radius. 2017.

**Other Clinical Trials  
(Co-investigator or Subinvestigator)**

1. A 26-Week Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BRL49653C when Administered Once Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on at Least ½-Maximal Dose ( $\geq 10$  mg/day) of Glyburide. SmithKlineBeecham 49653C/096. Closed 1998.
2. A Placebo and Active Comparator-Controlled, Parallel-Group, 6-Week, Double-Blind Study, Conducted Under In-House Blinding Conditions to Assess the Safety and Efficacy of MK-0966 Versus Ibuprofen in Patients with Osteoarthritis of the Knee or Hip. Merck 033. Closed 1996.
3. A Study to Evaluate the Effect of Lansoprazole 30 mg QD versus Omeprazole 20 mg QD on Relief of Symptoms in Patients with Erosive Reflux Esophagitis. TAP M98-890. Closed 2000.
4. A Second, Double-Blind, Active Comparator-Controlled Extension of a Placebo-Controlled, Double-Blind Study to Assess Safety and Further Define the Clinically Effective Dose Range of Mk-0966 (L-748,731) in Patients with Osteoarthritis of the Knee or Hip. Merck 029. Closed 1996.
5. A Randomized, Double-Blind, Active-Controlled Evaluation of the Antihypertensive Response to Omapatrilat in Subjects Uncontrolled on Calcium-Channel Blocker Therapy. Bristol Myers Squibb CV 137-072. Phase 3b. Closed 2003.
6. A Randomized, Double-Blind, Active-Controlled Evaluation of the Antihypertensive Response to Omapatrilat in Subjects Uncontrolled on Ace Inhibitor Therapy. Bristol Myers Squibb CV 137-073. Phase 3b. Closed 2003.
7. A Study to Compare Lansoprazole to Ranitidine in Patients with Heartburn. TAP M96-548. Closed 1997.
8. A Study to Evaluate the Effects of Lansoprazole 30 mg or 15 mg QD Versus Placebo in Patients with Non-Ulcer Dyspepsia. TAP M97-671. Closed 1999.
9. Study to Evaluate the Effect of EM574 5 mg QID, 10 mg TID, 20 mg BID Versus Placebo in Females with Non-Erosive Gastroesophageal Reflux Disease. TAP M97-032. Closed 1999.
10. A Phase IV, Parallel, Randomized, Double-Blind Study Comparing the Analgesic Efficacy and Safety of Acetaminophen, Naproxen Sodium, Ibuprofen, and Aspirin in Patients with Osteoarthritis. McNeil 93-320. Closed 1996.

11. A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 1- mg Administered Once a Day for 28 Days in the Prevention of Symptomatic Influenza A & B Viral Infections in Community Dwelling High Risk Subjects Aged  $\geq$  12 Years. GlaxoWellcome NAI 30034. Closed.
12. A Randomized, Double-Blind, Multicenter Trial Comparing 10 Days of Oral Therapy With CP-99,219 (200 mg Daily) and 14 Days of Oral Clarithromycin (500 mg BID) for the Treatment of Acute Sinusitis #154-115-5101. Pfizer CP-99,219 and CP-116,517. Closed 1996.
13. A Randomized, Double-Blind, Parallel Trial Comparing Lotrel 5/10 mg Once Daily, Lotrel 5/20 mg Once Daily Amlodipine 5 mg Once Daily, and Amlodipine 10 mg Once Daily in Patients Age 18 – 80 Years With Essential Hypertension Inadequately Controlled With Amlodipine 5 mg Once Daily Followed by a Single-Blind Extension of Lotrel 5/20 mg Once Daily. Novartis 103 M0574V. Closed 1997.
14. Long Term Safety Study of Zileuton Controlled-Release Plus Usual Care Versus Placebo Plus Usual Care in Patient With Asthma. Abbott M96-464. Closed 1997.
15. A Parallel, Double-Blind, Randomized, Single Dose Study, Comparing the Analgesic Efficacy & Safety of Acetaminophen 1000 mg, Naproxen 375 mg, and Placebo in the Treatment of Tension Headache. McNeill 92-206. Closed.
16. A Multi-Center, Randomized Study to Compare the Safety & Efficacy of Oral Levofloxacin with Amoxicillin / Clavulanate Potassium in the Treatment of Acute Sinusitis in Adults. RW Johnson M92-040. Closed.
17. A Double-Blind, Double-Dummy, Multi-Center, Parallel Group Study to Compare the Efficacy & Safety of FACTIVE Given Either as a Single Oral Dose of 640 mg or as 320 mg Once Daily for Three Days Versus Oral Ciprofloxacin 250 mg Twice a Day for Three Days in the Treatment of Uncomplicated Urinary Tract Infections (UTI) in Female Patients. SmikthKlineBeecham SB-265805/053. Closed 1999.
18. A Triple-Blind, Randomized, Parallel, Efficacy Study of Losartan versus Irbesartan in Patients with Mild to Moderate Essential Hypertension. Merck 183-00. Closed 1999.
19. Chronic Asthma and Quality of Life: Comparative Study of Salmeterol versus Current Treatments. BlaxoWellcome SLG-400. Closed.
20. A Phase IV, Parallel, Double-Blind, Randomized, Single Dose Study Comparing the Analgesic Efficacy & Safety of Acetaminophen 1000 mg, Naproxen Sodium 440 mg & Placebo in the Treatment of Tension Headaches. McNeill 93-318. Closed.

21. A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Ariflo (15 mg bid) in Patients with Chronic Obstructive Pulmonary Disease (COPD). SmithKlineBeecham SB 207499/156. Closed 2001.
22. A Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Nabametone 2 G, Celecoxib 400 mg and Ibuprofen 2400 mg Per Day on Blood Pressure Control in Patients with Hypertension Stabilized on Anti-hypertension Therapy. SmithKlineBeecham 14777/259. Closed 2001.
23. A Cost Minimization Comparison of Mibefradil (Posicor) Versus Amlodipine (Norvasc®) For The Treatment of Mild-To-Moderate Hypertension in Actual Practice Settings. Hoffman La-Roche OM 074-002. Closed 1997.
24. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Evaluation of Ranitidine for the Reduction of Severity or Prevention of Meal-Induced Heartburn. GlaxoWellcome RANA 4006. Closed 1997.
25. A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effectiveness and Safety of Migramist<sup>®</sup> (Dihydroergotamine Mesylate Nasal Spray) 2 mg for the Acute Treatment of Migraine Headache With or Without Aura in Migraineur Families. Sandoz DHE-454. Closed.
26. A Randomized Double-Blind, Double-Dummy, Multicenter, Parallel-Group Study to Assess the Efficacy & Safety of Oral SB-265805 320 mg Once Daily for 7 Days versus Oral Levofloxacin 500 mg Once Daily for 7 Days for the Treatment of Acute Exacerbation of Chronic Bronchitis. SmithKlineBeecham 265805/008. Closed 1999.
27. A Randomized Double-Blind, Double-Dummy, Multicenter, Parallel-Group Study to Assess the Efficacy & Safety of SB-265805 320 mg Once Daily versus Cefuroxime 500 mg Plus Clarithromycin for 7 or 14 Days in the Treatment of Bacterial Community Acquired Pneumonia in Adults. SmithKlineBeecham 265805/012. Closed 1999.
28. Comparative Safety and Efficacy of Cefditoren Pivoxil and Clarithromycin in the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis. TAP CEF-97-005. Closed 1999.
29. A 12-Week, Double-Blind, Placebo-Controlled, Randomized Trial of Naprelan 1000 mg QAM and Naprosyn® 500 mg BID in Patients With RA, Continuing to a Nine Month Open Label Trial of Naprelan 1000 mg QAM. Elan 1091002RA. Closed.

30. A Double-Blind 12-Week Study to Compare the Safety and Tolerability of the (st) Enantiomer of Ibuprofen in the Treatment of Pain Due to OA. Sterling Winthrop CHP 94-4. Closed.
31. A Prospective, Double-Blind, Randomized Comparison of Two Treatment Regimens: Losartan Potassium & Losartan / Hydrochlorothiazide versus Amlodipine and Amlodipine / Hydrochlorothiazide in the Treatment of Patients with Mild to Moderate Hypertension. Merck 136-00. Closed.
32. A Study to evaluate the Efficacy of Rosiglitazone (BRL 49653C) on Reduction of Microalbuminuria in Patients With Type 2 Diabetes Mellitus. SmithKlineBeecham BRL49653C. Closed 2002.
33. A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel-Group Study to Assess the Efficacy and Safety of Oral Gemifloxacin (Factive<sup>®</sup>) 320 mg Once Daily for 5 Days versus Oral Levofloxacin 500 mg Once Daily for 7 Days for the Treatment of Acute Exacerbations of Chronic Bronchitis. SmithKlineBeecham 265805/212. Closed 2000.
34. Fosfomycin Tromethamine Versus Nitrofurantoin Monohydrate / Macrocrystals in Uncomplicated Urinary Tract Infections – A Double-Blind Randomized Study. Forest MON-US-03. Closed.
35. A Multi-National, Randomized, Double-Blind, Active-Controlled Study for Evaluation of the Efficacy and Safety of Oral HMR 3647 800 mg Once a Day for 5 Days versus Cefuroxime Axetil 250 mg Twice a Day for 10 Days in the Treatment of Acute Maxillary Sinusitis in Adults. Aventis HMR 3647A/3011. Closed 2000.
36. A Multicenter, Randomized, Double-Blind, Active-Controlled, Comparative Three-Arm Study Evaluation of the Efficacy and Safety of Oral HMR 3647 800 mg Once a Day for 5 Days versus HMR 3647 800 mg Once a Day for 10 Days versus Amoxicillin / Clavulanic Acid 500 / 125 mg Three Times a Day for 10 Days in the Treatment of Acute Maxillary Sinusitis in Adults. Hoechst Marion Roussel HMR 3647A/3005. Closed 1999.
37. A Multicenter, Double-Blind, Active-Controlled, Two-Arm Parallel-Group Study of the Efficacy and Safety of Oral HMR 3647 800 mg Once a Day for 5 Days versus Oral Clarithromycin 250 mg Twice a Day for 10 Days in Subjects with Group A Beta-Hemolytic Streptococcal Pharyngitis/Tonsillitis. Hoechst Marion Roussel HMR 3647A/3008. Closed 1999.
38. A Double-Blind, Randomized, Placebo-Controlled Trial of a Tablet Formulation of Pleconaril in the Treatment of Viral Respiratory Infection in Adults. Viro Pharma 843-043. Closed 2001.

39. An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of BRL49653C When Administered Once or Twice Daily in Combination with Glyburide to Patients With Non-Insulin Dependent Diabetes Mellitus (NIDDUM) "SU Open Label Ext. Study". SmithKlineBeecham 49653/112. Closed 1999.
40. A Prospective, Open-Label, Randomized Comparison of Two Treatment Regimens; Losartan Potassium or Losartan / Hydrochlorothiazide versus Usual Care in Patients Being Treated for Mild to Moderate Hypertension Who Need to Switch Drug Therapy. (LET). Merck C02 355. Closed.
41. A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Six-Month Clinical Trial to Examine the Efficacy and Safety of Salmeterol Xinafoate 42 MCG BID, Beclomethasone Dipropionate 84 MCG QID and Placebo in Adolescent and Adult Subjects with Mild to Moderate Asthma. GlaxoWellcome SLGA 5015/5016. Closed.
42. A Multiple Dose-Response Study of Oral TAK-603 / A-165646 in Rheumatoid Arthritis Patients. TAP M96-598 (TAK-603). Closed.
43. Double-Blind, Randomized, Comparative, Multicenter Study of RP64206 (Sparfloxacin) versus Cefaclor in the Treatment of Community-Acquired Pneumonia. Rhone-Poulenc Rorer RP 64206-352. Closed.
44. A Double-Blind, Randomized, Placebo and Active-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Efficacy and Safety of Once Daily Oral Administrator of 5 mg, 10 mg, 25 mg, and 50 mg of M100240 for 8 Weeks in Subjects with Mild to Moderate Essential Hypertension. Aventis M100240 / 2004 / 0210 & LT Extension. Closed.
45. A Double-Blind, Randomized, Multicenter, Parallel Dose Study to Evaluate the Safety and Efficacy of Zonisamide 150 mg and 300 mg Per Day and Placebo in Subjects with Migraine Headache. Elan AN46046-228. Closed.
46. Flexibility of Biphasic Insulin Aspart 70 / 30 (BIAsp 30) Dosing. A Comparison of Safety and Efficacy of BIAsp 30 BID Injected Before versus After Meals: A Multicenter, Randomized, Open-Label, Cross-Over Design Study in Elderly Insulin-Treated Subjects with Type 2 Diabetes. Novo Nordisk BIAsp-1239. Closed.
47. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Trileptal® in Patients with Neuropathic Pain Due to Diabetic Neuropathy. Novartis CTRI476G2301. Closed.
48. Clinical Protocol for a Randomized, Double-Blind, Placebo-Controlled Study of SD-5613 as Monotherapy in Patients with Primary Hypercholesterolemia

(MONotherapy Assessment of Reducing CHolesterol [MONARCH]). GD Searle NB4-00-02-009. Closed.

49. A Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Nizatidine Extended Release (ER) 150 mg Twice Daily (BID), Nizatidine ER 300 mg Daily (QD) and Placebo in the Treatment of Subjects with Symptomatic, Endoscopically Confirmed Erosive Gastroesophageal Reflux Disease (GERD). Reliant. Rel-AX-002. Closed.
50. An Open-Label, Randomized, Multicenter, Clinical Trial to Assess the Long-Term Safety of Nizatidine Extended Release (ER) 150 mg Twice Daily, and Nizatidine ER 300 mg Once Daily in Subjects with Erosive Gastroesophageal Reflux Disease. Reliant Rel-AX-012. Closed.
51. A Randomized, Double-Blind, Long Term Comparative Study Evaluating the Safety and Efficacy of Acetaminophen (4000 mg/day) and Naproxen (750 mg/day) in the Treatment of OA of the Hip or Knee. McNeil 98-055. Closed.
52. A Multicenter, Blinded, Randomized, Placebo-Controlled Trial to Study the Ability of IL-1ra (anakinra) to Retard Joint Destruction, and Evaluate the Long-Term Safety of IL-1ra, in Subjects with Rheumatoid Arthritis. Amgen IL-1ra 990145. Closed.
53. A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88 mg BID, 220 mcg BID, and 440 mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma Who Are Maintained on Inhaled Corticosteroid Therapy. GlaxoWellcome FAP30007. Closed.
54. A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88 mg BID, 220 mcg BID, and 440 mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma Who Are Maintained on Bronchodilator Therapy. GlaxoWellcome FAP30008. Closed.
55. Safety and Efficacy of Clarithromycin Extended Release (ER) Tablets (500 mg QD or 1000 mg QD) for the Treatment of Penicillin-Resistant *S. pneumonia* / Macrolide-Resistant *S. pneumoniae* (PRSP / MRSP) in Community-Acquired Pneumonia. Abbott M98-935. Closed.
56. A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etorcoxib 90 mg QD versus Diclofenac Sodium 50 mg TID in Patients with Osteoarthritis. Etorcoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE Trial). Merck 061. Closed.



57. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study of the Safety and Effectiveness of Cerivastatin in Combo with Fenofibrate Alone, and Placebo in a Population of Type 2 Diabetic Men and Women. Fenofibrate And Cerivastatin Trial Optimizing Response. (FACTOR). Bayer 100311. Closed.
58. Efficacy and Safety of Phlogenzym® in Patients with Active Painful Gonarthrosis. MUCOS Pharma MU-699401. Closed.
59. A Phase II Pivotal Trial of Oxypurinol for the Treatment of Symptomatic Hyperuricemic Patients Who Are Unable to Tolerate Allopurinol. ILEX OXPL213-A4. Closed.
60. The Safety and Efficacy of PNU-182716 versus Rosiglitazone: A One-Year Randomized, Double-Blind, Parallel-Group, Active Comparator Study. Pharmacia & Upjohn 716-MET-0096-015. Closed.
61. One-Year Safety-In-Use Study of Ipratropium Bromide HFA-134a in Adults with Chronic Obstructive Pulmonary Disease (COPD). Boehringer Ingelheim 244.2453. Closed.
62. A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel-Group Study to Assess the Efficacy and Safety of Oral Augmentin SR2000 / 125 mg Twice Daily versus Oral Augmentin 875 / 125 mg Twice Daily for 7 Days in the Treatment of Adults with Bacterial Community Acquired Pneumonia. SmithKlineBeecham BRL-025000/600. Closed.
63. A Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group 6-week Treatment Study Comparing Telmisartan combined with Hydrochlorothiazide (40 mg/12.5 mg or 80 mg/12.5 mg) Tablets with Losartan combined with Hydrochlorothiazide (50 mg / 12.5 mg) Tablets using Ambulatory Blood Pressure Monitoring in Patients with Mild-to-Moderate Hypertension. (MICARDIS). Boehringer Ingelheim 502.387. Closed.
64. Phase II Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of Ro 205-2349 in Patients with Type 2 Diabetes Mellitus. Roche WM16177. Closed.
65. Phase II Dose – Ranging Study of OROS (Oxycodone HC1) in Patients with Chronic Pain Due to Osteoarthritis. ALZA C-2001-035. Closed.
66. A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel Group, Multicenter Study with a Withdrawal Phase to Investigate the Safety and Efficacy of Dexloxyglumide 200 MG T.I.D. or 200 MG B.I.D. in Female Patients with Constipation-Predominant Irritable Bowel Syndrome. Forest DEX-MD-02A. Closed.

67. A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel Group, Multicenter Study with a Withdrawal Phase to Investigate the Safety and Efficacy of Dexloxyglumide 200 MG T.I.D. or 200 MG B.I.D. in Female Patients with Constipation-Predominant Irritable Bowel Syndrome. Forest DEX-MD-02B. Closed.
68. A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel Group, Multicenter Study with a Withdrawal Phase to Investigate the Safety and Efficacy of Dexloxyglumide 200 MG T.I.D. or 200 MG B.I.D. in Female Patients with Constipation-Predominant Irritable Bowel Syndrome. Forest DEX-MD-03. Closed.
69. A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel Group, Multicenter Study with a Withdrawal Phase to Investigate the Safety and Efficacy of Dexloxyglumide 200 MG T.I.D. or 200 MG B.I.D. in Female Patients with Constipation-Predominant Irritable Bowel Syndrome. Forest DEX-MD-10. Closed.
70. A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients with Osteoarthritis. (EDGE). Merck 061-00. Closed.
71. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-dose, Multicenter Study of Weight-Reducing Effect and Safety of SR141715 in Obese Patients with Untreated Dyslipidemias. Sanofi-Synthelabo EFC4735. Closed.
72. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of a Modified Release Formulation of NBI-34060 in Adult Patients with Primary Insomnia. Neurocrine Biosciences NBI-34060-MR-0211. Closed.
73. A Phase III, Open-Label, Outpatient Extension Study to Assess the Long-Term Safety of a Modified Release Formulation of NBI-34060 in Adult Primary Insomnia Patients with Sleep Maintenance Difficulties. Neurocrine Biosciences NBI-34060-MR-0220. Closed.
74. A Randomized, Double-Blind, Placebo-Controlled Trial of 4-Hydroxy Tamoxifen Gel in Premenopausal Women with 50% to 80% Density in Breast Tissue Based on Digitized Analysis of Screening Mammography. Besins 01-4-OHT-01. Closed.
75. A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg versus Ibuprofen 2400 mg in Patients with Osteoarthritis (Study 2). Merck 073. Closed.

76. A prospective, multinational, multicenter, double-blind, randomized, active-controlled trial in patients with essential hypertension to compare the effect of Valsartan 80 and 160 mg, with or without the addition of hydrochlorothiazide, once daily to that of amlodipine 5 and 10 mg once daily, with or without the addition of hydrochlorothiazide, on cardiovascular morbidity and mortality. (VALUE). Novartis 48 933 01 405. Closed 2004.
77. Twelve-week, randomized, double-blind, placebo-controlled study with PRN BID and fixed dosing of Alosetron in female subjects with severe diarrhea-predominant IBS who have failed conventional therapy. GlaxoSmithKline S3B30048. Closed 2004.
78. A double-blind, Randomized placebo-controlled study of R-Tofisopam in outpatients with irritable bowel syndrome. Vela IBS VPI TFP-201. Closed 2004.
79. A randomized, double-blind study to compare the durability of glucose lowering and preservation of pancreatic Beta-Cell Function of Rosiglitazone Monotherapy compared to Metformin or Glyburide/Glibenclamide in patients with drug-naïve, recently diagnosed Type 2 Diabetes Mellitus. NIDDM. (ADOPT). SmithKlineBeecham 0496553/048.
80. A 12-week, randomized, open label 3-Arm parallel-group, multi-center, phase IIIb study comparing the efficacy and safety of Rosurastin with Atorvastatin a Simvastatin achieving NCEP ATP III LDL-C goals in high-risk subjects with Hypercholesterolemia in the managed care setting. Astra Zeneca 4522US/0003.
81. A randomized, double-blind, active-comparator-controlled, parallel-group study to evaluate the safety of Etoricoxib in patients with Osteoarthritis or Rheumatoid Arthritis. (MEDAL). Merck 066.
82. A multi-center, randomized, double-blind, double-dummy study evaluating the safety and efficacy of the addition of Amlodipine to Quinapril or Losartan in the treatment of Diabetic Hypertensive subjects. Pfizer A0531063.
83. A double-blind, randomized, placebo-controlled study of R-TOFISOPAM in outpatients with irritable bowel syndrome. Vela VPI-TOFP-201.
84. A double-blind, randomized, controlled, parallel-group, multi-center study evaluating the safety and efficacy of Civamide Cream 0.075% as a treatment in subjects with Osteoarthritis of the knee. Winston WL-1001-05-01.
85. A double-blind, randomized, placebo-controlled, Phase III safety study of Tramadol ER 300mg, taken once-daily for the relief of signs and symptoms of Osteoarthritis of the hip and knee. Cipher TRAMCT.02.04.

86. A 4-week, randomized, double-blind, placebo- and positive-controlled, parallel-group, multi-center study of SD-6010 in subjects with symptomatic Osteoarthritis of the knee. Pfizer A6171009.
87. An open label multi-center study evaluating the safety and efficacy of Civamide Cream 0.075% as a treatment in subjects with Osteoarthritis of the knee(s). Winston WL-1001-05-04 Open Label Extension.
88. A multi-center, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50mg qd or bid) to placebo as add-on therapy to Glimepride in patients with Type 2 Diabetes inadequately controlled with Sulfonylurea Monotherapy. Novartis CLAF237A2305.
89. A 28-week extension to a multi-center, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50mg qd or bid) to placebo as add-on therapy to Glimepride in patients with Type 2 Diabetes inadequately controlled with Sulfonylurea Monotherapy. Novartis CLAF237A2305E1.
90. A randomized, double-blind, parallel-filter study to evaluate the Antihypertensive efficacy and safety of Losartan-HCTZ combination as compared to Losartan Monotherapy in patients with Essential Hypertension. Merck MK0954A-264-00
91. A twelve-week, double-blind, placebo controlled study to assess the tolerability, efficacy, and safety of Ropinirole dosed PRN in subjects with Restless Legs Syndrome (RLS) who respond to open-label treatment with Ropinirole. (Treat RLS PRN). GSK GSK-100310.
92. A multi-center, standard of care-controlled study to evaluate the long-term safety of bificadine for the treatment of chronic low back pain. DOV. DOV-075-022-US. 2005.
93. A multi-center, double-blind, placebo-controlled randomized study of bificadine 200 mg BID, bificadine 300 mg BID, and bificadine 400 mg BID in the treatment of chronic low back pain. DOV. DOV-075-020-US. 2005.
94. A 4-week, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of L-000904218 in patients with osteoarthritis of the knee or hip. Merck 006-00. 2005.
95. Pulmonary outcomes within a 2-year period in subjects with diabetes mellitus treated with Technosphere®/Insulin or usual antidiabetic treatment and in subjects without abnormalities in glucose control. Mannkind Corporation. MKC-TI-030. Phase 3a. 2005.

96. A phase 3 study to evaluate the efficacy and safety of TAK-390MR (60 mg QD and 90 mg QD) compared to placebo on symptom relief in subjects with symptomatic non-erosive gastroesophageal reflux disease (GERD). TAP Pharmaceuticals. T-GD04-083. 2005.
97. A phase 3 study to evaluate the efficacy and safety of TAK-390MR (60 mg QD and 90 mg QD) and an active comparator, lansoprazole (30 mg QD) on healing of erosive esophagitis. TAP Pharmaceuticals. T-EE04-085. 2005.
98. A phase 3 study to evaluate the efficacy and safety of TAK-390MR (60 mg QD and 90 mg QD) compared to placebo in maintenance of healing in subjects with healed erosive esophagitis. TAP Pharmaceuticals. T-EE04-087. 2005.
99. A phase 3, open-label study to assess the long-term safety of TAK-390MR (60 mg QD and 90 mg QD). TAP Pharmaceuticals. T-GI04-088. 2005.
100. A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase 2 trial to evaluate the safety and efficacy of BMS-512148 as monotherapy in subjects with type 2 diabetes mellitus who are treatment naïve and have inadequate glycemic control on diet and exercise. Bristol-Myers-Squib. MB102008. 2006.
101. A randomized, double-blind, double-dummy, placebo-controlled, 3x4 factorial design trial to evaluate telmisartan 20 and 80 mg tablets in combination with ramipril 1.25, 10, and 20 mg capsules after eight weeks of treatment in patients with Stage I or II hypertension, with an ABPM sub-study. Phase 3. Boehringer Ingelheim. 2006.
102. A phase 3 prospective, multi-center, open-label, randomized, controlled clinical trial comparing the efficacy and safety in subjects with type 2 diabetes receiving subcutaneous basal insulin and prandial inhalation of Technosphere®/Insulin versus subcutaneous premixed insulin therapy over a 52-week treatment period and a 24-week follow-up. MannKind Corporation. MKC-TI-102. 2006.
103. A phase 2 study to investigate the safety and efficacy of dexloxiglumide for the relief of symptoms of functional dyspepsia. Forest Research Institute. DEX-MD-20. 2006.
104. A randomized, open-label, comparative, multi-center trial to evaluate contraceptive efficacy, cycle, control, safety and acceptability of monophasic combined oral contraceptive (COC) containing 2.5 mg norgestrel acetate (NOMAC) and 1.5 mg estradiol (E2), compared to a monophasic COC containing 3 mg drospirenone (DRSP) and 30 mcg ethinyl estradiol (EE). Organon. 292992. 2006.

105. A randomized, double-blind, multicenter, placebo-controlled, parallel study evaluating the safety of PT-141 in subjects with controlled essential hypertension (stage 1 or 2). Palatin Technologies. PT-141-2006-32. 2006.
106. A phase 3, open-label long-term safety study of tramadol hydrochloride extended release and meloxicam QD combination in the treatment of moderate to moderately severe pain associated with osteoarthritis. Biovail Laboratories International SRL. TMX-301. 2006.
107. The effect of dose titration and dose tapering on the tolerability of DVS SR in women with vasomotor symptoms associated with menopause: the PRIMMUS (PRIstiq for Managing Menopause and Understanding Symptoms) Study. Wyeth. 3151A2-405-NA. 2006.
108. A phase 3 study to evaluate the safety and efficacy of TAK-390MR (30 mg QD and 60 mg QD) compared to placebo in maintenance of healing in subjects with healed erosive esophagitis. TAP Pharmaceuticals. T-EE05-135. 2006.
109. A phase 3 study to evaluate the safety and efficacy of TAK-390MR (30 mg QD and 60 mg QD) compared to placebo on symptom relief in subjects with symptomatic non-erosive gastroesophageal reflux disease (GERD). TAP Pharmaceuticals. T-GD05-137. 2006.
110. A 12-week, randomized, double-blind, dose-ranging, placebo-controlled study of asimadoline in subjects with irritable bowel syndrome. Phase 2. Tioga Pharmaceuticals. ASMP2003. 2006..
111. A 36 week randomized, double-blind, parallel group, multi-center, active-controlled, optional titration study comparing an aliskiren-based regimen to a ramipril-based regimen in patients at least 65 years old with systolic essential hypertension. Phase 3b. Novartis. CSPP100A2344. 2006.
112. Worldwide, Multicenter, double-blind, parallel study to evaluate the tolerability of MK-0524A versus niacin extended-release. Phase 3. Merck. 054-00. 2006.
113. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Testosterone Gel 1.62% for the Treatment of Hypogonadal Men. Solvay. S176.3.104. 2007.
114. A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects with Gout. F-GT06-153, 2007.
115. A 2-Month Safety Follow-up Trial of Subjects from Mannkind Protocols MKC-TI-009, MKC-TI-102, MKC-TI-103, and MKC-TI-030. MKC-TI-126, 2007.

116. A double-blind, randomized, placebo-controlled study of 100, 200 and 300 mg BID R-tofisopam in women with Irritable Bowel Syndrome. VPI-Tofp-203, 2007.
117. A two-week, double-blind, placebo-controlled, randomized, parallel group, efficacy and safety, out-patient trial with ORG 50081 in patients with primary chronic insomnia. 176001, 2007
118. A fifty two week, open label extension trial to evaluate safety and efficacy of ORG 50081 in outpatients with primary chronic insomnia who completed Clinical Trial Protocol 176001 or 176002. 176004, 2007.
119. A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly Subjects With Primary Chronic Insomnia. 190-904, 2007.
120. A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 administered orally as monotherapy for 12 weeks in healthy postmenopausal women with moderate to extremely severe vasomotor symptoms SRM105106, 2007.
121. A multicenter, Multiple dose, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of AGN 203818 in Female Patients with Fibromyalgia Syndrome. 203818, 2007.
122. A Multicenter, randomized, double-blind, 'crossover" Design Study to evaluate the lipid altering efficacy and safety of Mk-0524B combination tablet compared to MK524A + Simvastatin Coadministration in patients with primary dyslipidemia. 063-MK0524, 2007.
123. A randomized, double-blind, placebo-controlled, multi-center to evaluate the efficacy of CRX-102 in subjects with symptomatic knee osteoarthritis. CRX-102-006, 2007.
124. A phase 2, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of 12-week administration of PF-00734200 to subjects with type 2 diabetes mellitus and insufficient glycemic control on metformin treatment. Pfizer. A7941006. 2008.
125. Pulmonary Outcomes within a 2-year Period in Subjects with Diabetes Mellitus Treated with Technosphere®/Insulin or Usual Antidiabetic Treatment and in Subjects without Abnormalities in Glucose Control. Evaluation of the Effect of Symptomatic Upper Respiratory Infections on Pharmacological Characteristics of Technosphere®/Insulin in Subjects with Diabetes Mellitus after a Meal Challenge. MKC-TI-030

126. NN1998-1683: Inhaled Mealtime Insulin with the AERx® iDMS plus Pioglitazone versus Pioglitazone alone in Type 2 Diabetes: A 26-Week, Open-Label, Multicentre, Randomised, Parallel Trial to Investigate Efficacy and Safety IND # 56,993
127. A Phase 2 Double-Blind Study to Evaluate the Safety and Efficacy of laprazole (5 mg QD, 20 mg OD and 40 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis. Study Z-EE05-123
128. Validation of Patient Reported Outcome Measures for Influenza disease for use in Phase II POC/Phase III Flu Peptide Vaccine Program (V512) V-512-003. Completed 2007.
129. Evaluation of the Effect of Symptomatic Upper Respiratory Infections on Pharmacological Characteristics of Technosphere®/Insulin in Subjects with Diabetes Mellitus after a Meal Challenge MKC-TI-112.
130. Comparison of the change in HbA1c and the safety of Bedford Laboratories 70/30 (Biphasic) 100 IU/mL rh-Insulin and Novo Nordisk Novolin® 70/30 rh-Insulin in subjects with type 1 and type 2 diabetes. Bedford Laboratories. INSU-170/30-PVCL-1.
131. A Phase 3, Multi-center, Open-label, Randomized, Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Subjects with Type 1 or Type 2 Diabetes and Mild Obstructive Pulmonary Disease over a 12-Month Treatment Period with a 3-Month Follow-up. Mannkind Corporation. MKC-TI-134.
132. A phase 3, randomized, double-blind, placebo-controlled multicenter study of the analgesic efficacy & safety of tanezumab in patients with osteoarthritis of the knee or hip. Pfizer. A4091011 (OA knee) & A4091014 (OA hip). 2008.
133. An adaptive dose-ranging, multi-center, single-blind, double-dummy, active-controlled trial to determine the target doses of canakinumab (ACZ885) in the treatment of acute flares in gout patients who are refractory or contraindicated to NSAIDs and/or colchicine. Novartis. CACZ885H2255. 2008.
134. An 8 week randomized, double-blind, parallel group, multi-center, active controlled study to evaluate the efficacy and safety of valsartan administered in combination with aliskiren (160/150 mg, 320/300 mg) versus valsartan alone (160 mg, 320 mg) in patients with stage 2 hypertension. Novartis. CSPV100AUS01. 2009.
135. A phase 3b multicenter, single-blind trial to evaluate the efficacy of dexlansoprazole MR 30 mg in maintaining control of gastroesophageal reflux disease in subjects on prior twice daily proton pump inhibitor therapy. Takeda. T-GD08-178. 2009.



136. A phase 3, double-blind, randomized, factorial, efficacy and safety study of TAK-491 plus chlorthalidone fixed-dose combination vs. Benicar HCT (olmesartan medoxomil-hydrochlorothiazide) in subjects with moderate to severe hypertension. Takeda. TAK-491CLD\_301. 2009.
137. A phase 3, double-blind, randomized, factorial, efficacy and safety study of TAK-491 plus chlorthalidone fixed-dose combination in subjects with moderate to severe hypertension. Takeda. TAK-491CLD\_302. 2009.
138. A 24-Week, Dose-Ranging, Multi-Center, Double-Blind, Double-Dummy, Active-Controlled Study To Evaluate Canakinumab (ACZ885) For Prophylaxis Of Signs And Symptoms Of Acute Flares In Chronic Gout Patients Initiating Allopurinol Therapy. Novartis. Protocol No. CACZ885H2251. 2009.
139. A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study To Investigate The Efficacy And Safety Of SER120 Nasal Spray Formulation In Patients With Nocturia. Protocol Number: Serneniyt Pharmaceuticals. SPC-SER120-DB1-200901. 2009.
140. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Of Linaclotide Administered Orally For 12 Weeks Followed By A 4-Week Randomized Withdrawal Period In Patients With Irritable Bowel Syndrome With Constipation. Forrest Research Institute. LIN-MD-31. 2009.
141. A Phase 3 Randomized, Double Blind Placebo And Naproxen Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee. Pfizer. Protocol A4091015
142. A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of Albiglutide When Used In Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, And Metformin Plus Placebo In Subjects With Type 2 Diabetes Mellitus GSK. GLP 112753. 2009.
143. A Randomized, Open-Label, Parallel-Group, Multicenter Study To Determine The Efficacy And Long Term Safety Of Albiglutide Compared With Insulin In Subjects With Type 2 Diabetes Mellitus. GSK. GLP 112754.
144. A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of Albiglutide Administered In Combination With Metformin And Glimepiride Compared With Metformin Plus Glimepiride And Placebo And With Metformin Plus Glimepiride And Pioglitazone In Subjects With Type 2 Diabetes Mellitus. GSK. GLP 112757.

145. A Multi-Center, Randomized, Double-Blind, Active-Controlled Study Of The Safety And Efficacy Of Rilonacept Administered Subcutaneously For The Treatment Of An Acute Gout Flare. Regeneron. Protocol Number IL1T-GA-0814.
146. A Phase 3, Double-Blind, Randomized, Factorial, Efficacy And Safety Study Of TAK-491 Plus Chlorthalidone Fixed-Dose Combination In Subjects With Moderate To Severe Hypertension. Takada. TAK-491CLD\_302.
147. A phase 3 randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of Ser120 nasal spray formulation in patients with nocturia. Serenity Pharmaceuticals Corp. SPC-SER120-200901.
148. A multi-center, randomized, double-blind, placebo controlled trial of the safety of rilonacept for the prophylaxis of gout flares in patients on urate lowering therapy. Regeneron. IL1T-GA-0815.
149. A phase 3b, double-blind, randomized, 12-week efficacy and safety study comparing the TAK-491 plus chlorthalidone fixed-dose combination vs olmesartan medoxomil-hydrochlorothiazide in subjects with moderate to severe hypertension. Takeda. TAK-491CLD\_303. 2010.
150. A one-year, randomized, open-label, parallel-group, multiple-dose long-term safety study with controlled adjustment of dose of tapentadol extended-release (ER) and oxycodone controlled-release (CR) in subjects with chronic, painful diabetic peripheral neuropathy (DNP). Johnson & Johnson. R331333PAI3028 (DM DPN). 2010.
151. A randomized, double-blind, placebo-controlled, parallel-group, 26-week, multicenter study with a 78-week extension, to evaluate the efficacy, safety, and tolerability of JNJ-28431754 (canagliflozin) compared with placebo, in the treatment of subjects with type 2 diabetes mellitus inadequately controlled on glucose lowering therapy. Johnson & Johnson. 2010.
152. A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram tiotropium inhalation solution delivered by the Respimat® inhaler with tiotropium inhalation capsules 18 microgram delivered by the HandiHaler®. Boehringer Ingelheim. 2010.
153. A randomized, double-blind, multi-center, placebo-controlled, combination study to evaluate the urate-lowering activity, safety and potential PK interaction of oral BCX4208 and allopurinol administration in subjects with gout. BioCryst BCX4208 202. 2010.

154. The effect of LY2189265 on blood pressure and heart rate as assessed by ambulatory blood pressure monitoring in patients with type 2 diabetes mellitus. Eli Lilly H9X-MC-GBDN. 2010.
155. Phase II, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy, safety, and tolerability of JNJ-42160443 (fulranumab) in subjects with neuropathic pain, followed by a double-blind safety extension and an open-label extension. Johnson & Johnson. Clinical protocol 42160443-NPP-2001. 2010.
156. A phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of S-707106 in subjects with type 2 diabetes mellitus and inadequate glycemic control with metformin therapy. Shionogi USA, Inc. Protocol 1010N0921. 2010.
157. A randomized, double-blind, dose response study of safety and efficacy of oral BCX4208 added to allopurinol in subjects with gout who have not adequately responded to allopurinol monotherapy. BioCryst. BCX4208-203. 2011.
158. A randomized, double-blind, placebo-controlled, 3-arm, parallel-group, 26-week, multicenter study with a 26-week extension, to evaluate the efficacy, safety and tolerability of canagliflozin in the treatment of subjects with type 2 diabetes mellitus who have moderate renal impairment. Johnson & Johnson. 28431754DIA3003. 2011.
159. Multicenter, randomized, ctive-0control, phase 3b study to evaluate the cardiovascular safety of febuxostat and allopurinol in subjects with gout and cardiovascular comorbidities. Takeda. TMX-67\_301. 2011.
160. A phase 3, multi-center global, open-label 52 week treatment study to assess the long-term safety of NKTR-118 in opioid-induced constipation in patients with non-cancer related pain. AstraZeneca. D3820C00008. 2011.
161. A Multicenter, Randomized, Placebo-Controlled, Blinded Study fo the Efficacy and Safety of Colchicine (Colcrys®) for the Prevention of Gout Flares During the Initiation of Allopurinol. Regeneron Pharmaceuticals IL1T-GA-1103. 2011.
162. A 52-week, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the effect of roflumilast 500 mcg on exacerbation rate in subjects with chronic obstructive pulmonary disease (COPD) treated with a fixed-dose combination of long-acting beta agonist and inhaled corticosteroid (LABA/ICS). Forest ROF-MD-07. 2011.
163. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of two fixed dose combinations of acclidinium bromide/formoterol fumarate and placebo for 24-weeks treatment in patients with

moderate to severe, stable chronic obstructive pulmonary disease (COPD). Forest LAC-MD-31. 2011.

164. A phase 3A, double-blind, placebo-controlled, randomized clinical trial assessing safety and efficacy of MF101 for hot flushes and menopausal symptoms in postmenopausal women. BioNovo, Inc. MF101-004. 2011.
165. A phase 3, randomized, double-blind, multicenter, placebo-controlled, combination study to evaluate the efficacy and safety of lesinurad and allopurinol compared to allopurinol alone in subjects with gout who have had an inadequate hypouricemic response to standard of care allopurinol. Ardea Biosciences, Inc. RDEA594-302. 2012.
166. A phase 3, randomized, double-blind, multicenter, placebo-controlled, study to assess the efficacy and safety of lesinurad monotherapy compared to placebo in subjects with gout and an intolerance or contraindication to a xanthine oxidase inhibitor. Ardea Biosciences, Inc. RDEA594-303. 2012. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC). AstraZeneca. D3820C00005. 2012.
167. A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma. Cephalon. C38072/3084. 2012.
168. TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control. Merck. MK-0431-082. 2012.
169. A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of JNJ-27018966 in the treatment of patients with diarrhea-predominant irritable bowel syndrome. Furiex Pharmaceuticals. 27018966IBS3001. 2012.
170. A randomized, double-blind, double-dummy, placebo-controlled, active controlled, parallel-group, multicenter trial of oxycodone/naloxone controlled-release tablets (OXN) to assess the analgesic efficacy (compared to placebo) and the management of opioid-induced constipation (compared to oxycodone controlled-release tablets (OXY) in opioid-experienced subjects with uncontrolled moderate to severe chronic low back pain and a history of opioid-induced constipation who require around-the-clock opioid therapy. Purdue Pharma. ONU3704. 2012.
171. A phase 3, long-term, randomized, double-blind, extension study of the efficacy, safety and tolerability of two fixed dose combinations of acclidinium bromide, formoterol fumarate and placebo for 28-weeks treatment in patients with moderate

to severe, stable chronic obstructive pulmonary disease (COPD). Forest Research Institute, Inc. LAC-MD-36. 2012.

172. A randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study jto compare the efficacy, tolerability, and safety of 3 doses of gabapentin enacarbil (GSK1838262) with placebo in the treatment of subjects with moderate-to-severe primary restless legs syndrome (RLS). GSK. 2011N117120\_01. 2012.
173. A phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, worldwide, dose-ranging, clinical trial with a proof-of-concept lead cohort to evaluate the safety, tolerability, and efficacy of MK-8457 + MTX in patients with active rheumatology despite methotrexate therapy. Merck. MK-8457-008. 2012.
174. 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-Month Safety Extension Period. Sanofi. EFC-12456. 2012.
175. 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycemic Drugs with a 6-Month Safety Extension Period. Sanofi. EFC-12347. 2012.
176. Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events. TAKEDA. TAK-875\_306. 2012.
177. A long-term open-label extension study for subjects completing phase 3 efficacy and safety study of lesinurad monotherapy in subjects with gout. Ardeas Biosciences. ADEA594-305. 2013.
178. A phase 4 multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk (CARMELINA). Boehringer Ingelheim. No. 1218.22. 2013.
179. A randomized, double blind, placebo controlled, multicenter study to investigate the efficacy and safety of SER12 nasal spray formulation in patients with nocturia. Serenity Pharmaceuticals. SPC-SER120-DB4-201301. 2013.
180. A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the blood pressure reduction with ambulatory blood pressure reduction with ambulatory blood pressure monitoring (ABPM), safety, and tolerability of

canagliflozen in the treatment of subjects with hypertension and type 2 diabetes mellitus. Janssen Scientific Affairs. Johnson & Johnson. 28431754DIA4002. 2013.

181. A randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of ETC-1002, ezetimibe, and the combination in hypercholesterolemic patients with or without statin intolerance. Esperion. 2013.
182. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled clinical trial to study the safety and efficacy of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in subjects with type 2 diabetes mellitus who have inadequate control on metformin. Merck MK-8835-002-00. 2014.
183. A phase 2, multicenter, randomized, double-blind (within dose), placebo-controlled, parallel-group, dose-range-finding study to evaluate the efficacy, safety, and pharmacokinetics of X0002 spray versus placebo in subjects with mild to moderate osteoarthritis of the knee. Techfields-Covance TF-X0002-21. 2014.
184. A phase 2, randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and safety of febuxostat 40 mg XR, 80 mg XR, 40 mg IR, and 80 mg IR in subjects with gout and moderate renal impairment. Takeda. FEB-XR\_201. 2014.
185. A phase 3, randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and safety of febuxostat 40 mg XR, 80 mg XR, 40 mg IR, and 80 mg IR in subjects with gout. Takeda. FEB-XR\_301. 2014.
186. Six-month, randomized, open-label, parallel-group comparison of SAR342434 to Humalog in adult patients with type 1 diabetes mellitus also using insulin glargine, with a 6-month safety extension period. Sanofi Group. EFC12619. 2014.
187. A 64-week, double-blind, randomized, placebo-controlled, parallel group study to confirm the efficacy and safety of dupilumab administered concomitantly with TCS in adult with moderate to severe atopic dermatitis. Regeneron. R668-1224.01US. 2014.
188. A randomized, double-blind, placebo- and active-controlled study of DS-5565 for treatment of pain associated with fibromyalgia. Daiichi Sankyo. DS5565-A-E310. 2014.
189. A prospective, non-interventional, registry study of patients initiating a course of drug therapy for overactive bladder. Astellas. 178-MA-1006. 2015.
190. A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy and safety of subcutaneously administered bremelanotide in premenopausal women with

hypoactive sexual desire disorder (HSDD) with or without decreased arousal. Pallatin Technologies, Inc. RECONNECT BMT-301. 2015.

191. A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THREE INTRA-ARTICULAR INJECTIONS OF AMPION™ (4 ML) ADMINISTERED TWO WEEKS APART IN ADULTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE. Ampio Pharmaceuticals. AP-008. 2015.
192. Randomized, double-blind, active controlled, multicenter, parallel-group, phase 3 study of the safety and efficacy of tanezumab when administered by SC injectin for 56 weeks compared to NSAIDs in subjects with osteoarthritis of the knee or hip. Pfizer. A4041058. 2015.
193. A phase 2, randomized, double-blind, placebo and active-controlled trial of LY2951742 in patients with mild to moderate osteoarthritis of the knee. Lilly. I5Q-MC-CGAF. 2015.
194. A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of ospemifene in patients with moderate to severe vaginal dryness, a symptom of vulvo-vaginal atrophy (VVA) due to menopause. Shionogi. 151710231. 2016.
195. A 26-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tenapanor for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). Ardelyx. TEN-1-01-302. 2016.
196. An open-label study of dupilumab in patients with atopic dermatitis who participated in previous dupilumab clinical trials. Regeneron. R668-AD-1225.04. 2016.
197. A double-blind, randomized, placebo-controlled, multicenter study to evaluate safety, tolerability, and efficacy of evolocumab (AMG 145) on LDL-C in subjects with type 2 diabetes mellitus and hypercholesterolemia/mixed dyslipidemia. Amgen. 20130287. 2016.
198. A phase 3 randomized, double-blind, placebo-controlled, multicenter study of the analgesic efficacy and safety of a dose titration regimen for the subcutaneous administration of tanezumab in subjects with osteoarthritis of the hip or knee. Pfizer. A4091056. 2016.
199. A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of AXS-02 (disodium zoledronate tetrahydrate) administered orally to subjects with knee osteoarthritis associated with bone marrow lesions. Axsome. AXS02-K301. 2016.

200. Phase1b multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LY3090106 in subjects with Sjogren's syndrome. Lilly. 16M-MC-SSAD. 2016.
201. A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of fedovapagon in the treatment of nocturia in men with benign prostatic hyperplasia. Vantia. 483-013. 2016.